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General introduction 
 
The mammalian brain is by far the most complex system in the body. The human 
brain consists of approximately 100 billion nerve cells (neurons), which form a 
highly complex wiring scheme. How this complex wiring is achieved is still 
poorly understood. The brain contains several clusters of cells which contain a 
certain neurotransmitter, such as dopaminergic cells in the substantia nigra or 
acetylcholinergic cells in ventral and dorsal striatum. 
Another example of such clusters are the raphe nuclei in the midbrain that 
secrete serotonin (5-hydroxytryptamine, 5-HT). 5-HT has diverse modes of 
action in the central nervous system and is involved in brain development as will 
be described in this introduction. There are a few remarkable characteristics of 
the 5-HT system. First of all, the 5-HT system consists of only a few neurons 
(~1000 in rodents, ~0.5 million in humans) compared to the total number of 
neurons. Nevertheless, these neurons send projections to virtually every other 
brain area. It is estimated that each 5-HT neuron makes more than 1 x 105 
connections. Secondly, 5-HT is predominantly released extrasynaptically (so 
called volume or paracrine transmission), which implies that 5-HT acts on a 
slower and longer-lasting time scale compared to classical neurotransmitters like 
glutamate. Thirdly, emerging evidence shows that 5-HT has a role during brain 
development. Finally, the 5-HT system is involved in certain behavioural and 
psychopathological processes including anxiety, depression, aggression and 
obsessive-compulsive disorder (OCD). 
In this chapter the main aspects of the 5-HT system will be introduced and 
the diverse modes of action which 5-HT has are described. First, there will be a 
description about the anatomical organization and development of the 5-HT 
system. Subsequently, the role of 5-HT in brain development will be introduced 
and the relation between the 5-HT system and behavioural and 
psychopathological processes will be discussed. Finally, the aim and scope of this 
thesis will be outlined. 
 
Anatomical organization of 5-HT cell clusters 
 
After the initial discovery of 5-HT (see box I), it took about 20 years before the 
cellular distribution of 5-HT was described by Dahlstrom and Fuxe using the 
Falck-Hillarp technique. They showed that 5-HT cell bodies are clustered in nine 
cell groups close to the midline in the rhombencephalon, called the raphe nuclei. 
The nine nuclei are divided in two groups, the rostral and caudal group. The 
caudal group consists of clusters B1 to B5 and send projections predominantly in 
the midbrain itself and towards the spinal cord. On the other hand, the rostral 
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cell group consists of clusters B6 to B9 and sends projections to the forebrain. 
The largest clusters of cells are the dorsal raphe nucleus (DRN) and the median 
raphe nucleus (MRN) (B7 and B8 respectively). These raphe nuclei also contain 
several types of non-5-HT neurons, such as GABA-ergic and noradrenergic 
neurons. The 5-HT neurons densely innervate virtually every brain area, with the 
most dense 5-HT innervations in the cortex and limbic structures including the 
hippocampus and basal ganglia.  
 
   Box I    The discovery of 5-HT 
 
In the 1930’s Dr. Vittorio Erspamer tried to extract chemical compounds from 
enterochromaffin cells capable of causing smooth muscle contraction in the gut. In an 
extract of rabbit gastric mucosa, he identified a substance that could cause smooth 
muscle contraction. He called this substance enteramine, since it was an amino acid 
derivative (amine) found in enterochromaffin cells.  
In the 1940’s another group identified a substance which had vasoconstrictive 
activity in serum. This serum influenced the tone, hence the name serotonin. When 
analyzing both substances, it was found that enteramine and serotonin were the same 
substance.  
The first indication for a role of 5-HT in the brain came from Woolley, who 
showed that 5-HT and the hallucinogenic compound lysergic acid diethylamide (LSD) 
had comparable actions in the cortex of the cat. This eventually led to the discovery of 
5-HT in the vertebrate brain like man and dog. 
Dahlstrom and Fuxe were the first to describe the distribution of 5-HT cell bodies 
in the brain by histochemical detection of the 5-HT derivative indoleamine. The 
description of 5-HT projections from the 5-HT cell bodies towards the telencephalon 
and the diencephalon followed one year later. It was found that in the brain stem a 
relatively small population of 5-HT neurons was present, with the largest clusters in 
the dorsal and median raphe nuclei. 
 
The development of the 5-HT system 
 
In the mouse brain, 5-HT neurons are generated around embryonic day (E) 10, 
and these cells are among the first neurons expressing a specific 
neurotransmitter. In the neural tube, 5-HT precursor cells are formed by the 
combined action of sonic Hedgehog, Fgf4 and Fgf8. The proper position of these 
5-HT precursor cells is defined by the midbrain-hindbrain organizing centre 
(MHO), Shh signaling and the transcription factor Nkx2.2 (see figure 1).  
In a knockout (KO) mouse for Nkx2.2, no 5-HT neurons are present in the 
midbrain raphe nuclei, except in the DRN, showing that Nkx2.2 is essential for 5-
HT neuron differentiation (Briscoe et al., 1999). Another transcription factor that 
is involved in the initial development of 5-HT neurons is GATA3 (van Doorninck 
et al., 1999). After 5-HT precursor cells are formed, other  
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Figure 1. Genetic factors involved in determining the 5-HT system. At the MHO, Fgf4 and 
Fgf8 are involved in the specification of the 5-HT precursor neurons. Image adapted from 
Gaspar et al., 2003.  
 
factors are required to establish mature 5-HT neurons. Among these factors are 
two transcription factors, LIM homeobox transcription factor 1 (Lmx1) and PC12 
Ets factor (Pet1). 
Lmx1b expression starts at E10.75 in the ventral part of the hindbrain 
including the floor plate and from E13.5 Lmx1b is present in the raphe nuclei 
(Ding et al., 2003). Lmx1b KO mice die within 24 hours after birth (Chen et al., 
1998). Lmx1b-deficient mice lack all 5-HT neurons, even when Lmx1b was only 
deleted in 5-HT neurons, (Ding et al., 2003; Zhao et al., 2006). These studies 
show that Lmx1b is not required for the initial generation of 5-HT neurons, but is 
necessary for the differentiation and survival of 5-HT neurons during postnatal 
development. 
Pet1 was found in a screen in PC12 cells to identify novel ETS domain 
transcription factors (Fyodorov et al., 1998). Pet1 expression is restricted to the 
raphe nuclei and precedes the expression of 5-HT by approximately half a day 
(Hendricks et al., 1999). Furthermore, several genes specific for 5-HT neurons, 
such as the rate limiting enzyme tryptophan hydroxylase (Tph) and the 5-HT 
reuptake transporter (SERT) have a conserved Pet1 binding site in their 
promoter (Hendricks et al., 1999). This suggests that Pet1 is involved in the final  
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differentiation of 5-HT neurons. In a Pet1 KO mouse, there is an approximately 
70% reduction in number of 5-HT neurons. The fact that there are still 30% of 5-
HT neurons remaining suggests that these are either independent of Pet1 or 
there is another unknown transcription factor. 
After this genetic cascade, at approximately E11.5, 5-HT neurons start 
expressing the enzymes necessary for 5-HT synthesis (see box II) and proteins 
necessary for reuptake (SERT) and degradation of 5-HT (Monoamine-A (MAO-
A)). Shortly after initiation of expression of these genes, 5-HT neurons start to  
 
Box II    Synthesis of 5-HT 
 
5-HT is a neurotransmitter which belongs to the group of the biogenic amines, to 
which also the catecholamines (dopamine, adrenaline and noradrenaline) belong. All 
biogenic amines are derived from amino acids: the catecholamines from tyrosine, and 
5-HT from tryptophan. 5-HT and the precursor tryptophan belong to a group of 
chemical compounds called the indoles, with a benzene ring joined to a five-member 
ring containing nitrogen. Tryptophan is an essential amino acid, which means that this 
amino acid cannot be made in the body from other amino acids and must therefore be 
ingested through the diet. 
For synthesis of 5-HT in the brain, tryptophan is actively transported through the 
blood brain barrier via the large neutral amino acid transporter (LAT1). Once in the 
brain, tryptophan is metabolized to 5-HT using two different enzymes. First, 
tryptophan is hydroxylated in the 5-position to generate 5-hydroxy-L-tryptophan. This 
reaction is catalyzed by Tph, which is the rate limiting enzyme in 5-HT synthesis. 
Subsequently 5-hydroxy-L-tryptophan is converted to 5-hydroxytryptamine (5-HT) by 
the enzyme 5-hydroxytryptophan decarboxylase. 5-HT is stored in synaptic vesicles 
and large dense cored vesicles and transported into these vesicles by the enzyme 
Vesicular Monoamine Transporter 2 (VMAT2). After being released, 5-HT is 
transported back into the terminal using SERT, and either recycled or converted to 5-
hydroxyindolacetic acid (5-HIAA) by MAO-A. 
The rate limiting enzyme Tph has a (6R)-L-erythro-5,6,7,8-Tetrahydrobiopterin 
(Tetrahydrobiopterin, BH4) binding site. BH4 is an essential cofactor for the proper 
functioning of Tph. Without BH4, Tph cannot hydroxylate its substrate and thus 5-HT 
cannot be synthesized. BH4 is also required for dopamine synthesis by acting as a 
cofactor for tyrosine hydroxylase. Mice deficient for the BH4 gene die within 48 hours 
after birth and have extremely low levels of 5-HT and dopamine. 
It has long been thought that only one Tph gene was present in the mammalian 
brain, although in zebrafish, two Tph genes were identified. However, in a mouse 
deficient for the Tph gene, no difference in brain 5-HT levels was found compared to 
control mice. This led to the discovery of the second Tph gene, called neuronal Tph or 
Tph2 (Walther et al., 2003). By using immunohistochemical analysis and in situ 
hybridization, it has been shown that Tph1 is expressed in the periferic system in the 
enterochromaffin cells and in the pineal gland in the brain, whereas Tph2 is 
exclusively expressed in the raphe nuclei in brain and in the myenteric plexus in the 
gut (Patel et al., 2004; Malek et al., 2005; Gutknecht et al., 2009). 
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 release 5-HT and start to send axon branches towards the spinal cord and via the 
medial forebrain bundle towards the cortex. Only after birth the 5-HT network is 
fully matured.  
In the human brain, 5-HT neurons are for the first time detected when the 
embryo is five weeks old (Sundstrom et al., 1993). At ten weeks of age, 5-HT 
neurons are detected in all nuclei of the reticular formation and after 15 weeks, 
the 5-HT neurons are clustered in the raphe nuclei (Shen et al., 1989). After 
birth, 5-HT levels increase during the first two years and then decline to adult 
levels at the age of five years (Hedner et al., 1986).   
 
5-HT release is both synaptic and extrasynaptic 
 
Several classical neurotransmitters such as GABA, acetylcholine and glutamate 
are released from small synaptic vesicles (SSVs) at synaptic sites with a 
postsynapse in close proximity. However, neurotransmitters such as dopamine 
and 5-HT are released not only synaptically, but there is also so-called 
extrasynaptic release (also called paracrine transmission or volume 
transmission; here there will be referred to this type of release as volume 
transmission). A major difference between synaptic release and volume 
transmission is that there is no postsynapse present, so upon release the 
neurotransmitters diffuse away and can mediate effects distant from the release 
site. In this manner volume transmission can produce paracrine effects. In 
contrast to synaptic release, where SSVs are only released from axonal terminals,  
volume transmission of 5-HT occurs also in the soma and in dendrites, the so-
called somatodendritic release. In 5-HT neurons, vesicles storing 5-HT are not 
only present in axonal terminals, but also in somata, dendrites and axonal 
varicosities (Hery and Ternaux, 1981). It was shown in Retzius neurons of the 
leech that 5-HT is released from both SSVs and large dense core vesicles 
(LDCVs), where there is an average discharge of 4700 and 80.000 molecules of 
5-HT for SSVs and LDCVs respectively (Bruns and Jahn, 1995). In another study 
of the same authors, several differences between SSV and LDCV release of 5-HT 
were shown. First of all there was a difference in distribution: while SSVs were 
exclusively found in axons, LDCVs were also found at the soma. Furthermore 
LDCV release was slower compared to SSV release (Bruns et al., 2000).  
There are several lines of evidence for volume transmission of 5-HT, some of 
which are indirect. First of all it has been shown that 5-HT varicosities contain 5-
HT vesicles, but lack a postsynaptic specialization in close proximity (Moukhles 
et al., 1997). 5-HT receptors and the SERT are localized at sites away from 
release sites, indicating that 5-HT diffuses over larger distances to activate these 
receptors (Ridet et al., 1993). The presence of SERT distant from release sites 
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suggests that these are required to transport 5-HT back into the cells to 
terminate the action of 5-HT in the extracellular space. Secondly, it has been 
shown by carbon fiber amperometry that upon stimulation an increase of 5-HT 
levels in the extracellular medium occurs (Bunin and Wightman, 1998). This 
suggests that upon stimulation, not all 5-HT is buffered by synaptic receptors 
and transporters, but diffuses away into the extracellular medium (Bunin and 
Wightman, 1998). 
In contrast to extrasynaptic release, synaptic release occurs predominantly 
from SSVs. Apart from vesicular release of 5-HT, there is also evidence for non-
vesicular release of 5-HT using a carrier-mediated mechanism (Levi and Raiteri, 
1993). 
The ratio between volume transmission and synaptic transmission of 5-HT 
depends on the location in the brain. In the DRN itself, 5-HT release is 
predominantly paracrine, and here somatodendritic 5-HT release activates 5-
HT1A autoreceptors which are present at the somata and dendrites. These 
activated receptors activate a G protein-activated inwardly rectifying K+ (GIRK) 
current. In target areas of the 5-HT system, the ratio between volume 
transmission and synaptic transmission is still under debate. However, there are 
electron microscopy studies that quantified the percentage of 5-HT varicosities 
which formed a complex with a postsynaptic specialization. This revealed that 
~25%, 48% and 38% of 5-HT varicosities formed a synaptic complex in rat 
hippocampus, suprachiasmatic nuclei and supraoptic nuclei of the hypothalamus 
respectively (Oleskevich and Descarries, 1990; Boulaich et al., 1994). It is 
noteworthy that 5-HT is not released exclusively from 5-HT neurons. During 
development, thalamocortical fibers transiently express SERT, capture 5-HT and 
use it as a borrowed transmitter (Lebrand et al., 1996). In the striatum, 
dopamine transporters can take up 5-HT and subsequently co-release dopamine 
and 5-HT from dopaminergic terminals (Zhou et al., 2005a). 
 
5-HT has several effects on synaptic transmission 
 
5-HT not only functions to activate postsynaptic receptors, but also has diverse 
functions in the presynapse. Several studies were performed on invertebrates, 
such as crayfish, lamprey and aplysia. It was observed at the crayfish 
neuromuscular junction that a brief exposure to 5-HT resulted in increased 
release of glutamate (Dixon and Atwood, 1989a). Injection of a protein kinase A 
inhibitor or an adenylate cyclase inhibitor abolished this effect, suggesting that 
the facilitatory effect of 5-HT required the action of both the phosphatidylinositol 
and adenylate cyclase second messenger pathway (Dixon and Atwood, 1989b).  
In a study by Wang and colleagues, they made use of the styryl dye FM1-43, a 
fluorescent dye which is taken up by endocytosis following vesicle release, thus 
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specifically labeling recycled vesicles (Betz and Bewick, 1992). Using this 
approach, application of 5-HT at the crayfish neuromuscular junction did not 
affect the rate of recycling. Instead, 5-HT increased the number of vesicles which 
are available for release, the ready-releasable pool (RRP) of vesicles (Wang and 
Zucker, 1998).  
In contrast to this stimulatory effect in the crayfish neuromuscular junction, 
5-HT has an inhibitory action on synaptic transmission in the lamprey giant 
synapse (Buchanan and Grillner, 1991). This effect of 5-HT is likely mediated via 
G protein !" subunits, since injection of these subunits mimic the effect of 5-HT 
(Blackmer et al., 2001). Furthermore the presynaptic protein SNAP25 is involved 
in this effect, since injection of Botulinum toxin A, which cleaves SNAP25, 
abolished the effect of 5-HT (Gerachshenko et al., 2005). Again using FM-dyes it 
was demonstrated that the inhibitory effect of 5-HT on the lamprey giant 
synapse is mediated via a change in vesicle fusion properties since 5-HT seemed 
to prevent full fusion of vesicles (Photowala et al., 2006). 
In aplysia the effect of 5-HT on the gill-withdrawal reflex is well studied. In 
the 70’s it was shown for the first time that local application of 5-HT sensitized 
the gill-withdrawal reflex. This effect was also shown after application of cyclic 
adenosine monophosphate (cAMP), suggesting that this effect of 5-HT is 
mediated via an increase in cAMP (Brunelli et al., 1976). Both 5-HT and cAMP 
can close single potassium channels in aplysia sensory neurons, resulting in an 
increased transmitter release (Siegelbaum et al., 1982). This K+ channel, called 
the S (serotonin)-type K+ channel is modulated by 5-HT, cAMP and protein 
kinase A (PKA) (Shuster et al., 1985). Using calcium imaging on isolated 
synapses in culture, it was shown that 5-HT application results in a calcium 
influx in the terminal (Eliot et al., 1993). A brief single pulse of 5-HT resulted in 
short-term facilitation lasting minutes, whereas five subsequent pulses of 5-HT 
over 1.5 hours resulted in long-term facilitation lasting more than one day 
(Montarolo et al., 1986). 5-HT does not only affect release characteristics at 
single synapses, but upon application also activates silent presynaptic terminals. 
This results in the generation of new functional release sites within hours after 
application (Kim et al., 2003). This 5-HT-related growth of new synapses 
requires Cdc42, N-WASP and PAK (Udo et al., 2005).  
In summary, 5-HT affects synaptic transmission in several ways. In crayfish 
neuromuscular junctions, 5-HT increases synaptic transmission by increasing 
the size of the RRP of vesicles. In the lamprey giant synapse 5-HT inhibits 
transmission by affecting single vesicle release kinetics. Finally, in aplysia 
sensory neurons, application of 5-HT can induce both short term facilitation and 
long term facilitation via an increase in transmitter release and the formation of 
new functional release sites. 
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5-HT has a role during development in maturation of the brain. 
 
An increasing amount of evidence points towards a role of 5-HT in brain 
development and maturation. Additionally, several studies show that 5-HT has 
an important role during early embryogenesis. 5-HT is present at early stages in 
sea urchins, chick embryos and rodents (Emanuelsson et al., 1988; Buznikov, 
1991). Application of a 5-HT antagonist to sea urchin embryos significantly 
delayed cell division, implicating a role in the regulation of cell division (Renaud 
et al., 1983). In sea urchin blastulae, 5-HT, but also dopamine and noradrenaline 
stimulate ciliary activity. Application of these monoamines was associated with 
changes in intracellular calcium and adenylyl cyclase activity (Soliman, 1983). In 
the chick embryo, 5-HT is synthesized by the notochord (Wallace, 1982). 
Monoamine inhibitors cause malformation in the chick embryo such as neural 
tube defects. Exposure of mouse embryos to 5-HT resulted in craniofacial 
malformations and increased cell death in craniofacial and cardiac mesenchyme 
(Yavarone et al., 1993); (Shuey et al., 1993). Several studies in rodents used 
injections of either p-chlorophenylalanine (PCPA) to inhibit Tph or the 5-HT-
specific neurotoxin 5,7-dihydroxytryptamine. Injection of PCPA in mouse 
embryos from E12-E17 resulted in subtle alterations in pyramidal and non-
pyramidal neuronal populations (Vitalis et al., 2007). 5,7-dihydroxytryptamine 
was injected at the day of birth in mice embryos in the medial forebrain bundle. 
These injected mice had a decreased 5-HT innervation towards the cortex and 
hippocampus and male mice showed a decreased novelty-induced exploration, 
suggesting an anxiety-like phenotype (Hohmann et al., 2007).  
KO mice have shown to be a valuable tool in studying the role of the 5-HT 
system in development. KO mice for tryptophan hydroxylase 1 (Tph1), the rate 
limiting enzyme involved in periferic 5-HT synthesis, lack periferic 5-HT 
(Walther et al., 2003). Although these KO mice do not have an overt phenotype, 
approximately 80% of pups born from homozygous mothers are smaller and 
show developmental abnormalities compared to embryos born from 
heterozygous or wildtype mothers (Cote et al., 2007).  
This phenotype was only observed in Tph1 KO embryos born from Tph1 KO 
mothers, showing that maternal 5-HT is crucial for normal embryonic 
development. Tryptophan hydroxylase 2 (Tph2) is the Tph isoform that is 
exclusively expressed in the raphe nuclei (Gutknecht et al., 2009). Deletion of 
Tph2 does not result in an overt phenotype, nor does deletion of both Tph1 and 
Tph2, although in another study a reduced viability in these mice was observed 
(Savelieva et al., 2008; Alenina et al., 2009). Thus it appears that maternal 5-HT 
is indispensable for proper embryonic (brain) development, but 5-HT synthesis 
in the embryo is not.  
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5-HT as a neurotrophic factor 
 
In addition to the role of 5-HT in (early) neurodevelopment, 5-HT also functions 
as a neurotrophic factor. Application of 5-HT to buccal ganglion neuron 19 in 
helisoma caused a cessation in filopodial motility and an inhibition of neurite 
outgrowth (Haydon et al., 1984). Application of 5-HT results in a rise in 
intracellular calcium levels in the growth cone which probably links directly to 
the inhibition in outgrowth (McCobb et al., 1988). Application of 5-HT to 5-HT 
neurons also resulted in decreased outgrowth (Whitaker-Azmitia and Azmitia, 
1986). In contrast to this inhibitory effect of 5-HT on growth of 5-HT neurons, 5-
HT acts as a stimulatory signal on thalamic neurons which display more 
processes per cell and increased length of processes upon 5-HT administration 
(Lieske et al., 1999).  
 
Mouse models with an impaired 5-HT system 
 
Since the introduction of the knockout technique in mice, several genes of the 5-
HT system have been assessed for their effect on development and behaviour. 
The most important genes with striking effects on brain development or 
behaviour will be mentioned here. Mice lacking the MAO-A gene involved in the 
degradation of 5-HT to 5-hydroxyindolacetic acid (5-HIAA) display increased 
levels of 5-HT (Cases et al., 1996). These mice have a lack of barrels in the 
somatosensory cortex that is restored by application of PCPA, suggesting that 
this effect is due to excess levels of 5-HT (Cases et al., 1996). Additionally, mice 
lacking MAO-A display increased aggressive behaviour (Cases et al., 1995).  
On the contrary, deleting the Vesicular Monoamine Transporter 2 (VMAT2) 
which is necessary for 5-HT packaging in vesicles, results in mice with brain 5-
HT levels of ~1% compared to control (Wang et al., 1997; Fon et al., 1997). These 
KO mice are significantly smaller compared to wildtype littermates and the 
majority dies within a few days after birth. 5-HT fibers are almost completely 
absent in the cortex at that age. VMAT2 heterozygotes display prolonged 
immobility times in the forced swim test, suggesting depressive-like behaviour 
(Fukui et al., 2007). This behaviour was normalized by the antidepressant 
imipramine. 
Deletion of the SERT which is essential for 5-HT reuptake results in mice 
with increased extracellular 5-HT levels (Mathews et al., 2004). These mice have 
a reduced number of 5-HT neurons in the DRN, a reduced firing rate of these 
neurons and these mice display behavioural alterations (Lira et al., 2003). 
Notably, these behavioural effects were mimicked by applying the SERT blocker 
fluoxetine to young control mice between postnatal day 4 and 21 (Ansorge et al., 
2004).  
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In addition to these genes involved in 5-HT synthesis, packaging, breakdown or 
reuptake, several 5-HT receptor genes have also been ablated in mice (for an 
overview of 5-HT receptors see Box III). The 5-HT1A receptor acts as a 
heteroreceptor on non-5-HT neurons, but also as a 5-HT autoreceptor in the 
DRN. Mice with a deletion of the 5-HT1A receptor spent less time in the center of 
the open field in the open field test and avoid the open arms in the elevated plus 
maze, suggesting that these mice display an increased anxiety-related behaviour 
(Parks et al., 1998; Ramboz et al., 1998). A very elegant study demonstrated that 
this effect on behaviour in the 5-HT1A receptor KO occurs during development. In 
this study a second mouse line was made in which the expression of the 5-HT1A 
receptor could be restored specifically in the forebrain. Rescue of 5-HT1A receptor 
expression in the forebrain was sufficient to restore normal anxiety-related 
behaviour (Gross et al., 2002). In contrast, deletion of the 5-HT1A receptor 
during development and rescue of the receptor after postnatal day 21 did not 
restore normal anxiety-related behaviour (Gross et al., 2002). This clearly shows 
that the 5-HT1A receptor is required during development to establish normal 
anxiety-related behaviour. 
 
Box III   5-HT receptors 
 
At least 14 different 5-HT receptor subtypes are known which are divided into 6 
different groups. The first and largest group of 5-HT receptors is the 5-HT1 group 
consisting of the 1A, 1B, 1D, 1E, 1F and 1P receptors. All receptors in this group are 
coupled to G proteins, and activation results in a decrease in cAMP levels. The most 
important receptor of this group is the 5-HT1A  receptor, which is expressed in the 
raphe nuclei on 5-HT cell bodies and functions as a 5-HT autoreceptor. Binding of 5-
HT to the 5-HT1A  receptor results in activation of a GIRK channel which results in 
hyperpolarization of the 5-HT neuron; in this way, the 5-HT1A  receptor is involved in 
fine-tuning 5-HT release.  
To the 5-HT2 receptor group belong the 2A, 2B and 2C receptors. These receptors 
are also coupled to G proteins, and activation of these receptors results in an increase 
of inositol 3-phosphate (IP3). The 5-HT3 receptor is the only 5-HT receptor which is a 
(Na+/K+) ion channel. The 5-HT4  and 5-HT6,7 receptors are coupled to Gs proteins and 
activation results in an increase of cAMP. Finally, activation of the 5-HT5A,B receptor 
results in cAMP decrease. For the majority of these 5-HT receptors there are agonists 
and antagonists known. For example, the 5-HT1A  receptor is agonized by 8-OH-DPAT 
whereas it is antagonized by WAY-100635.  
 
Mice lacking the 5-HT1B receptor display an increased aggressive-related 
behaviour: they have a shorter latency to attack in the resident  intruder 
paradigm (Saudou et al., 1994). The 5-HT innervation is increased in the 
hippocampus and the amygdala of these mice, possibly contributing to the 
aggressive phenotype of these mice (Ase et al., 2001). Another receptor known to 
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be localized in the DRN is the 5-HT2C receptor (Clemett et al., 2000). This 
receptor is localized on GABA-ergic neurons and activation of this receptor 
results in a decreased firing of 5-HT neurons (Boothman et al., 2006). Mice that 
lack the 5-HT2C receptor are overweight and suffer from seizures (Tecott et al., 
1995). Moreover, studies have been performed to show that these mice display 
compulsive-like behaviour (Chou-Green et al., 2003). 
An additional study showed that 5-HT2C KO mice display decreased 
inhibition in the conflict anxiety paradigm (Weisstaub et al., 2006). This 
decreased inhibition was rescued by selective restoration of the 5-HT2C receptor 
in the cortex, suggesting that 5-HT2C receptors in the DRN are not involved in 
this effect (Weisstaub et al., 2006).  
Thus, 5-HT receptor KO mice do not exhibit overt developmental defects, 
but anxiety- or aggressive-related behaviour of these animals is affected as 
assessed in various behavioural paradigms.  
 
The 5-HT system in relation to psychopathological processes 
 
Anxiety & depression 
 
The notion that the 5-HT system could be involved in psychopathological 
conditions such as major depression and anxiety-related disorders came only 
after the discovery that drugs used to treat these conditions exerted their 
function (partially) via the 5-HT system. In the late 50’s, compounds such as 
iproniazide and G22355 (later named imipramine) were prescribed to patients 
suffering from tuberculosis. However, serendipitously it was found that these 
compounds were also effective in treating depression (Bloch et al., 1954; Kuhn, 
1958). Only several years after it was found that these drugs had an 
antidepressant response, the mode of action of these drugs was elucidated; 
iproniazide inhibited the degradation of mono-aminergic compounds (5-HT, 
noradrenaline and dopamine), whereas imipramine blocked the reuptake of 5-
HT and noradrenaline into the terminal. These findings led to the postulation of 
the monoamine hypothesis of depression in the late 60’s, which stated that a 
decreased concentration of 5-HT and noradrenaline in the extracellular space 
might be responsible for depression. It was poorly understood, however, why 
there was such a discrepancy between the immediate modes of action of these 
compounds in contrast to the delayed therapeutic effects. Also, it was not clear 
why only ~2/3 of all patients responded to these drugs.  
 These considerations abandoned the monoamine hypothesis and the so-
called network hypothesis of depression was postulated. This hypothesis states 
that depression results from an alteration in certain neuronal networks, and 
antidepressants restore these networks, which explains the time lag between 
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starting antidepressant administration and the onset of therapeutic actions. 
Evidence for this hypothesis, however, is still limited and mostly indirect. 
Human studies using functional magnetic resonance imaging (fMRI) or positron 
emission tomography (PET) imaging on patients suffering from major 
depression have shown volume reductions in cortex and hippocampus. Although 
farfetched, one could argue that this reflects a decreased network density.  
The last few years a new hypothesis was proposed, largely based on the work 
by Santarelli and colleagues: the neurogenesis hypothesis. It had already been 
shown that treatment with antidepressants increased adult neurogenesis in the 
dentate gyrus (Malberg et al., 2000; Perera et al., 2007). Santarelli and 
colleagues showed that blocking neurogenesis in the dentate gyrus by X-
irradiation blocked the behavioural effects of the antidepressant fluoxetine 
(Prozac) (Santarelli et al., 2003). In other words neurogenesis is required for the 
behavioural effects of antidepressants. However, several studies have shown that 
neurogenesis is not involved in the etiology of depression.  
Thus, although it is clear that there is a link between the 5-HT system and 
anxiety and depression, it is still far from clear what this exact link is.  
 
Aggression 
 
Aggressive behaviour is defined as violent and impulsive behaviour often 
resulting in breaking the law. 5-HT is one of the neurotransmitters which is 
implicated in the etiology of aggression. A mutation in the MAO-A gene caused 
aggression-related abnormal behaviour (impulsive aggression, arson, attempted 
rape, and exhibitionism) in five males of a large kindred (Brunner et al., 1993). 
Several studies have shown a reduced concentration of the 5-HT metabolite 5-
HIAA in cerebrospinal fluid (CSF) of individuals suffering from aggressive 
behaviour (Asberg et al., 1976; Coccaro et al., 1997). In rhesus monkeys, there 
was a negative relation found between high aggression and CSF 5-HIAA levels 
(Higley et al., 1992). A number of studies implicate the 5-HT2 receptor subtypes 
in aggressive behaviour. A study by Winstanley and colleagues showed that 5-HT 
depletion increased the number of premature responses in the 5-choice serial 
reaction time task in rats (Winstanley et al., 2004). Also, in this study it was 
found that application of a 5-HT2A antagonist decreased impulsive behaviour, 
whereas application of a 5-HT2C antagonist had the opposite effect (Winstanley 
et al., 2004). A clinical study showed that antipsychotic drugs which had anti-
aggressive properties were 5-HT2A antagonists (Krakowski et al., 2006). PET 
imaging studies show an increased 5-HT2A receptor binding in aggressive 
patients or in borderline personality disorder patients (Siever et al., 2002; Soloff 
et al., 2007). These abovementioned studies indicate increased 5-HT2A receptor 
sensitivity in aggressive behaviour patients.  
22
Autism 
 
Autism is a behavioural disorder with unknown etiology, although impaired 
brain development may underlie this disorder. The link between autism and 5-
HT was made after the discovery that autistic patients had elevated platelet 5-HT 
levels (Boullin et al., 1970; Ritvo et al., 1970). Additionally, depletion of the 5-HT 
precursor tryptophan resulted in a deterioration in autistic patients (McDougle 
et al., 1993). Chugani and colleagues used alpha-[11C]methyl-L-tryptophan as a 
tracer for PET to measure 5-HT synthesis. They showed that in autistic boys 
there is a decreased 5-HT synthesis in frontal cortex, thalamus, and dentate 
nucleus of the cerebellum, although there is an increased 5-HT synthesis in the 
contralateral dentate nucleus (Chugani et al., 1997).  Possibly increased levels of 
5-HT during early brain development result in the loss of 5-HT terminals which 
could explain why several drugs which show great efficacy in treating autism 
enhance 5-HT neurotransmission (Brodkin et al., 1997; Fatemi et al., 1998). 
More evidence for this hypothesis is the fact that prenatal exposure to cocaine, 
which is a releaser of 5-HT, is a risk factor for developing autism (Davis et al., 
1992). Furthermore, several studies using the 5-HT agonist 5-
methoxytryptamine during development in rodents show that this results in 
autistic-like behaviour (Winslow and Insel, 1990; Kahne et al., 2002). 
 
Polymorphisms in genes involved in the 5-HT system  
 
SERT 
 
In several genes involved in the 5-HT system, polymorphisms and short 
nucleotide polymorphisms (SNPs) have been found. An example of a gene in 
which polymorphisms have been found which correlates with psychopathological 
processes is SERT. Soon after the cloning of the human SERT, several 
polymorphisms have been found (Furlong et al., 1998; Battersby et al., 1999). 
These include two SNPs in the promoter region, a variable number of tandem 
repeats polymorphism in intron 2, and rare Ile-425-Val and Pro-339-Leu SNPs 
which affects function and surface expression (Kilic et al., 2003; Prasad et al., 
2005). One polymorphism has been found in the promoter region. This 
polymorphism, a 44 bp insertion has been called the 5-HTT gene-linked 
polymorphic region, 5-HTTLPR. The two polymorphisms, called the short (s) 
and long (l) variant have been shown to modulate SERT transcriptional activity 
(Lesch et al., 1996). In a luciferase assay in human placental choriocarcinoma 
cells it was shown that the l variant has approximately a threefold higher 
transcriptional activity compared to the s variant (Heils et al., 1996). 
Additionally, cells expressing the l/l variant of the SERT displayed a twofold 
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higher uptake rate of 5-HT compared to cells expressing the s/s variant. In 
human postmortem brain material, reduced mRNA concentrations of SERT were 
found in the raphe nuclei from subjects having the s/s variant of the SERT 
promoter polymorphism. This shows that both in vitro and in vivo, the s/s 
variant is associated with a decreased SERT expression and reduced 5-HT 
reuptake (Little et al., 1998). 
In 1996, the first study was published which demonstrated a link between 
the SERT promoter polymorphism and anxiety, aggression and depression traits 
(Lesch et al., 1996). Since then, several studies have demonstrated a link between 
the s/s promoter variant and aggression, anxiety and depression. Moreover, 
several studies show that individuals carrying the s/s variant have a poorer 
response to antidepressant treatment than individuals carrying the l/l or l/s 
variant (Smeraldi et al., 1998; Zanardi et al., 2000).  
  
MAO-A  
 
MAO is involved in the degradation of 5-HT to 5-HIAA, and there are 2 isoforms 
encoded by different genes, MAO-A and MAO-B. MAO-A has a higher affinity for 
5-HT than MAO-B. These genes are both localized on the X chromosome (Lan et 
al., 1989). In humans a point mutation in the MAO-A gene has been found in the 
8th exon, resulting in a truncated MAO-A protein. The family in which the point 
mutation was identified suffered from abnormal behaviour including disturbed 
regulation of impulsive aggressiveness (Brunner et al., 1993). In the promoter 
region of MAO-A a 30 bp repeat polymorphism was found. The low-activity 3-
repeat allele was associated with antisocial behaviour in a German population 
(Samochowiec et al., 1999). In the rhesus macaque, a repeat polymorphism in 
the promoter affected transcription of the MAO-A gene and was associated with 
aggressive behaviour (Newman et al., 2005).  
 
Tph2 
 
Tph1 and Tph2 are the rate limiting enzymes for 5-HT synthesis. Tph1 is 
expressed in the enterochromaffin cells in the gut and in the pineal gland, 
whereas Tph2 is the neuronal form and exclusively expressed in the raphe nuclei 
(Patel et al., 2004; Zill et al., 2004a). In Tph2 a C1473G mutation, resulting in a 
Pro-447-Arg substitution results in a reduction in 5-HT synthesis. BALB/cJ 
mice, which are homozygous for the 1473G mutation, have a 50 to 70% reduction 
in 5-HT synthesis in the frontal cortex resulting in ~40% reduction in 5-HT 
content in the frontal cortex (Zhang et al., 2004). In the human Tph2 gene, a 
G1463A SNP resulting in a Arg441His replacement was identified which, when 
transfected in PC12 cells, resulted in a ~80% loss of function in 5-HT synthesis 
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(Zhang et al., 2005). In a cohort of 87 patients suffering from major depression, 
9 were found to carry this SNP, while among 219 controls, only 3 subjects had 
this SNP (Zhang et al., 2005). Knockin mice carrying this human mutation 
displayed behavioural abnormalities (Beaulieu et al., 2008). In contrast to SNPs 
found in exons, also SNPs in introns of the Tph2 gene have been found. In intron 
5, a SNP has been found which was associated with major depression and suicide 
(Zill et al., 2004b; Harvey et al., 2004).   
As in the SERT promoter, also in the Tph2 promoter polymorphisms have 
been found. One of these polymorphisms, rs4570625, has been associated with 
increased amygdala reactivity to emotional stimuli (Canli et al., 2005). Two 
polymorphisms, rs4570625 and rs11178997, were linked to anxiety disorder and 
major depression (Zhou et al., 2005b). As shown by a luciferase assay in 5-HT 
neurons, the polymorphism rs11178997 significantly reduced Tph2 
transcriptional activity by 22% (Scheuch et al., 2007).  
 
Conclusions 
 
5-HT is a transmitter that has several modes of action in the central nervous 
system. First of all, 5-HT has a role during brain development and maturation. 
Secondly, due to the volume transmission, 5-HT can influence several aspects of 
behaviour, depending on the receptor(s) to which 5-HT binds. 5-HT can also 
regulate synaptic transmission. KO mice for the 5-HT1A, 5-HT1B or SERT gene 
display altered anxiety-related, depression-related and aggression-related 
behaviour. Finally, polymorphisms in several genes functioning in the 5-HT 
system are implicated in depression, anxiety, aggression and autism.  
 
Aim and outline of this thesis 
 
In this thesis the outgrowth and connectivity of the brain 5-HT system is studied. 
To study these aspects we used a number of different approaches. First of all, we 
used organotypic slice cultures to study the outgrowth of the 5-HT system in 
vitro. Secondly, we used neuronal cultures to study trafficking of two 
components of the 5-HT system, SERT and Tph2. Thirdly, we investigated 
whether a SNP in a presynaptic gene which associates with major depressive 
disorder, affects trafficking of the SERT. Fourthly, we used a genetic approach in 
mice to study the effect of a silenced 5-HT system on mouse development. 
Finally, we describe our approach to generate a mouse model in which the 5-HT 
system is labeled with fluorescent reporter genes to study the outgrowth and 
connectivity in vivo. 
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In chapter 2, we used organotypic slice cocultures of the dorsal raphe 
nucleus and the hippocampus as a target area. We have used this model system 
to study the outgrowth of the 5-HT system in vitro. Moreover, we investigated 
whether this system could be used to assess the effect of pharmacological 
manipulations on the outgrowth of the 5-HT system.   
In chapter 3, we tagged SERT with the red fluorescent protein mCherry, 
and expressed this protein in hippocampal neurons to investigate the trafficking 
dynamics of SERT. 
In chapter 4, we tagged Tph2 with EGFP and took the same approach as in 
chapter 3 to investigate the subcellular distribution and trafficking of Tph2 in 
neurons. 
In chapter 5, we studied whether knockdown of the presynaptic gene 
Piccolo affects SERT trafficking and incorporation into the membrane. A SNP in 
the C2A domain of this protein was found which associated with major 
depressive disorder. We expressed these two variants and investigated whether 
there is a difference in SERT localization. Also, we investigated whether 
knockdown of Piccolo affects SERT trafficking.  
In chapter 6, we used a genetic approach to silence the 5-HT system. We 
crossed floxed Munc18-1 mice with mice expressing Cre recombinase in SERT 
expressing neurons, which include 5-HT neurons. We used these mice to study 
the effect of Munc18-1 removal in 5-HT neurons on the development of the 5-HT 
system and viability. We used heterozygous Munc18-1wt/lox mice to study whether 
deletion of one allele of Munc18-1 in the 5-HT system affects mouse behaviour. 
In chapter 7, we describe an approach to specifically label 5-HT neurons 
and projections with fluorescent markers which could eventually be used to 
study 5-HT outgrowth and connectivity in vivo. 
Finally, in chapter 8, the main findings of this thesis will be summarized, 
discussed and future directions are suggested. 
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Abstract 
 
The serotonin system densely innervates the brain and is implicated in 
psychopathological processes. Here we studied the effect of serotonin and 
serotonin pharmacological compounds on the outgrowth of serotonergic 
projections using organotypic slice co-cultures of hippocampus and dorsal raphe 
nuclei. Immunohistochemical analysis showed that several serotonergic neurites 
had grown into the target slice within 7 days in culture, after which the neurite 
density stabilized. These projections expressed the serotonin-synthesizing 
enzyme tryptophan hydroxylase and the serotonin transporter and contained 
several serotonin positive varicosities that also accumulated presynaptic 
markers. Chronic application of a 5-HT2 agonist reduced the serotonergic neurite 
density, without effects on survival of serotonergic neurons. In contrast, 
application of a 5-HT1A agonist or the serotonin transporter inhibitor fluoxetine 
did not affect serotonergic neurite density. We conclude that serotonergic 
connectivity was reproduced in vitro and that the serotonin neurite density is 
inhibited by chronic activation of the 5-HT2 receptor. 
 
Introduction 
 
The serotonin (5-hydroxytryptamine (5-HT)) system has its cell bodies clustered 
in the midbrain raphe nuclei and sends abundant projections to virtually every 
brain area (Hornung, 2003; Rubenstein, 1998). The 5-HT system influences a 
wide variety of physiological processes, such as sleep-wake rhythm, feeding, 
sexual behaviour and nociception (Jacobs and Azmitia, 1992). Moreover, the 5-
HT system is implicated in several psychopathological processes, such as anxiety, 
aggression, obsessive compulsive disorder and depression (Castren, 2005).   
During brain development, the 5-HT neurons are one of the first groups of 
cells expressing a specific neurotransmitter (Lauder, 1990; Gaspar et al., 2003). 
Accumulating evidence shows that alterations in brain 5-HT levels during 
development could result in alterations in brain development and behavioural 
alterations. 5-HT reuptake transporter (SERT) knockout (KO) mice have an 
increase in extra neuronal 5-HT but a reduction in overall brain 5-HT levels 
(Bengel et al., 1998; Mathews et al., 2004). They exhibit behavioural alterations, 
reduced number of 5-HT neurons in the dorsal raphe nuclei (DRN) and reduced 
firing of 5-HT neurons in the DRN (Lira et al., 2003). These behavioural 
alterations observed in SERT KO mice can be mimicked by application of the 
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SERT inhibitor fluoxetine during development between postnatal day 4 and 21 
(Ansorge et al., 2004).  
In contrast to reduction in brain 5-HT content after disruption of the SERT 
gene, there is a significant increase in brain 5-HT levels after inactivation of the 
Monoamine Oxidase-A (MAO-A) gene (Cases et al., 1996). The chronic elevation 
of 5-HT levels during brain development results in lack of barrels in the barrel 
cortex (Cases et al., 1996). These data suggest that either reductions in brain 5-
HT levels or excess 5-HT levels during a critical period in the development of the 
brain can lead to abnormalities in brain development and behavioural 
alterations. In vitro experiments have shown that 5-HT can inhibit the outgrowth 
of neurites or even cause growth cone collapse on 5-HT neurons (Haydon et al., 
1984; Koert et al., 2001). Whether alterations in brain 5-HT levels during 
development of the brain result in alterations in 5-HT outgrowth, branching or 
connectivity, or whether the behavioural alterations observed are a result of 
alterations in the 5-HT outgrowth and connectivity is currently unknown. 
Organotypic slice cultures of the DRN and a target slice could be a valuable 
reduced model system to study 5-HT outgrowth in vitro. 
Therefore the aim of this study was to investigate whether organotypic slice 
co-cultures of DRN and hippocampus, a method that has previously been 
characterized, can be used to study 5-HT outgrowth and the effect of 
pharmacological manipulations in vitro (Papp et al., 1995; Guthrie et al., 2005). 
We show that within seven days of culturing several 5-HT neurites have grown 
into the hippocampal slice. Using these slice co-cultures, we studied whether 
chronic application of 5-HT pharmacological compounds affects the outgrowth 
of 5-HT neurites from the DRN. To this end we used a 5-HT1A receptor agonist, a 
5-HT2 receptor agonist and the SERT inhibitor fluoxetine since it has been 
shown before, also on non-5-HT cells, that (chronic) activation of a 5-HT1A or 5-
HT2 receptor or blockade of the SERT can affect (5-HT) outgrowth or 
synaptogenesis (Wilson et al., 1998; Kondoh et al., 2004; Fricker et al., 2005; 
Zhou et al., 2006). We show here that chronic application of a 5-HT2 agonist 
results in a reduction in 5-HT neurite density. We conclude that these 
organotypic slice co-cultures can be used to study 5-HT outgrowth and the effect 
of 5-HT pharmacological compounds on this outgrowth in vitro. 
 
Results 
 
Development and outgrowth of 5-HT neurons in organotypic slice co-cultures 
To study the outgrowth of 5-HT neurites ex vivo, we used organotypic slice co-
cultures of the DRN and a hippocampal slice. We positioned the slices close to 
each other to allow 5-HT neurites to grow into the hippocampal slice. Within 
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seven days of culturing the slices flattened out and several non-neuronal cells 
migrated away from the slices (Fig. 1). 
 
 
 
We performed immunohistochemistry for 5-HT to investigate whether 5-HT 
neurons survived in the slices. This showed that in several DRN slices 5-HT 
neurons were present, which resembled the topology of 5-HT neurons in the 
DRN in vivo (Fig. 2A). However, there were also DRN slices which contained 
only few 5-HT neurons, possibly resulting from a variation in the dissection of 
the DRN slice. A Z-stack of 5-HT cell somata showed that these cells have several 
primary neurites which contain numerous varicosities (Fig. 2B). In the growth 
cones of 5-HT neurites, 5-HT was also detected (Fig. 2C). Next, we focussed on 
the expression of tryptophan hydroxylase (Tph) and SERT, two markers for the 
5-HT system. In 5-HT immunopositive cell bodies and in the 5-HT neurites and 
varicosities Tph was expressed (Fig. 2D,E). We found that all the 5-HT neurites 
were positive for SERT labelling, with the highest level of SERT staining on the 
soma and in the 5-HT varicosities (Fig. 2F,G). Moreover, SERT was also 
expressed in a punctate pattern in the 5-HT growth cones. (Fig. 2H). In vivo, 5-
HT is released from varicosities in 5-HT axons and dendrites and 5-HT release is 
predominantly paracrine (Bunin and Wightman, 1999). In the slices, the 5-HT 
neurites contain several round and fusiform shaped varicosities (Fig. 3A,B).  
 
 
 
 
Figure 1. Overview of the 
culturing method 
The DRN and hippocampal 
slice were positioned close to 
each other to allow 5-HT 
neurites to grow into the 
hippocampal slice. After 
culturing for 7 days, the 
slices flatten and several cells 
(e.g. macrophages) migrate 
away from the slices. Scale 
bar: 500 #m.  
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Figure 2. 5-HT neurons survive in the slice and grow out several 5-HT 
neurites 
(A) A DRN slice cultured for 7 days which is stained for 5-HT shows that several 5-HT cells 
are present in the slice. Note the presence of the lateral wings of the DRN (arrows) and the 
group of 5-HT neurons in the ventral part of the DRN (arrowhead). (B) A Z stack of two 
cells shows that the cells project several neurites that are 5-HT positive. (C) The growth 
cones also contain 5-HT, both in the core (arrowhead) and in the filopodia (arrows). (D,E) 
Staining for the rate limiting enzyme Tph shows that Tph is present both in the cell bodies 
and in the varicosities in the neurites. (F,G) The other marker for the 5-HT system, SERT, 
is present in 5-HT cell bodies and 5-HT neurites. (H) Moreover, there is also a punctate 
SERT staining in 5-HT growth cones, both in the core (arrowhead) and in the filopodia 
(arrows). Scale bars: 200 #m in A, 50 #m in B and D, 20 #m in F and G, 5 #m in C and E, 2 
#m in H. 
 
Immunohistochemistry revealed that in these varicosities the calcium sensor 
Synaptotagmin and the active zone marker Bassoon are present, suggesting that 
the varicosities are presynaptic sites where calcium dependent 5-HT release 
occurs (Fig. 3C,D) (Perin et al., 1991; tom Dieck et al., 1998). This showed that in 
organotypic slice co-cultures of DRN and hippocampus 5-HT neurons survive 
and grow out neurites that contain 5-HT varicosities with immunoreactivity for 
all tested components of the 5-HT release machinery. 
 
Dense ingrowth of 5-HT neurites into hippocampal slices 
To study the outgrowth, we fixed slice cultures at different time points and 
quantified the 5-HT outgrowth. To this end the images were converted to binary 
images and the 5-HT neurite density in the slices was quantified (Fig. 4A-C). 
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Figure 3. 5-HT neurites contain several varicosities which are positive for 
presynaptic markers 
(A) A Z-stack in the hippocampal slice shows that several thin, highly branching 5-HT 
neurites have grown into the slice. (B) A blow-up of the red box in A shows that these 
neurites contain several varicosities.  (C,D) These varicosities are positive for the protein 
involved in calcium dependent secretion, Synaptotagmin (Syt), and for the active zone 
marker Bassoon. Scale bars: 50 !m in A, 10 !m in B and D and 2 !m in C. 
 
We quantified the 5-HT neurite density as the area in the slice occupied by 5-HT 
neurites compared to the total area of the slice. Immunohistochemistry for 5-HT 
on hippocampal slices cultured without the DRN for seven days revealed that 
there were no 5-HT neurites present (Fig. 4E). Thus, 5-HT neurites observed in 
the hippocampal slice in co-cultures are the result of re-growth of 5-HT neurites 
from the DRN slice. In co-cultures fixed at four days in vitro (DIV) we observed 
that the DRN slice already contained several 5-HT neurites, and the first 5-HT 
neurites started to grow into the hippocampal slice (Fig. 4F,I). At DIV7, also the 
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hippocampal slice contained several 5-HT neurites (Fig. 4G,J). Quantification of 
the 5-HT neurite density in the slices at DIV14 and DIV21 revealed that this was 
not significantly different from DIV7 (Fig. 4D,H; DIV7 DRN 8.42 ± 0.8%, HIP 
6.31 ± 0.84% n=16; DIV14 DRN 9.49 ± 1.42%, HIP 5.12 ± 0.9% n=12; DIV21 
DRN 9.26 ± 1.16%, HIP 6.61 ± 1.43% n=4). We investigated whether there is 
regional variation in the 5-HT neurite distribution in the hippocampus. At DIV4 
the first 5-HT neurites which start growing into the hippocampal slice do not 
appear to display a preference for a certain region. (Fig. 4K). At DIV7, 5-HT 
neurites have grown in a uniform distribution into the hippocampus, and there 
are no regions which contain a higher density of 5-HT neurites than other 
regions (Fig. 4L). Thus, the initial outgrowth of the 5-HT neurites occurs in the 
first 7 days, after which the network stabilizes and the homogenous distribution 
suggests that 5-HT neurites do not have any preferential target region within the 
hippocampal slice in vitro. 
 
The effect of 5-HT pharmacological compounds on the outgrowth of 5-HT 
projections 
Finally, we studied whether this culture model system can be used to study the 
effect of chronic application of 5-HT pharmacological compounds on the 
outgrowth of 5-HT neurites. There are several 5-HT receptors which are 
expressed in both the DRN and the hippocampus.  
 
 
Figure 4 next page. Dense ingrowth of 5-HT neurites into hippocampal slices 
within seven days of culturing 
An original image of a hippocampal slice co-cultured with a DRN slice shows that there is 
abundant ingrowth of 5-HT neurites, but there is also a lot of red background staining. (B) 
When this image is converted to a binary image using the steps described in experimental 
procedures, the 5-HT neurites are positively labelled (black), whereas the background is 
removed (white).  (C) A blow up of part of the binary image shows that all 5-HT neurites 
are detected, and the red background is removed. (D) Quantification of the 5-HT neurite 
density (Y-axis) in the DRN and hippocampal slices at DIV7, DIV14 and DIV21. (E) A 
hippocampal slice cultured without the DRN contains only background staining, and no 5-
HT neurites. (F,I)  Maximal 5-HT ingrowth of the slices is reached in the first seven days of 
culturing. At DIV4, the DRN slice already contains several 5-HT neurites, and the first 5-
HT neurites start to grow into the hippocampal slice. (G,J) At DIV7, both the DRN and 
hippocampal slice contain abundant 5-HT neurites. (H) At DIV21 the 5-HT neurite density 
in the slices has not changed. (K,L) No regional variation in 5-HT neurite density in the 
hippocampal slice at DIV4 (K) and DIV7 (L). Figures I and J are a blow up of the black box 
in F and G respectively. Figures K and L are blow ups of the hippocampal slices in figure F 
and G respectively. Scale bars: 500 !m in A, B, E, F, G, H, I, J, K and L, 20 !m in C. 
43
 
 
These include the 5-HT1A receptor, the 5-HT2 receptor and the 5-HT7 receptor 
(Gustafson et al., 1996; Clemett et al., 2000; Xu and Pandey, 2000; Bickmeyer et 
al., 2002; Garcia-Alcocer et al., 2006). Since it has been shown before, also on 
non-5-HT cells, that (chronic) activation of a 5-HT1A or 5-HT2 receptor or 
blockade of the SERT can affect (5-HT-ergic) outgrowth or synaptogenesis, we 
decided to use a 5-HT1A receptor agonist 8-hydroxy-2-(di-n-
propylamino)tetraline (8-OH-DPAT), a 5-HT2 receptor agonist (+-)-2,5-
dimethoxy-4-iodoamphetamine hydrochloride (DOI hydrochloride) and the 
SERT inhibitor fluoxetine (Wilson et al., 1998; Kondoh et al., 2004; Fricker et al., 
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2005; Zhou et al., 2006). We chronically applied the pharmacological 
compounds in 10 µM concentrations during the first seven days of outgrowth. 
First of all, we studied the effect of chronic blockade of the SERT by fluoxetine. 
Fluoxetine did not affect 5-HT neurite density (Fluoxetine: DRN: 8.44 ± 0.72%, 
HIP: 6.12 ± 1.12% n=10) compared to control condition (Fig. 5A,B,E,F). 
Subsequently, we tested the effect of chronically activating the 5-HT1A and 5-HT2 
receptor, two receptors which are present on 5-HT neurons. Moreover, it has 
been shown previously that activation of these receptors can affect outgrowth of 
Purkinje cells (Kondoh et al., 2004). First we investigated the effect of the 5-HT1A 
receptor agonist 8-OH-DPAT. Activation of the autoreceptor by 5-HT or an 
agonist results in a reduction in 5-HT release (Quick, 2003). However, 8-OH-
DPAT did not affect 5-HT neurite density (DRN 10.67 ± 0.79%, HIP 7.21 ± 0.9% 
n=9) (Fig. 5 C,E,F).  
 
 
 
Figure 5. Chronic application of a 5-HT2 agonist reduces 5-HT neurite density 
in the slices 
(A) In control condition, after seven days of culturing several 5-HT neurites have grown 
into the slices. (B) Chronic blockade of the SERT with the SERT inhibitor fluoxetine did 
not affect 5-HT neurite density in the slices. (C) Chronic activation of the 5-HT1A receptor 
with 8-OH-DPAT also did not affect 5-HT neurite density in the slices. (D) However, 
chronic activation of the 5-HT2 receptor with DOI significantly reduced 5-HT neurite 
density both in the DRN and hippocampal slice. (E,F) Quantification of 5-HT neurite 
density in the DRN slice and hippocampal slice, respectively. Scale bar: 500 !m. * p< 0.05, 
** p<0.01, *** p<0.001. 
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Next, we investigated the effect of chronic 5-HT2 receptor activation. Activation 
of the 5-HT2 receptor results in an increased protein kinase C activity and release 
of calcium from internal stores. We chronically activated the 5-HT2 receptor by 
applying the 5-HT2 receptor agonist DOI hydrochloride. Chronic application of 
the 5-HT2 receptor agonist DOI hydrochloride resulted in a significantly 
decreased 5-HT neurite density (Fig. 5 D,E,F) (DRN 2.94 ± 1.01%, HIP 2.29 ± 
1.05% n=5).  To exclude the possibility that pharmacological treatment affected 
the survival of 5-HT neurons, we counted the number of 5-HT cells per group. 
This showed that treatment with fluoxetine, 8-OH-DPAT or DOI hydrochloride 
did not affect the number of 5-HT neurons in the slices (data not shown). Hence, 
changes in viability of 5-HT neurons cannot explain the effect of DOI 
hydrochloride. We conclude that these organotypic slice co-cultures can be used 
to study the 5-HT outgrowth and ingrowth into a target area in vitro and that 
chronic activation of the 5-HT2 receptor results in a decreased 5-HT neurite 
density.  
 
Discussion 
 
An organotypic co-culture model system to study 5-HT outgrowth ex vivo 
We used organotypic slice co-cultures to study the outgrowth of the 5-HT system 
ex vivo. Neurite projections of 5-HT neurons grew into the slices and at 7 days a 
dense network had formed with many serotonergic boutons that had 
accumulated presynaptic markers. The regional differences in 5-HT innervation 
observed in the hippocampus in vivo were not reproduced ex vivo and it has been 
observed that fewer synapses form in slices than in vivo (see discussion in (Papp 
et al., 1995). However, also in vivo the majority of the 5-HT release sites (70-
80%, (Oleskevich and Descarries, 1990), are not classical synapses, i.e. with a 
juxtaposed postsynaptic specialization. Hence, the in vivo connectivity of the 5-
HT system appears to depend largely on non-synaptic release. Therefore, despite 
some discrepancies compared to the in vivo situation, the slice co-culture system 
is an excellent, reduced model system to unravel the basic principles that 
orchestrate 5-HT neurite outgrowth and connectivity. Such a reduced system is a 
valuable supplementation of in vivo studies, which are often complicated by the 
exceptionally complex and dynamic connectivity of the 5-HT system, with for 
instance large fluctuations in innervation over the course of a few days (transient 
hyper-innervation, see (Fujimiya et al., 1986; D'Amato et al., 1987).  
  
Chronic activation of the 5-HT2 receptor decreased 5-HT neurite density 
We found that chronic application of a 5-HT2 agonist decreased the neurite 
density of 5-HT neurites. Since DOI hydrochloride treatment did not affect 5-HT 
neuron survival, 5-HT mediated cytotoxicity cannot explain the decrease in 5-HT 
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neurite density. Hence, the decreased neurite density appears to be the result of 
a specific effect of the activation of the 5-HT2 receptor on the neurites (decreased 
outgrowth/increased pruning). In contrast, chronic activation of the 5-HT1A 
receptor did not mimic the effects of 5-HT, although the 5-HT1A receptor has 
often been implicated in shaping 5-HT connectivity (Gross et al., 2000; Gross et 
al., 2002). Activation of somatotodendritic 5-HT1A receptors results in 
hyperpolarisation and a decrease in 5-HT release (Quick, 2003). However, 
chronic activation results in rapid desensitization  (Assie et al., 2006) which may 
explain why we do not observe an effect of chronic 5-HT1A receptor activation. On 
the other hand, 5-HT2 receptor activation increases intracellular calcium and 
activates protein kinase C (Tamir et al., 1992). This suggests that (chronic) 
activation of the 5-HT2 receptor affects outgrowth, since elevation of calcium 
levels in growth cones reduces outgrowth (Gomez and Spitzer, 1999). Since DOI 
hydrochloride has a comparable affinity for the 5-HT2A and 5-HT2C receptor 
subtype, based on these data we cannot conclude which of the two subtypes is 
involved in the effect of DOI hydrochloride.  
However, although the 5-HT2A receptor is widely expressed throughout the 
brain, the receptor seems not to be expressed in the DRN (Xu and Pandey, 
2000). In contrast, the 5-HT2C receptor is present in the DRN (Clemett et al., 
2000; Serrats et al., 2005). Moreover, it has been shown previously, that 
activation of the 5-HT2C receptor in the DRN results in a reduction in 5-HT 
neuron firing (Boothman et al., 2006). Therefore, based on the anatomical 
distribution we speculate that the effect of DOI hydrochloride is predominantly 
mediated via the 5-HT2C receptor. Fluoxetine did not affect 5-HT neurite density. 
It could be expected that fluoxetine application mimics a 5-HT1A receptor 
agonist, i.e. SERT blockade results in an increase in extracellular 5-HT which 
could activate 5-HT1A autoreceptors. However, possibly upon application of 
fluoxetine extracellular 5-HT is rapidly diluted in the culture medium in vitro, 
and therefore extracellular 5-HT will not reach high enough concentration levels 
to mimic the effect of a 5-HT1A receptor agonist. Also chronic fluoxetine 
treatment in vivo failed to produce effects similar to chronic 5-HT application 
(Zhou et al., 2006). In fact, chronic fluoxetine enhanced neurite density in this 
case (Zhou et al., 2006).  
 
Conclusions 
 
We have shown here that in DRN – hippocampus organotypic slice co-cultures 5-
HT projections grow into the target slice. After four days of culturing in the DRN 
slice already several 5-HT projections were present, and the first 5-HT 
projections started to grow into the target slice. Within seven days of culturing 
also the target slice contained several 5-HT neurites. These 5-HT neurites, 
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contained several varicosities, which are presumably sites of 5-HT release, since 
presynaptic markers were present in these varicosities. Finally, we have shown 
that this culture model system can be used to study the effect of pharmacological 
manipulations on the outgrowth of 5-HT neurites, and that application of a 5-
HT2 agonist results in a reduction in 5-HT neurite density in the slices. 
 
EXPERIMENTAL PROCEDURES 
 
Laboratory animals 
Wildtype C57BL/6 mouse fetuses were obtained from caesarean section at 
embryonic day 18 or postnatal day 1. Animals were housed and bred according to 
institutional, Dutch and U.S. governmental guidelines. 
 
Pharmacological compounds and antibodies 
Mouse monoclonal anti-Tph antibody, which detects both Tph1 and Tph2, was 
obtained from Sigma-Aldrich and used in a 1:1000 dilution. Rabbit anti 5-HT 
polyclonal and mouse anti-SERT monoclonal were obtained from 
Immunostar/Diasorin and used in a 1:1000 dilution. Bassoon and 
Synaptotagmin monoclonal antibodies were used in a 1:500 and 1:1000 dilutions 
respectively and obtained from Stressgen. As secondary antibodies Alexa593-
conjugated goat anti rabbit and Alexa488-conjugated goat anti mouse were used 
in a 1:1000 dilution (Molecular probes). 8-OH-DPAT and DOI hydrochloride 
were obtained from Sigma-Aldrich. Fluoxetine was obtained from Tocris. 
 
Organotypic slice co-cultures 
Organotypic slice cultures were made as follows. After decapitation of the 
fetuses, the heads were immediately transferred to ice-cold dissection Gey’s 
balanced salt solution (dGBSS, Invitrogen, supplemented with 0.65 g/l glucose 
and 200 #M kynurenic acid). For isolation of a DRN slice, the brains were 
dissected in dGBSS and the midbrain cut into 400 #m thick slices using a 
McIlwain tissue chopper (Mickle Engineering, Gomshall, UK). Individual slices 
were separated in dGBSS and the hindbrain slice containing the rostral DRN was 
identified by visual inspection. The DRN was dissected out using a dissection 
knife. The entire hippocampus was dissected out of the brain and individual 
slices (400 #m) were sagitally cut perpendicular to the hippocampus’ 
longitudinal axis. The hippocampal and DRN slices were allowed to recuperate in 
dGBSS at 4ûC for 60 minutes. A hippocampal and DRN slice were cultured in 
close proximity on a poly-D-lysine coated 12x24 glass coverslip (O. Kindler 
GmbH & Co. Mikroskopische Gläser, Freiburg, Germany) in a plasma clot 
(chicken plasma, Cocalico Biologicals Inc. Reamstown, U.S.) which was 
coagulated with thrombin (Merck, Darmstadt, Germany). Culturing medium 
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consisted of 50% BME Hanks, 25% Hanks balanced salt solution and 25% horse 
serum supplemented with 1.3 g/l glucose and 200 #M glutamine. For culturing 
700 #l of culturing medium was added to the slices in a Nunc flat-bottomed tube. 
The slices were incubated in a roller drum at 36ûC. After the first week, medium 
was changed twice a week. 
 
Pharmacological treatments 
All pharmacological compounds were dissolved in ddH2O, filter sterilized and 
aliquots stored at -80ûC. After DIV1 10 #M of the pharmacological compound 
was added to the slices. Every day a new aliquot of pharmacological compound 
was added to the slices. In control slices only vehicle was added (sterile ddH2O). 
At DIV7 the slices were fixed, processed and analyzed as described below.  
 
Immunohistochemistry  
Slices were fixed for 20 minutes in 4% paraformaldehyde dissolved in phosphate 
buffered saline. After fixation the slices were washed three times five minutes in 
phosphate buffered saline (PBS) and nonspecific binding was blocked by 
incubating the slices in PBS containing 0.1% Triton X-100 and 2% normal goat 
serum for two hours. The slices were incubated overnight with the primary 
antibodies diluted in PBS containing 0.1% Triton X-100 supplemented with 2% 
normal goat serum at 4ûC. After incubation in the primary antibodies, the slices 
were washed three times two hours in PBS on a shaking platform. The secondary 
antibodies were diluted in PBS supplemented with 2% normal goat serum and 
incubated for one hour.  After incubation in the secondary antibodies, the slices 
were washed again three times two hours in PBS and mounted in Dabco-Mowiol 
(Sigma) on glass coverslips. All reactions were carried out at room temperature 
unless otherwise stated. No labeling was observed when omitting the primary 
antibodies. 
 
Confocal analysis 
Confocal analysis of the slices was performed on a LSM 510 microscope (Carl 
Zeiss b.v. Weesp, the Netherlands) and a 63x Plan-Neofluar lens (Numerical 
aperture 1.4, Carl Zeiss). To excite the Alexa 488 antibody a HeNe1 laser was 
used and for excitation of the Alexa 593 antibody a HeNe2 laser was used. For 
analysis of the 5-HT neuron morphology and the 5-HT neurites, Z-stacks of 1 #m 
were made. Images were analyzed and further processed in Zeiss CLSM software. 
 
Histological quantification of 5-HT neurite density 
Quantification of 5-HT immunopositive neurites and cells was performed using 
an MCID Elite imaging system (Imaging Research Inc., Ont., Canada). Images of 
the immunostained co-cultures were digitized using an objective magnification 
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of 20x on a Leica DM/RBE photo-microscope with a Sony (DXC-950P, 640 x 512 
pixels) camera using epifluorescence microscopy. The 5-HT-immunopositive 
neurites were segregated from background using several point operators and 
spatial filters combined in an algorithm designed to detect local changes in 
relative optical density. Briefly, images underwent histogram equalization and 
smoothing (low-pass filter, kernel size 7x7). The unfiltered image was subtracted 
from the smoothed image, followed by a series of steps to optimize the processed 
image and make it a suitable measuring template for detecting objects the size 
and shape of 5-HT neurites or cell bodies. This algorithm was preferred over 
relative optical density thresholding since it does not involve an observer-
dependent operation. Finally, a line was manually drawn around the DRN or 
hippocampal slice and the number of positive pixels (i.e. pixels representing 5-
HT neurites) compared to the total number of pixels was calculated. The number 
of 5-HT neurons was counted manually in the slices. 
 
Data analysis 
In order to analyze differences in neurite density between different 
pharmacological treatments, ANOVA was used with the Bonferonni test for post 
hoc analysis. Data shown are mean values ± standard error of the mean (SEM). 
Significance levels were set at <0.05. 
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Abstract 
 
The serotonin (5-HT) reuptake transporter (SERT) has an important role in 5-
HT transmission by terminating the action of 5-HT in the synaptic cleft. Here we 
address the question how SERT is transported in neuronal cells. We studied the 
trafficking of SERT in hippocampal neurons by tagging SERT with a fluorescent 
protein. We show that SERT displays a punctate distribution in axons and a 
more uniform distribution in dendrites. The majority of SERT puncta do not co-
localize with the synaptic marker Synapsin, showing that SERT is predominantly 
localized extra-synaptically. SERT is transported in secretory vesicles as SERT 
co-localizes with the secretory vesicle marker tissue plasminogen activator (tPA). 
Live cell imaging revealed a highly dynamic trafficking of SERT along the 
neurites. Approximately 35% of the vesicles moved, with an average velocity of ~ 
1.2 #m/s. SERT vesicles do not display a preference for direction. We conclude 
that SERT, tagged with a fluorescent protein, displays a highly dynamic 
character in hippocampal neurons. These data are important to achieve a better 
understanding of the dynamics of treatment with 5-HT reuptake inhibitors. 
 
Introduction 
 
The projections of the 5-HT system abundantly innervate several brain areas. 5-
HT is released both synaptically and extra-synaptically. After being released, 5-
HT is cleared from the extracellular space by the SERT. Since this protein 
regulates the termination of the action of 5-HT, it is very important in regulating 
efficacy of 5-HT transmission. Moreover, SERT is the primary target for the 
selective serotonin reuptake inhibitors (SSRIs) class of antidepressants, several 
tricyclic antidepressants, and may mediate the effects of amphetamines such as 
3,4-methylenedioxy-N-methylamphetamine (MDMA).  
SERT is a sodium and chloride neurotransmitter symporter and belongs to 
the solute carrier family 6, to which also transporters for dopamine, 
noradrenaline/adrenaline, glycine and GABA belong (Chen et al., 2004). In the 
adult brain, SERT is expressed in 5-HT neurons, but during development also 
transiently in the cortex, hippocampus, thalamocortex and the lateral geniculate 
nucleus (Lebrand et al., 1996; Zhuang et al., 2005). In 5-HT neurons, SERT is 
predominantly localized in axons but also in the cytoplasm of the soma and 
dendrites (Zhou et al., 1998; Tao-Cheng and Zhou, 1999). In axons SERT is not 
only associated with varicosities, sites where 5-HT is released, but also with the 
plasma membrane of the axons (Zhou et al., 1998). 
Several lines of evidence indicate that 5-HT has a role during brain 
development. In mice, deletion of SERT results in a 60-80% reduction in total 
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brain tissue 5-HT level, although there is a 7-8 fold increase in extracellular 5-HT  
levels in the striatum and substantia nigra (Fabre et al., 2000; Mathews et al., 
2004). Analysis of emotional behaviour of these mice revealed that deletion of 
SERT results in abnormalities in anxiety-related behaviour (Holmes et al., 
2003a; Holmes et al., 2003b). Additionally, blockade of SERT during 
development with the SSRIs fluoxetine, clomipramine or citalopram results in 
mice which display altered emotional behaviour in adulthood (Ansorge et al., 
2004; Ansorge et al., 2008). These studies show that SERT is important in 
establishing normal emotional behaviour during development, presumably by 
regulating the extracellular concentration of 5-HT in the brain.  
The level of SERT present at the cell membrane at synaptic boutons 
determines the rate of 5-HT reuptake and hence the efficacy of 5-HT 
transmission. Therefore, there is extensive regulation of the level of cell-surface 
expressed SERT. The trafficking and regulation of SERT cell-surface expression 
has been studied in many different cell types, including HEK293 cells, 1C11 cells, 
basophilic leukemia 2H3 cells and 5-HT neurons (Zhu et al., 2004; Lau et al., 
2008a; Lau et al., 2008b). A study using biotinylated SERT in 5-HT neurons 
showed that citalopram reduced the amount of cell surface-expressed SERT (Lau 
et al., 2008b)  However, live cell imaging to investigate the trafficking dynamics 
of SERT has not been studied in neurons before.  
Here we investigated the trafficking of SERT in hippocampal neurons. To 
this end we expressed SERT tagged with the fluorescent protein mCherry in 
hippocampal neurons. SERT displays a polarized distribution, as in axons SERT 
is distributed in a punctate manner, whereas in dendrites SERT is present in a 
uniform distribution. SERT is transported in secretory vesicles through the 
neurites, as it co-localized with the secretory vesicle marker tPA. Live cell 
imaging revealed that SERT displays a highly dynamic vesicular trafficking. 
Analysis of direction of movement showed that SERT does not display a 
preference for a direction of movement. In future experiments, live cell imaging 
of mCherry-SERT can be used to address whether 5-HT reuptake inhibitors 
affect the highly dynamic SERT trafficking. 
 
Results 
 
Localization of mCherry-SERT in hippocampal neurons differs between axons 
and dendrites 
To study the trafficking we tagged the N-terminus of SERT with the red 
fluorescent protein mCherry, which is an improved variant of monomeric red 
fluorescent protein in terms of maturation and photostability (Shaner et al., 
2004). Tagging the N-terminus of SERT with a fluorescent protein does not 
interfere with the function of SERT (Schmid et al., 2001; Just et al., 2004; 
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Fjorback et al., 2009). We used hippocampal neurons that do not express SERT, 
although it is expressed transiently in a subpopulation of hippocampal neurons 
during development (Narboux-Neme et al., 2008).  
The expression of mCherry-SERT in dissociated hippocampal neurons was 
analyzed between 9-12 days in vitro (DIV) using live cell imaging and 
immunocytochemistry on fixed neurons. This revealed that the whole neuron 
was extensively labelled with mCherry-SERT (Fig. 1A). Immunocytochemistry 
for the dendritic marker Microtubule Associated Protein 2 (MAP2) was used to 
discern between the dendrite and axon (Fig. 1B,C). SERT localization differed 
between axons and dendrites. In dendrites SERT is predominantly uniformly 
distributed where only occasionally a puncta of SERT is observed. However in 
axons, SERT displays a more punctate distribution suggesting that SERT is 
transported in vesicles through the axon (Fig. 1D,E,F). Alternatively, the 
punctate pattern may reflect local accumulation of SERT in varicosities. To 
further explore whether these puncta are varicosities or vesicles, we used 
immunocytochemistry and live cell imaging.  
Figure 1. Distribution of mCherry-SERT differs between axons and dendrites 
(A-C) Expression of mCherry-SERT in a hippocampal neuron (DIV11). (A) mCherry-SERT 
is present in all the neurites and the cell body. (B) MAP2 labelling to discern between 
axons and denrites. (C) Merged image. (D-F) Blow up of the white box in C. (D) mCherry-
SERT distribution differs between axons and dendrites, as in the axon mCherry-SERT 
displays a punctate distribution, whereas in dendrites mCherry-SERT displays a more 
uniform distribution where only occasionally a mCherry-SERT puncta is observed. (E) 
MAP2 labelling. (F) Merged image. Scale bars in C and F are 10 µm. 
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SERT is transported in secretory vesicles 
Since SERT displayed a punctate distribution in neurites, we investigated 
whether these puncta are secretory vesicles. To this end mCherry-SERT was co-
expressed with tPA-GFP, which is transported in secretory vesicles in 
hippocampal neurons (Lochner et al., 1998; Silverman et al., 2005). In neurons 
expressing both mCherry-SERT and tPA-GFP, the majority of SERT puncta co-
localized with tPA-GFP (Fig. 2A-F). Therefore, these data strongly suggest that 
SERT is transported in secretory vesicles along the axons in hippocampal 
neurons. 
Figure 2. mCherry-SERT is transported in secretory vesicles 
(A-C) Co-expression of mCherry-SERT and tPA-GFP in a hippocampal neuron (DIV11). 
(A) mCherry-SERT displays a punctate distribution. (B) tPA-GFP is transported in 
secretory vesicles. (C) The majority of mCherry-SERT puncta co-localize with tPA-GFP, 
suggesting that mCherry-SERT is transported in secretory vesicles. (D-F) Blow-up of the 
white box in C. (D) mCherry-SERT expression. (E) tPA-GFP expression. (F) Merged 
image. Arrows show the co-localization between mCherry-SERT and tPA-GFP. Scale bars 
in C and F are 10 µm. 
 
To investigate whether vesicles of SERT co-localized with presynaptic terminals, 
we performed immunocytochemistry for the synaptic marker Synapsin on 
neurons transfected with mCherry-SERT. Although several mCherry-SERT 
puncta are in close vicinity of Synapsin puncta (Fig. 3 A-F), only few mCherry-
SERT puncta co-localized with Synapsin. Thus, mCherry-SERT is transported in 
secretory vesicles and several of those vesicles localize to the vicinity of 
presynaptic terminals. 
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Figure 3. Several mCherry-SERT vesicles are localized in the vicinity of 
presynaptic terminals 
(A-C) Expression of mCherry-SERT in a hippocampal neuron (DIV11). (A) mCherry-SERT 
expression. (B) Synapsin labelling. (C) Merged image. Several mCherry-SERT vesicles are 
localized in the vicinity of presynaptic terminals, and some co-localized with the 
presynaptic marker Synapsin. (D-F) Blow up of the white box in C. (D) mCherry-SERT 
expression. (E) Synapsin labelling. (F) Merged image. Arrows in F show mCherry-SERT 
vesicles which are localized in the vicinity of presynaptic terminals. Arrowhead shows a 
mCherry-SERT vesicle which co-localizes with a Synapsin puncta. Scale bars in C and F 
are 10 µm. 
 
 
 
Figure 4 next page. Trafficking dynamics of mCherry-SERT secretory vesicles 
Live cell imaging of mCherry-SERT trafficking dynamics in hippocampal neurons (DIV 9-
11). (A) Two frames 5 seconds apart (green is 1 s, red is 5 s) from a 1 minute movie reveal 
the different modes of trafficking of mCherry-SERT. There are mCherry-SERT vesicles 
which move in the anterograde direction (arrow), in the retrograde direction (arrowhead) 
or are stationary (yellow puncta, asterisks). (B) Corresponding kymograph of part of the 
neurite displays the different trafficking modes of mCherry-SERT. Vesicle 1 is a stationary 
vesicle, vesicle 2 moves in the anterograde direction, whereas vesicle 4 moves in the 
retrograde direction. Vesicle 3 is a vesicle which pauses for a while and then continues 
moving. Vesicle numbers are shown in the individual images taken 10 seconds apart and 
vesicle trajectories are highlighted in the kymograph. (C) No difference between average 
anterograde and retrograde velocity as can be observed in the histogram of the average 
velocity. (D) No difference between average velocity of mCherry-SERT vesicles which 
move in the anterograde or retrograde direction or which display bidirectional 
movements. (E) Percentage moving vesicles does not differ between vesicles which move 
anterogradely, retrogradely or bidirectionally. (F) Also, percentage pausing time for 
moving vesicles is not different between vesicles which move anterogradely, retrogradely 
or bidirectionally. Scale bars in A and B are 10 µm. 
62
  
SERT trafficking is highly dynamic 
We analyzed the trafficking dynamics of SERT using live-cell imaging of 
hippocampal neurons expressing mCherry-SERT. We observed rapid movements 
of mCherry-SERT vesicles in both the anterograde and retrograde direction. 
Additionally, also stationary mCherry-SERT puncta were observed (Fig. 4A). To 
illustrate different types of movement we show part of a neurite with 10 second 
time intervals. In this neurite a stationary  vesicle can be observed (vesicle 1), but 
also a vesicle which moves in an anterograde direction (vesicle 2) and a vesicle 
which moves in a retrograde direction (vesicle 4). Additionally, vesicles are 
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observed which are temporarily stationary but then continue moving (vesicle 3 in 
Fig. 4B). In the corresponding kymograph of this part of the neurite the 
trajectories of the numbered vesicles are shown (Fig. 4B). We quantified the 
direction of vesicle movement, percentage of moving vesicles, average velocity of 
moving vesicles and percentage pausing time of moving vesicles using the 
automated vesicle detection program Fluotrack (Broeke et al., 2008). First we 
measured the average velocity of anterogradely and retrogradely moving vesicles. 
The frequency histogram plotting the velocities of mCherry-SERT vesicles 
moving in the anterograde or retrograde direction showed that the velocity 
distributions for anterogradely and retrogradely moving vesicles did not differ 
(Fig. 4C). The average velocity of all moving vesicles was 1.22 ± 0.03 µm/s. The 
average velocity of anterograde vesicles was 1.31 ± 0.05 µm/s compared  to 1.34 
± 0.06 µm/s in retrograde direction. Vesicles moving bidirectional (vesicles that 
changed direction during imaging) moved with an average velocity of 1.12 ± 
0.055 µm/s (Fig. 4D).  Next, we determined the percentage of puncta which 
moved in the anterograde or retrograde direction, moved bidirectional or were 
stationary. This revealed that on average 34.52 ± 5.31% of mCherry-SERT puncta 
were moving during one minute of imaging. Further analysis of fraction of 
moving mCherry-SERT vesicles which moved in the anterograde or retrograde 
direction or moved bidirectional, revealed that there was no difference (Fig. 4E, 
see also table 1). Finally, we calculated the pausing time for the moving vesicles, 
which is the fraction of time moving vesicles pause during the 1 minute movie. 
There was no difference in percentage pausing time between mCherry-SERT 
vesicles which moved anterogradely, retrogradely or bidirectionally (Fig. 4F, see 
also table 1).  
We conclude that mCherry-SERT displays highly dynamic vesicular 
trafficking in hippocampal neurons and that these mCherry-SERT vesicles do not 
have a preference for a direction of movement.  
 
 
 
 
 
Velocity data are shown as mean ± standard error of the mean (SEM). Data of 927 
mCherry-SERT puncta in 6 neurons. 
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Discussion 
 
Here we studied the trafficking of SERT in hippocampal neurons. We used 
human SERT cDNA tagged at its N-terminus with the red fluorescent protein 
mCherry. Overexpression of mCherry-SERT in hippocampal neurons resulted in 
a distinct pattern of expression between axons and dendrites; in dendrites SERT 
displayed a uniform distribution, whereas in axons SERT displayed a punctate 
distribution. Using electron microscopy, it has been shown that in 5-HT neurons 
endogenous SERT predominantly localized to varicosities and the membrane in 
axons, and in soma and dendrites SERT localized predominantly in the 
cytoplasm (Zhou et al., 1998; Tao-Cheng and Zhou, 1999). Thus, although we are 
using hippocampal neurons, mCherry-SERT distribution seems to mimic the 
distribution of endogenous SERT in 5-HT neurons.  
Ultrastructural studies revealed that SERT labeling was associated with 
vesicular organelles, which possibly are large dense cored vesicles (LDCVs) 
(Pickel and Chan, 1999). Here, we co-transfected mCherry-SERT with tPA-GFP 
for which it has been shown that these are transported in LDCVs (also called 
secretory vesicles) (Silverman et al., 2005). The majority of mCherry-SERT 
puncta co-localized with tPA-GFP, strongly suggesting that SERT is transported 
in secretory vesicles. Several mCherry-SERT vesicles are localized in close 
proximity (~1 µm), and some co-localized, with presynaptic terminals. This 
suggests that the majority of SERT is not localized in the presynaptic terminal 
itself, but rather is localized close to a synapse. Indeed, previous research found 
that presynaptic membranes lacked SERT, but SERT was present on 
extrasynaptic domains, either in close proximity or at some distance away from 
synapses (Zhou et al., 1998). 
Live cell imaging revealed that mCherry-SERT vesicles display highly 
dynamic transport, i.e. there are vesicles which move anterogradely or 
retrogradely without interruptions, stationary vesicles or vesicles which move 
bidirectional. Analysis of average velocity revealed that both anterograde and 
retrograde vesicles moved with an average velocity of ~1.3 #m/s. The average 
velocity is in analogy with other transport or transport associated proteins which 
are transported in secretory vesicles, like the p75 neurotrophin receptor and 
Gephyrin (Maas et al., 2006; Formaggio et al., 2008). Surprisingly, we found 
that mCherry-SERT vesicles did not display a preference for direction of 
movement. For other releasable fluorescent cargos that are transported in 
secretory vesicles, such as Sema3A, BDNF and CCL21 it has been shown that 
transport is predominantly anterogradely (Adachi et al., 2005; de Wit et al., 
2006; de Jong et al., 2008). In contrast, the p75 neurotrophin receptor, which is 
transported in vesicular structures, does not display a preference for direction of 
movement (Formaggio et al., 2008). Moreover, the scaffold protein Gephyrin, 
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which is associated and co-transported with the glycine receptor also does not 
display a preference for anterograde or retrograde movement (Maas et al., 
2006). Therefore, it appears that proteins which can be secreted and are 
transported in secretory vesicles predominantly move in the anterograde 
direction, whereas receptor/transporter proteins move both in the anterograde 
and retrograde direction.  
An explanation for this could be that cargos which can be secreted are 
transported towards synaptic release sites distant from the cell soma. After a 
vesicle has been released, the secreted compounds either diffuse in the 
extracellular space (as is the case for Sema3A) or are taken up again and 
degraded in the presynaptic terminal. Hence, releasable cargos are hardly 
transported back towards the cell soma. On the other hand, the level of 
membrane expression for receptor and transporter protein is tightly regulated, 
and these proteins can be rapidly internalized (Loder and Melikian, 2003; 
Melikian, 2004; Zhu et al., 2004). Upon internalization, transporters are 
packaged in vesicles again and are recycled. Finally, receptors and transporters 
can maintain functioning without a need for intracellular transport, whereas 
secreted components are dependent on a new supply of vesicles. Therefore, 
vesicles containing transporters or receptors can be transported both in 
anterograde and retrograde directions.  
In conclusion, expression of mCherry-SERT in hippocampal neurons differs 
between axons and dendrites. In axons mCherry-SERT is distributed in puncta, 
which co-localize with tPA-GFP and therefore presumably are secretory vesicles. 
Several of these mCherry-SERT vesicles are localized in close proximity of 
presynaptic terminals, but only few mCherry-SERT vesicles co-localized with 
presynaptic terminals. Live cell imaging revealed that mCherry-SERT displays 
highly dynamic trafficking behaviour with no preference for direction of 
movement.  
 
EXPERIMENTAL PROCEDURES 
 
Plasmids 
Construction of the human SERT cDNA with ECFP at the 5’ end (ECFP-SERT in 
the pECFP-C1 backbone (Clontech)) has been described before ((Schmid et al., 
2001); a kind gift of Dr. H. Sitte). To construct mCherry-SERT, ECFP was 
excised with AseI and BsrGI and replaced for mCherry.  
 
Neuronal culturing and transfection 
Hippocampi from embryonic day 18 C57/Bl6 mouse embryos were dissected free 
of meninges and collected in Hanks Balanced Salt Solution (HBSS; Invitrogen) 
supplemented with 7 mM HEPES (Invitrogen). Hippocampi were digested with 
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0.25% trypsin (Invitrogen) in HBSS supplemented with 7 mM HEPES for 15 
minutes at 37ºC. After digestion tissue was washed three times with HBSS 
supplemented with 7 mM Hepes and subsequently triturated with a fire-polished 
glass pipette. Dissociated neurons were plated at a density of 25.000 cell/well on 
rat glial cells on 18 mm glass coverslips (Menzel Glaser, Braunschweig, 
Germany) in 12 well plates. Cells were cultured in neurobasal medium 
supplemented with B27 supplement, 18 mM HEPES, 0.5 mM Glutamax and 
penicillin/streptomycin (Invitrogen). Once a week half of the medium was 
replaced. The hippocampal cultures were transfected using Lipofectamine 2000 
(Invitrogen). Before transfection, half of the neurobasal medium was collected 
from each well and replaced with new neurobasal medium. For one well, 1 #l of 
Lipofectamine 2000 was added to 25 #l of serum free glutamax medium 
(Invitrogen) and incubated for 5 minutes. Subsequently, from each construct 1 
#g of DNA was added to 25 #l of serum free glutamax and immediately mixed 
with the 25 #l of serum free glutamax containing Lipofectamine 2000. This 
mixture was incubated for 30 minutes at room temperature before adding to the 
cells. After 4-6 hours of incubation on the cells at 37°C, half of the neurobasal 
medium was replaced again with the earlier collected neurobasal medium. Cells 
were routinely transfected at DIV2-7 and imaged at DIV9-12. 
 
Live cell imaging 
Cells were imaged in a chamber perfused with Tyrode’s solution (119 mM NaCl, 
2.5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 30 mM glucose, 25 mM HEPES, pH 7.4) 
on an Axiovert II Microscope (Zeiss, Oberkochen, Germany) equipped with a 
Coolsnap HQ camera (Photometrics, Tucson, Arizona, USA) and a Polychrome 
IV illumination unit (TILL photonics, Grafelfing, Germany). Images were 
acquired in MetaMorph 6.2 software (Universal Imaging, Downingtown, 
Philadelphia, USA) using a 100x oil objective. 
 
Immunocytochemistry and confocal microscopy 
For immunocytochemistry, neurons were fixed by incubation in 4% 
paraformaldehyde in phosphate buffered saline (PBS) for 20 minutes. 
Subsequently, to block aspecific binding and for permeabilization, the neurons 
were incubated in PBS containing 0.2% Triton X-100 and 4% fetal calf serum for 
20 minutes. Neurons were incubated in primary antibody diluted in PBS 
containing 0.2% Triton X-100 for one hour. After washing three times in PBS, 
neurons were incubated in secondary antibodies in PBS for one hour. Neurons 
were washed again three times in PBS and mounted in Dabco-Mowiol. All 
reactions were carried out at room temperature. As primary antibodies, 
monoclonal MAP2 (Chemicon) and polyclonal Synapsin (E028) were used. As 
secondary antibodies Alexa fluor-conjugated antibodies were used (Invitrogen). 
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For confocal analysis, neurons were examined on a confocal LSM510 microscope 
(Zeiss, B.V. The Netherlands) 
 
Trafficking analysis 
In order to analyze the trafficking dynamics of SERT, one minute movie image 
stacks with 1 s interval between images, were analyzed in the custom written 
software program Fluotrack (Broeke et al., 2008). To this end, metamorph files 
(.stk) were converted to .avi files using ImageJ, and analyzed using Fluotrack. 
Data analysis was performed using the SPSS statistical package. Data shown are 
mean values ± SEM.   
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Abstract 
 
Tryptophan hydroxylase (Tph) is the rate limiting enzyme in serotonin (5-HT) 
synthesis. Two genes named Tph1 and Tph2 synthesize 5-HT in peripheral 
tissues and the central nervous system, respectively. When expressed in neurons, 
Tph1 displays a cytoplasmic distribution in the cell body and is associated with 
microtubules in the axon and dendrites. Axonal Tph1 is associated with 5-HT 
varicosities. Here, we studied the subcellular distribution of Tph2. To this end we 
expressed Tph2-EGFP in hippocampal neurons. In young neurons, before 
synaptogenesis has occurred, Tph2-EGFP displayed a cytoplasmic distribution 
throughout the neurites. Live cell imaging revealed that Tph2-EGFP is not 
transported in vesicles. In mature neurons, Tph2-EGFP accumulated in 
presynaptic terminals of axons, whereas in dendrites it was distributed 
throughout the cytoplasm, also in spines. In live cell imaging, Tph2-EGFP hardly 
displayed any movement. These results suggest that Tph2 is freely diffusible in 
the dendrites and soma, but accumulates at the synaptic terminal by a 
mechanism that deserves further study.  
 
Introduction 
 
The neurons of the 5-HT system are among the first neurons in the brain 
synthesizing a specific neurotransmitter. Two enzymes are necessary to 
synthesize 5-HT from its precursor L-tryptophan. Of these, the rate limiting 
enzyme is Tph which converts L-tryptophan to 5-hydroxy-L-tryptophan. For 
decades only one Tph isoform was known in the mammalian brain. However, 
deletion of this gene did not result in a significant decrease in brain 5-HT levels, 
which led to the discovery of a second Tph gene called Tph2 (Walther et al., 
2003). Tph2 is exclusively expressed in the raphe nuclei, whereas Tph1 is 
expressed in the pineal gland and in the peripheral 5-HT system (Patel et al., 
2004; Gutknecht et al., 2009). 
Since 5-HT projections are distributed throughout the brain, it is unlikely 
that Tph2 is only present in the cell body to synthesize 5-HT. Indeed, previous 
research showed that Tph was present in the cytoplasm of the cell body, and in 
axons and dendrites where it was associated with microtubules (Joh et al., 1975). 
Additionally, Tph was associated with 5-HT varicosities, suggesting local 
synthesis of 5-HT (Pickel et al., 1976; Pickel et al., 1977).  
Although the subcellular distribution of Tph1 is known, it is currently 
unknown how Tph is transported to synaptic terminals and whether Tph2 also 
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localizes to presynaptic terminals. Therefore we tagged Tph2 with EGFP, and 
expressed this chimaeric protein in hippocampal neurons. We show here that in 
young neurons (before synaptogenesis), Tph2-EGFP is homogenously 
distributed throughout the neurites. However, in mature neurons, Tph2-EGFP 
accumulated at presynaptic terminals in the axon. In the dendrites of mature 
neurons, Tph2-EGFP displayed a homogenous distribution, and also localized to 
spines. Live cell imaging suggested that Tph2 is a soluble protein and is not 
transported in vesicles to presynaptic terminals. We conclude that Tph2-EGFP 
accumulates at presynaptic terminals in mature hippocampal neurons. 
 
Results 
 
Cytoplasmic distribution of Tph2-EGFP in young neurons 
To study the distribution of Tph2 in neurons, we inserted EGFP at the N-
terminus of Tph2 and expressed Tph2-EGFP in hippocampal neurons. First, we 
started with imaging Tph2-EGFP in neurons at 9 days in vitro (DIV), which are 
still immature neurons in terms of synapse development (Basarsky et al., 1994) 
Transfected neurons showed a uniform distribution of Tph2-EGFP through the 
whole neuron, indicating that Tph2-EGFP is cytoplasmic (Fig. 1A). We did not 
observe Tph2-EGFP puncta, suggesting that Tph2-EGFP is not transported in  
 
 
 
Figure 1. Tph2-EGFP expression in 
young neurons 
Tph2-EGFP was expressed in young 
hippocampal neurons before 
synaptogenesis and imaged at DIV9. (A) 
Tph2-EGFP displays a cytoplasmic 
distribution throughout all the neurites. 
(B) Live cell imaging revealed that Tph2-
EGFP is not transported in vesicles, and 
only little movement is detected. Images 
are taken 10 seconds apart, first image is 
green and image 10 seconds later is in 
red. (C) Zooming in on the axon (arrow 
in A), as identified by its smaller 
diameter compared to dendrites shows 
that already puncta are observed which 
might be immature synapses or 
varicosities (arrows). (D) In the 
dendrites, Tph2-EGFP distribution is 
cytoplasmic, and Tph2-EGFP also 
localized to dendritic filopodia. Scale 
bars: 10 µm in B, 5 µm in C and D. 
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Figure 2 previous page. Tph2-EGFP localizes to presynaptic terminals in 
mature neurons 
Neurons expressing Tph2-EGFP and the presynaptic marker Synaptophysin-mCherry 
were imaged at DIV23. (A) Tph2-EGFP was expressed in the cytoplasm of dendrites. (B) 
Expression of Synaptophysin-mCherry in the same neuron. (C) Merged image. (D) Blow 
up of the white box in C shows that some Tph2-EGFP appears to accumulate in the tip of 
dendritic spines (asterisks). (E) Synaptophysin-mCherry expression. (F) Merged image. 
(G) Axon of a neuron expressing Tph2-EGFP. Tph2-EGFP displays a punctate expression, 
indicative of presynaptic localization. (H) Indeed, Tph2-EGFP co-localizes with 
Synaptophysin-mCherry. (I) Merged image. (J) A EGFP expressing neuron as a control 
shows that EGFP is homogenously distributed in the dendrites (asterisks) and in the axon 
as identified by the absence of MAP2 staining (arrows). (K) MAP2 staining. (L) Merged 
image. (M) Live cell imaging revealed that Tph2-EGFP is static. Images are taken 30 
seconds apart, with the green image after 1 second, and the red image after 30 seconds. 
(N) Blow up of the white box in J shows that some dendrites which contain Tph2-EGFP 
displayed some movement (arrows). Scale bars: 10 µm in C, 5 µm in F, 10 µm in I, 10 µm 
in L, 10 µm in M and 5 µm in N.  
 
vesicles, but instead is a soluble protein. Live cell imaging revealed that Tph2-
EGFP is rather static, and no Tph2-EGFP puncta or other movements were 
observed (Fig. 1B). The axon, as identified by its smaller diameter and larger 
length as compared to dendrites, also had a uniform distribution of Tph2-EGFP, 
although some Tph2-EGFP appeared to accumulate in puncta along the axon 
(arrows in Fig. 1C). As in axons, in dendrites Tph2-EGFP displayed a uniform 
distribution and also filopodia were labelled (Fig. 1D).  
 
Tph2-EGFP localizes to presynaptic terminals in mature neurons 
Next, we investigated the distribution of Tph2-EGFP in mature neurons after 
synaptogenesis had occurred. To this end we transfected hippocampal neurons 
with Tph2-EGFP at DIV18 and imaged Tph2-EGFP at DIV23. Tph2-EGFP was 
uniformly distributed in the cell body, dendrites and dendritic spines (Fig. 2A-C). 
We expressed EGFP in neurons as a control to compare the distribution of EGFP 
with Tph2-EGFP (Fig. 2J-L). In contrast to EGFP, which labels the whole 
dendritic spine, it appeared that in neurons transfected with Tph2-EGFP in some 
spines Tph2-EGFP accumulated in the tip of the spine, suggesting that Tph2-
EGFP was enriched in postsynaptic structures (Fig. 2D-F). We co-transfected 
Tph2-EGFP with Synaptophysin-mCherry, which is a marker for synaptic 
vesicles and presynaptic terminals (Jahn et al., 1985; Granseth et al., 2006). In 
the axon, identified by the punctate labelling of Synaptophysin-mCherry, Tph2-
EGFP displayed a punctate distribution (Fig. 2G). The Tph2-EGFP puncta co-
localized with Synaptophysin-mCherry puncta, strongly suggesting that Tph2-
EGFP accumulated at presynaptic terminals (Fig. 2H,I). In neurons transfected 
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with EGFP as a control, EGFP displayed a uniform distribution throughout the 
axon (Fig. 2J-L). Next, we imaged the neurons expressing Tph2-EGFP during 1 
minute. Hardly any Tph2-EGFP movement could be observed (Fig. 2M). The 
only movement which could be observed was some motility in postsynaptic 
spines (Fig. 2N).  
To further test if Tph2-EGFP is localized to presynaptic terminals in mature 
neurons, we fixed neurons expressing Tph2-EGFP at DIV23 and performed 
immunocytochemistry for the synaptic marker Synapsin and the dendritic 
marker MAP2 to discriminate dendrites and axons (Fig. 3A-C). In the axon, as 
identified by the absence of MAP2 labelling, Tph2-EGFP displayed a punctate 
distribution (Fig. 3D-F). Immunocytochemistry for Synapsin showed that in 
dendrites of neurons expressing Tph2-EGFP, spines were labelled, and some 
spine heads were localized in close proximity with Synapsin puncta, suggesting 
that this is a synapse (Fig. 3G-I). Finally, we focussed on the axon of a neuron 
expressing Tph2-EGFP which we stained for Synapsin. The boutons with Tph2-
EGFP co-localized with Synapsin, strongly suggesting that Tph2-EGFP localized 
to presynaptic terminals (Fig. 3J-L).  
Premium Content Area 
Discussion 
 
We have shown here that Tph2, the rate limiting enzyme in 5-HT synthesis 
localized to presynaptic terminals in mature hippocampal neurons. Moreover, in 
dendrites and in the cell body Tph2-EGFP had a cytoplasmic distribution and 
appeared to accumulate in the tip of some dendritic spines. Thus, it appears that 
Tph2-EGFP displayed a polarized distribution in mature hippocampal neurons. 
Live cell imaging revealed that hardly any Tph2-EGFP movement could be 
observed, and no Tph2-EGFP vesicles were observed, indicating that Tph2 is a 
soluble protein. Accordingly, Tyrosine hydroxylase, an enzyme related to Tph2, 
also was shown to be a soluble protein (Mockus et al., 1997). Electron microscope 
studies on Tph and TH localization revealed that these proteins were enriched on 
presynaptic terminals, and were associated with microtubules in 
somatodendritic compartments (Pickel et al., 1976). Therefore, Tph2-EGFP 
seems to mimic the endogenous distribution of Tph in 5-HT neurons.  
Tph2-EGFP displayed a polarized distribution in mature hippocampal 
neurons, i.e. in dendrites the protein is distributed throughout the cytoplasm, 
whereas in the axon the protein accumulated in presynaptic terminals. This 
suggests that in presynaptic terminals and in 5-HT varicosities, there is local 
synthesis of 5-HT. In dendrites, Tph2-EGFP localized to spines, which prompts 
the question whether 5-HT could be synthesized in dendrites.  
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Figure 3. Immunocytochemistry on a mature neuron expressing Tph2-EGFP 
Neurons (DIV23) expressing Tph2-EGFP were fixed and immunocytochemistry was 
performed for MAP2 and Synapsin. (A) Tph2-EGFP expression. (B) MAP2 
immunostaining to distinguish between dendrites and the axon. (C) Merged image. (D) 
Blow up of the white box in C shows a dendrite (asterisk) which has Tph2-EGFP through 
the whole cytoplasm, and the axon (arrows) in which Tph2-EGFP displays a punctate 
distribution. (E) MAP2 staining. (F) Merged image. (G) Tph2-EGFP expressing neurons 
were stained for the presynaptic marker Synapsin. (H) Synapsin staining. (I) Merged 
image, which shows that in the close proximity of some dendritic spines there is a 
Synapsin puncta, suggesting that these are true synapses (asterisks). (J) Distribution of 
Tph2-EGFP in an axon. (K) Synapsin staining. (L) Tph2-EGFP puncta were positive for 
Synapsin (arrows), showing that these are presynaptic terminals. Scale bars: 20 µm in C, 
10 µm in F, 5 µm in I and L.  
 
Tph is localized in  dendrites, where it associated with microtubules (Joh et al., 
1975). Correspondingly, 5-HT vesicles are detected in dendrites, either 
associated with a synaptic specialization or with the membrane (Chazal and 
Ralston, 1987). After stimulation of Retzius neurons in the leech, which contain 
large dense core vesicles (LDCVs) filled with 5-HT, several vesicles are localized 
close to the cell membrane as studied by electron microscopy (Trueta et al., 
79
2004). Therefore, this strongly suggests that 5-HT release can occur from the 
somatodendritic compartment. Our results indicate that 5-HT can also be 
synthesized in the somatodendritic compartment. 
Tph2-EGFP was not associated with vesicles and the protein interactions for 
its presynaptic accumulation remain unclear. Tph is associated with 
microtubules, suggesting it could interact with molecular motors of the dynein 
and kinesin family which move along microtubules (Hirokawa and Takemura, 
2005). For Tph2, several polymorphisms are known, some of which associate 
with neuropsychiatric conditions (Zhang et al., 2006). Both in humans and in 
mice a polymorphism in the Tph2 gene is found which results in a marked 
reduction in Tph2 activity (Zhang et al., 2004; Zhang et al., 2005). Finally, it 
would be interesting to investigate whether these polymorphisms not only affect 
Tph2 activity, but could also affect Tph2 transport and localization. 
 
EXPERIMENTAL PROCEDURES 
 
Plasmids 
Tph2 cDNA in pCR4-TOPO vector was obtained from Geneservice. To clone 
Tph2 in an expression vector, EGFP was digested using PstI and cloned in the 
PstI site of pBiotag-EGFP-C1. Synaptophysin-mCherry was a kind gift from Dr. 
A. Jeromin (Allen Brain Institute). 
 
Neuronal culturing and transfection 
Hippocampi from embryonic day 18 C57/Bl6 mouse embryos were dissected free 
of meninges and collected in Hanks’ Balanced Salt Solution (HBSS; Invitrogen) 
supplemented with 7 mM HEPES (Invitrogen). Hippocampi were digested with 
0.25% trypsin (Invitrogen) in HBSS supplemented with 7 mM HEPES for 15 
minutes at 37ºC. After digestion tissue was washed three times with HBSS 
supplemented with 7 mM Hepes and subsequently triturated with a fire-polished 
glass pipette. Dissociated neurons were plated at a density of 25.000 cell/well on 
rat glial cells on 18 mm glass coverslips (Menzel Glaser, Braunschweig, 
Germany) in 12 well plates. Cells were cultured in neurobasal medium 
supplemented with B27 supplement, 18 mM HEPES, 0.5 mM Glutamax and 
penicillin/streptomycin (Invitrogen). Once a week half of the medium was 
replaced. The hippocampal cultures were transfected using Lipofectamine 2000 
(Invitrogen). Before transfection, half of the neurobasal medium was collected 
from each well and replaced with new neurobasal medium. For one well, 1 #l of 
Lipofectamine was added to 25 #l of serum free glutamax medium and incubated 
for five minutes. Subsequently, from each construct 1 #g of DNA was added to 25 
#l of serum free glutamax and immediately mixed with the 25 #l of serum free 
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glutamax containing Lipofectamine. This mixture was incubated for 30 minutes 
before adding to the cells. After 4-6 hours of incubation on the cells, half of the 
neurobasal medium was replaced again with the earlier collected neurobasal 
medium. Cells were routinely transfected at DIV2-7 and DIV18 and imaged at 
DIV10-14 and DIV23. 
 
Live cell imaging 
Cells were imaged in a chamber perfused with Tyrode’s solution (119 mM NaCl, 
2.5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 30 mM glucose, 25 mM HEPES, pH 7.4) 
on an Axiovert II Microscope (Zeiss, Oberkochen, Germany) equipped with a 
Coolsnap HQ camera (Photometrics, Tucson, Arizona, USA) and a Polychrome 
IV illumination unit (TILL photonics, Grafelfing, Germany). Images were 
acquired in MetaMorph 6.2 software (Universal Imaging, Downingtown, 
Philadelphia, USA) using a 100x oil objective. 
 
Immunocytochemistry 
For immunocytochemistry, primary antibodies against MAP2 (monoclonal, 
Chemicon) and synapsin (polyclonal E028) were used in a 1:1000 dilution. As 
secondary antibodies, goat-anti-mouse Alexa488 and goat-anti-rabbit Alexa 543 
were used (Invitrogen). To perform immunocytochemistry, cells were incubated 
in 4% paraformaldehyde dissolved in phosphate buffered saline (PBS, pH 7.4), 
for 20 minutes. Subsequently, cells were washed two times with PBS and 
incubated in PBS containing 0.2% Triton X-100 and 4% fetal calf serum for 20 
minutes. Cells were incubated in primary antibody in PBS containing 0.2% 
Triton X-100 for one hour, washed three times with PBS and incubated in the 
secondary antibody in PBS for one hour. After washing the cells three times with 
PBS, coverslips were mounted using Dabco-Mowiol. All reactions were 
performed at room temperature. Cells were analyzed on a confocal LSM510 
microscope (Zeiss, B.V. The Netherlands) using a 63x oil immersion lens and 
appropriate lasers and filters to visualize EGFP fluorescence and secondary 
antibodies.  
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Abstract 
 
The active zone protein Piccolo is involved in formation of synapses and 
stabilization of existing synapses. Recently, a short nucleotide polymorphism 
(SNP) in the C2A domain of Piccolo was found in association with depression. In 
this study we addressed whether knockdown of Piccolo affected the localization 
and trafficking of the serotonin reuptake transporter (SERT) in hippocampal 
neurons. We co-expressed a short nucleotide RNA which resulted in an efficient 
knockdown of Piccolo with mCherry-SERT to evaluate the effect of knockdown of 
Piccolo on SERT localization and trafficking in hippocampal neurons. We found 
that knockdown of Piccolo did not alter SERT trafficking dynamics. 
Subsequently, we expressed the two variants of the Piccolo C2A domain together 
with SERT in heterologous cells. SERT displayed a uniform distribution at the 
membrane upon co-expression of the wildtype C2A variant. However, upon co-
expression of the mutant C2A variant, SERT displayed a more patchy 
distribution at the membrane, indicating that membrane levels of SERT might be 
decreased. These data suggest that knockdown of Piccolo does not alter SERT 
trafficking dynamics, but the mutant variant of the Piccolo C2A domain might 
alter SERT membrane localization. 
 
Introduction 
 
Major depression is a neuropsychiatric disorder affecting millions of people 
world wide each year. The serotonin (5-HT) system is implicated in depression. 
An important protein in the 5-HT system is the SERT which regulates the 
transport of 5-HT back into the synapse after its release, thus regulating the 
extracellular 5-HT concentration. Therefore, SERT is an important factor in 
determining efficacy of 5-HT neurotransmission. Several polymorphisms have 
been described in SERT which associate with psychopathological processes such 
as depression, anxiety, aggression and autism (Murphy et al., 2004; Serretti et 
al., 2006). 
Several decades ago it was hypothesized that psychopathological processes 
such as depression and anxiety were the result of an alteration in extracellular 5-
HT content. This hypothesis, the so-called monoamine hypothesis, was based on 
the fact that blockade of the SERT by selective 5-HT reuptake inhibitors (SSRIs) 
resulted in an alleviation in depressive symptoms, possibly due to the increase in 
extracellular 5-HT levels. However, between starting SSRI treatment and 
alleviation of depressive symptoms was a time period of 3-4 weeks, whereas 5-
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HT levels increased immediately after SSRI intake. Therefore the monoamine 
hypothesis was abandoned and shifted towards the so-called network hypothesis, 
which stated that psychopathological processes such as anxiety and depression 
could be the result of an altered 5-HT network connectivity (Castren, 2005). The 
evidence for this hypothesis was based on human imaging studies which showed 
that humans with depression had a reduced grey matter volume in cortex and 
hippocampus. However, evidence for this hypothesis on a cellular level is still 
lacking. Recently, a SNP in the presynaptic gene Piccolo was found which might 
be associated with major depressive disorder (Sullivan et al., 2008). Therefore, 
this revitalizes the network hypothesis for depression and opens up new 
opportunities to study the relation between the presynaptic terminal, proper 
formation of networks, and the relation between 5-HT network (formation) and 
psychopathological processes such as depression. 
Piccolo is a 420 kDa protein which is enriched in presynaptic terminals 
where it is a structural component of the presynaptic cytoskeletal cytomatrix 
(PCM) (Cases-Langhoff et al., 1996). Piccolo is a multidomain zinc finger protein 
which is structurally related to Bassoon, another component of the PCM (tom 
Dieck et al., 1998; Fenster et al., 2000). Piccolo contains several coiled coil 
domains, a PDZ domain and two C2 domains (Fenster and Garner, 2002). The 
C2A domain functions as a low-affinity calcium sensor in presynaptic terminals 
(Gerber et al., 2001). Piccolo and Bassoon, along with other presynaptic 
constituents, are transported in 80 nm large dense core vesicles (LDCVs) to 
nascent synapses, and 2 or 3 of these vesicles are sufficient to form an active 
synapse (Zhai et al., 2001; Shapira et al., 2003; Tao-Cheng, 2007). The recent 
described nonsynonymous SNP rs2522833 in Piccolo encodes a common 
variation in the C2A domain, where a serine is substituted for an alanine 
(Sullivan et al., 2008).   
Piccolo is involved in the regulation of the internalization of the dopamine 
transporter (DAT) in heterologous cells. Specifically, expression of the C2A 
domain of Piccolo reduces methamphetamine-induced DAT internalization. (Cen 
et al., 2008). DAT and SERT are structurally related proteins, which belong to 
the solute carrier superfamily. It could be likely that membrane incorporation 
and internalization of these proteins is regulated in the same manner. 
Additionally, Piccolo influences synaptic function by negatively regulating 
synaptic vesicle exocytosis (Leal-Ortiz et al., 2008). These data led us to 
hypothesize that possibly, Piccolo might contribute to the overall risk of 
depression by affecting the membrane incorporation of SERT. 
To test this hypothesis we expressed mCherry-SERT in hippocampal 
neurons and investigated whether knockdown of Piccolo or the variation 
rs2522833 affected the localization and trafficking of SERT. We show here that 
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knockdown of Piccolo in neurons did not affect SERT trafficking. However, 
expression of the Piccolo C2A domain variation rs2522833 in heterologous cells 
might affect membrane localization of SERT. 
 
Results 
 
Piccolo localized to neurotransmitter release sites in hippocampal and 5-HT 
neurons 
First, we analyzed the cellular localization of Piccolo in hippocampal neurons 
and 5-HT neurons. Hippocampal neurons (14 days in vitro (DIV)) were fixed and 
immunocytochemistry was performed for Piccolo and for the presynaptic 
terminal marker Synaptobrevin-2 (VAMP2). Piccolo immunoreactivity was 
distributed in a punctate pattern, indicative for labeling of presynaptic terminals 
(Fig. 1A). Indeed, the majority of Piccolo puncta co-localized with VAMP2 
puncta, showing that these represented presynaptic terminals (Fig. 1B,C). 
Zooming in on part of a neurite showed that >90% of Piccolo puncta co-localized 
with VAMP2 (Fig. 1D-F). Thus, Piccolo was present in presynaptic terminals. 
Next, we investigated the localization of Piccolo in 5-HT neurons. We used a 
coronal brain slice from an adult mouse through the dorsal raphe nucleus 
(DRN), the region in the brain where the majority of 5-HT neurons is localized. 
We performed immunocytochemistry for tryptophan hydroxylase (Tph), the rate 
limiting enzyme for 5-HT synthesis and a marker for the 5-HT system. In a DRN 
slice, several 5-HT neurons were present (Fig. 1G). Immunocytochemistry for 
Piccolo resulted in a punctate labeling in the DRN slice (Fig. 1H). Piccolo staining 
was barely detectable in the 5-HT cell bodies (Fig. 1I). However, Piccolo puncta 
co-localized with Tph puncta.  Tph is present in varicosities and presynaptic 
terminals (chapter 4 of this thesis) (Pickel et al., 1976).  
 
Figure 1 next page. Piccolo localizes to presynaptic terminals in neurons 
(A-C) Hippocampal neurons were fixed at DIV14, and immunocytochemistry was 
performed for Piccolo (A) and the presynaptic marker VAMP2 (B). (C) Merged image 
shows that several Piccolo puncta co-localized with VAMP2 puncta. (D-F) Blow up of the 
white box in C shows that almost every Piccolo puncta co-localizes with a VAMP2 puncta. 
(D) Piccolo staining. (E) VAMP2 staining. (F) Merged image. (G) A coronal brain slice 
through the DRN from an adult mouse was stained against the 5-HT marker Tph. This 
shows that 5-HT cell bodies and fibers are present. (H) Piccolo staining on this slice shows 
that Piccolo expression is low in 5-HT cell bodies. (I) Merged image. (J) Blow up of the 
white box in I shows a 5-HT cell body and several Tph puncta, which might be 5-HT 
varicosities. (K) Piccolo staining shows that in several of the Tph puncta Piccolo is present. 
(L) Merged image. Scale bars: 20 µm in C and I, 10 µm in F and L. 
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 These Tph puncta might therefore represent 5-HT varicosities, axonal sites 
where 5-HT release occurs, often without a post-synaptic specialization. 
Therefore, it seems that also in 5-HT neurons Piccolo is localized in release sites 
(Fig 1J-L). 
 
Efficient knockdown of Piccolo in hippocampal neurons 
Next, we investigated whether knockdown of Piccolo affected trafficking of 
mCherry-SERT. In hippocampal neurons, mCherry-SERT is transported in 
secretory vesicles which move through the axon with no preference for direction 
of movement (Chapter 3, this thesis). To achieve efficient knockdown of Piccolo, 
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we designed six short hairpin RNA (shRNA) nucleotides, targeted towards the N-
terminus of Piccolo. These short hairpins were inserted in a vector containing 
also an internal ribosomal entry site (IRES) and EGFP, as a control for 
transfected neurons. We tested the shRNAs for their Piccolo knockdown 
efficiency. To this end we transfected the shRNA constructs in hippocampal 
neurons, and four days later fixed and processed the neurons for 
immunocytochemistry. Several constructs tested did not show any knockdown of 
Piccolo. We decided to use shRNA#5 as a negative control. Analysis of Piccolo 
expression in MAP2 negative axons of neurons transfected with shRNA#5 was 
not reduced compared to untransfected cells (Fig. 2A-D). The axon had a 
punctate labeling of Piccolo, which was indistinguishable from untransfected 
neurons. On the other hand, transfection of shRNA#6 caused a reduction in  
levels of Piccolo in axons (Fig. 2E-H, 2I-L).  
Quantification of the number of Piccolo puncta per µm neurite revealed that 
in control condition there was on average one Piccolo puncta per two µm neurite, 
whereas in shRNA#6 mediated knockdown there was on average one Piccolo 
puncta per ten µm neurite (control 0.49 ± 0.11 Piccolo puncta per µm axon; 
knockdown 0.11 ± 0.02 Piccolo puncta per µm axon, p=0.002) (Fig. 2M). Thus, 
shRNA#6 resulted in an efficient, approximately 80%, reduction in number of 
Piccolo puncta. Therefore, we used this construct to test the effect of Piccolo 
knockdown on mCherry-SERT localization and trafficking.  
 
Knockdown of Piccolo does not affect SERT trafficking 
We used shRNA#6 to investigate the effect of Piccolo knockdown on mCherry-
SERT localization and trafficking. SERT tagged with mCherry is transported in 
secretory vesicles, which move in anterograde and retrograde direction, with no 
preference for direction of movement (chapter 3 of this thesis). We transfected 
mCherry-SERT and shRNA#6 in hippocampal neurons, and used EGFP as a 
control. One minute movies of mCherry-SERT trafficking were made, and the 
movies were analyzed using the custom written Fluotrack software program 
(Broeke et al., 2008). The velocity of moving puncta was quantified, as well as 
the direction of movement. For direction we discerned anterograde direction, 
retrograde direction and bidirectional, vesicles which changed direction during 
imaging. Both in neurons expressing shRNA#6 and EGFP, we observed several 
puncta of mCherry-SERT, which displayed rapid movements in both the 
anterograde and retrograde direction. Additionally, also stationary vesicles were 
observed (Fig. 3A-D). We quantified the average velocity of mCherry-SERT 
moving puncta in control neurons expressing EGFP, and neurons expressing 
shRNA#6. A velocity histogram shows the distribution of the average velocity 
and direction of movement between control and knockdown (Fig. 3E). 
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 Figure 2. Efficient shRNA-mediated knockdown of Piccolo 
Several shRNA constructs against Piccolo were tested for their efficacy to reduce Piccolo 
expression in cultured hippocampal neurons. ShRNA#5 did not result in Piccolo 
knockdown. (A) EGFP expression, showing that the shRNA construct is expressed. (B) 
Piccolo staining. (C) Neurite is MAP2 negative, showing that this is an axon. (D) Merged 
image. (E) EGFP expression in a neuron transfected with shRNA#6-EGFP. (F) Piccolo 
staining. (G) MAP2 staining. (H) Merged image, showing that shRNA#6 results in efficient 
knockdown of Piccolo in the axon. (I-L) Blow up of the white box in H, with EGFP, Piccolo 
staining, MAP2 staining and merged image respectively. (M) Quantification of the level of 
Piccolo knockdown shows that shRNA#6 resulted in a ~80% reduction in Piccolo puncta 
(control 0.49 ± 0.11 Piccolo puncta per µm axon (n=7); knockdown 0.11 ± 0.02 Piccolo 
puncta per µm axon (n=8)). Scale bars: 5 µm in D and L, 10 µm in H.  
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Trafficking of mCherry-SERT did not differ between control and knockdown 
(average velocity control 1.30 ± 0.042 µm/s  (n=8 neurons); knockdown 1.36 ± 
0.039 µm/s, (n=18 neurons) (Fig. 3F). Also, percentage of moving vesicles was 
not different between control and knockdown (control 46.69 ± 5.03%; 
knockdown 39.88 ± 3.39%) (Fig. 3G). Additionally, percentage of vesicles 
moving anterogradely, retrogradely or bidirectionally did not differ between 
control and knockdown (data not shown). 
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Figure 3 previous page. Piccolo knockdown does not affect SERT trafficking 
dynamics             
(A) Neurons transfected with EGFP and mCherry-SERT. Images are taken 5 seconds 
apart. Several mCherry-SERT puncta are observed which are either stationary (yellow), or 
are moving anterogradely or retrogradely. (B) A neuron transfected with shRNA#6EGFP 
and mCherry-SERT. Images taken 5 seconds apart show that after Piccolo knockdown also 
several mCherry-SERT puncta are observed, some of which are stationary, and other 
which display anterograde or retrograde movements. (C) and (D) are blow ups of the white 
boxes in A and B, respectively. (E) Velocity histogram of mCherry-SERT puncta in control 
neurons and Piccolo knockdown neurons. Negative values are retrograde movements, 
positive values are anterograde movements. (F) Average velocity of mCherry-SERT puncta 
in control neurons and Piccolo knockdown neurons. (G) Percentage moving mCherry-
SERT puncta in control neurons and Piccolo knockdown neurons. Scale bars: 10 µm in A 
and B, 5 µm in C and D.  
Expression of C2A variant rs2522833 alters  SERT distribution at the 
membrane in heterologous cells 
Finally, we were interested whether the SNP in the C2A domain of Piccolo which 
was found to associate with major depression, affected the membrane 
localization of SERT. Therefore, we constructed the C2Awt domain of Piccolo in 
an IRES2-EGFP vector and a C2Amut domain with the rs2522833 SNP which 
results in a serine to alanine substitution at amino acid 4684. We transfected 
these constructs, together with mCherry-SERT, in heterologous Neuro2A cells, 
which do not express endogenous Piccolo. In Neuro2A cells transfected with 
mCherry-SERT together with Piccolo C2Awt, SERT was localized predominantly 
at the cell membrane. The majority of cells displayed this SERT distribution, 
although also in some cells mCherry-SERT was homogenously distributed. This 
may be due to the level of expression, since in several cells which showed this 
mCherry-SERT distribution, also EGFP fluorescence intensity was increased 
compared to other cells (Fig. 4A-C). Zooming in on a few cells expressing EGFP 
and mCherry-SERT showed that SERT is localized at the membrane, as mCherry 
fluorescence appeared like a ring at the membrane. Moreover, mCherry-SERT 
also seemed to associate with intracellular organelles, as some mCherry-SERT 
appeared as puncta in the cytoplasm. (Fig. 4D-F). Expressing mCherry-SERT 
together with Piccolo C2Amut resulted in cells in which mCherry-SERT was 
localized at the membrane, but also some cells in which mCherry-SERT 
displayed a more uniform distribution in the cytoplasm which might again be 
due to the level of expression (Fig. 4G-I). A typical example of three cells 
expressing both constructs showed that in one cell mCherry-SERT was localized 
at the membrane, and in the other cells mCherry-SERT displayed a more 
uniform distribution in the cytoplasm (Fig. 4J-L). Strikingly, membrane bound 
mCherry-SERT in Piccolo C2Amut expressing cells displayed a more patchy 
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distribution than in Piccolo C2Awt expressing cells (Fig. 4M-O). A line scan 
profile of a typical cell co-expressing mCherry-SERT with Piccolo C2Awt showed 
that the highest level of fluorescence was at the membrane (Fig. 4P). In contrast, 
a line scan profile of a cell c0-expressing mCherry-SERT with Piccolo C2Amut 
showed that fluoresence levels in the cytoplasm were comparable with 
fluorescence levels at the membrane (Fig. 4Q). 
Thus, it appeared that co-expression of the Piccolo C2Amut with the 
rs2522833 SNP resulted in an altered distribution of mCherry-SERT at the 
membrane. These data suggest that Piccolo is not involved in the trafficking of 
SERT, but might be involved in regulating SERT membrane levels. 
 
Discussion 
 
Piccolo is a large protein, which is part of the active zone in the presynaptic 
terminal. There, Piccolo probably has a scaffolding role, but Piccolo also contains 
a PDZ domain and two C2 domains. Piccolo can be alternatively spliced, 
resulting in absence or presence of the C2B domain (Wang et al., 1999). 
Additionally, in the C2A domain a nine-residue sequence has been found which 
is subject of alternative splicing, resulting in variants of the C2A domain with 
different calcium affinities (Garcia et al., 2004). In this study we focused 
exclusively on the long C2A variant. The gene region in which Piccolo is localized 
has been linked to autism (Nabi et al., 2003). The SNP rs2522833 is localized in 
the C2A domain (Sullivan et al., 2008). The C2A domain has a low calcium 
affinity, suggesting an involvement in presynaptic plasticity processes (Gerber et 
al., 2001). It is currently unknown whether the SNP affects PIP2 or Ca2+ binding 
to the C2A domain.  
Figure 4 next page. Expression of Piccolo C2Awt and C2Amut with mCherry-
SERT in heterologous cells                    
(A-C) Expression of C2Awt–IRES-EGFP and mCherry-SERT in Neuro2A cells. (D-F) Blow 
up of white box in C shows that in the majority of cells mCherry-SERT is localized at the 
membrane. In the cytoplasm, mCherry-SERT displays a punctate distribution, suggesting 
association with intracellular organelles. (G-I) Expression of C2Amut-IRES-EGFP and 
mCherry-SERT in heterologous cells. (J-L) Blow up of white box #1 in I shows that in 
several Neuro2A cells expressing C2Amut-IRES-EGFP, mCherry-SERT seems to have a 
more uniform cytoplasmic distribution. (M-O) Blow up of white box #2 in I shows that in 
cells in which mCherry-SERT is localized at the membrane, mCherry-SERT is not 
uniformly distributed at the membrane, but instead is distributed in patches along the 
membrane. (P,Q) Line scan profiles of a typical cell expressing mCherry-SERT with 
C2Awt–IRES-EGFP or C2Amut-IRES-EGFP (lines in figures E and K respectively). Arrows 
indicate cell membrane. Scale bars: 20 µm in C and I, 10 µm in Fand L and 5 µm in O. 
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The regulation of SERT membrane localization and internalization is important 
in determining efficacy of 5-HT transmission. Increases in membrane 
localization of SERT increase 5-HT reuptake and thereby reduce extracellular 
levels of 5-HT and binding of 5-HT to postsynaptic 5-HT receptors. In contrast, 
internalization of SERT results in increased extracellular levels of 5-HT and 
increased postsynaptic activation of 5-HT receptors.  
Protein kinase C (PKC) reduces the expression level of SERT, presumably by 
altering the membrane localization of SERT (Qian et al., 1997). Indeed, 
application of phorbol esters results in increased internalization of SERT. In 
contrast, substrates of SERT, such as 5-HT, reduce PKC dependent SERT 
internalization, whereas SERT antagonists, such as antidepressants, block this 5-
HT mediated reduction in SERT internalization (Ramamoorthy and Blakely, 
1999). On the other hand, protein kinase G (PKG) activity increases the 
membrane localization of SERT (Zhu et al., 2004). Therefore, there is an 
extensive level of regulation of membrane expression of SERT. There is an 
indirect link between Piccolo and SERT; Syntaxin1A is known to interact with 
SERT, and to regulate SERT activity (Quick, 2003). The C2A domain of 
Synaptotagmin, which shares similarity with the C2A domain of Piccolo, 
interacts with Syntaxin1A (Shao et al., 1997). Therefore this makes it likely that 
also the C2A domain of Piccolo is able to interact with Syntaxin1A, and thus 
possibly with SERT.  
We used heterologous Neuro2A cells, which do not express Piccolo 
endogenously, to study the effect of expression of both C2A variants on SERT 
localization. We showed that distribution of SERT at the membrane might be 
altered after co-expression with the mutant C2A variant. Previously it has been 
shown that DAT trafficking and internalization is not altered in heterologous 
cells upon Piccolo knockdown. However, upon treatment of cells with 3,4-
methylenedioxy-N-methylamphetamine (MDMA), there is a significant increase 
in DAT internalization. Thus, Piccolo seems to regulate the MDMA dependent 
internalization of DAT. For SERT, it has been shown that application of 
antidepressants and the PKC activator !-phorbol 12-myristate 13-acetate (!-
PMA) results in an increased internalization of SERT (Lau et al., 2008a; Lau et 
al., 2008b). In view of this, it would be interesting to challenge SERT with an 
antidepressant after expression of both C2A variants, to investigate whether this 
results in an altered distribution of SERT between the two C2A variants. 
Several studies show that the expression level, membrane level, or transport 
activity of SERT might be affected in psychopathological processes. Levels of 
SERT expression in DRN are reduced in brains of depressed suicide victims 
(Arango et al., 2001). In contrast, long-term administration of antidepressants 
seemed to also reduce SERT surface expression (Hirano et al., 2005). Recent 
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studies showed that a SNP in SERT which associated with obsessive compulsive 
disorder resulted in increased transport activity of SERT (Kilic et al., 2003). 
Thus, further studies are required to investigate the relation between the SNP in 
Piccolo, SERT expression and activity, and major depression disorder. 
 
EXPERIMENTAL PROCEDURES 
 
Plasmids 
Human SERT (hSERT) cDNA tagged with ECFP at the 5’ end in the Clontech 
ECFP-C1 vector was a kind gift from Dr. H. Sitte. To clone a red fluorescent 
version of hSERT we replaced ECFP for the red fluorescent protein mCherry. To 
this end mCherry was digested out of the vector using AseI and BsrGI and cloned 
sticky in the ECFP-hSERT vector from which ECFP had been excised.  For 
construction of pSuper-CMV-EGFP-shRNA-Piccolo, pSuper was digested using 
EcoRI and PstI and CMV-EGFP was inserted after isolation of this fragment 
from pEGFP-C3 (Clontech) using BsrGI and NsiI. The shRNA against Piccolo 
was constructed using the following primers: forward 5’-
GATCCCCACCCCACAAATATAAAGCTTTCAAGAGAAGCTTTATATTTGTGG 
GGTTTTTTGGAAA-3’ and reverse 5’-AGCTTTTCCAAAAAACCCCACAAA 
TATAAAGCTTCTCTTGAAAGCTTTATATTTGTGGGGTGGG-3’. These primers 
were annealed by heating to 100°C, cooling down to room temperature and 
inserted in pSuper-CMV-EGFP by digesting this vector with BglII and HindIII. 
For construction of C2Awt, this fragment was isolated from a Yeast-2-Hybrid 
mouse cDNA bank using the following primers: forward 5’-
GGCGTGGATCCCAAGCAGCTG-3’ and reverse 5’- 
GTTTTGACTGGAGTGAGACTTG-3’ and subsequently a PCR was performed 
using the following primers: forward 5’-
AAGGATCCGCCTCTCACCCAATTACAGGA-3’ and reverse 5’-
TTTGCGGCCGCATGCTTTCAGTCTGTTCTTTCAG-3’ to add BamHI and NotI 
sites. For C2Amut (S4684A), the C2A domain was isolated using two PCR 
reactions using the following primers: forward 5’-
AAGGATCCGCCTCTCACCCAATTACAGGA-3’ and reverse 5’- 
CGAGGAGTGTTGTCCAGATGAGCAGTACTAGATAAATCAATCAATAC-3’ and 
forward 5’-GTATTGATTGATTTATCTAGTACTGCTCATCTGGACAACACTCCTCG 
-3’ and reverse 5’- TTTGCGGCCGCATGCTTTCAGTCTGTTCTTTCAG-3’. These 
two PCR products were annealed and a PCR was performed on this product 
using primers: forward 5’-AAGGATCCGCCTCTCACCCAATTACAGGA-3’ and 
reverse 5’-TTTGCGGCCGCATGCTTTCAGTCTGTTCTTTCAG-3’ to add BamHI 
and NotI sites and C2Awt and C2Amut fragments were ligated in pGEX.  To 
construct pCMV-C2A-IRES2EGFP, both fragments were isolated from pGEX by 
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PCR using the following primers: forward 5’- 
AAAGGATCCACCATGGCCTCTCACCCAATTACAGG-3’and reverse 5’- 
TTTGAATTCTCAGCTTTCAGTCTGTTCTTTCAG-3’to add BamHI and EcoRI 
sites and a Kozak and stop sequence. Fragments were inserted in pIRES2EGFP 
by ligating this vector with BglII and EcoRI.  
 
Cell culture and transfections 
Hippocampi from embryonic day 18 C57/Bl6 mouse embryos were dissected free 
of meninges and collected in Hanks’ Balanced Salt Solution (HBSS; Invitrogen) 
supplemented with 7 mM HEPES (Invitrogen). Hippocampi were digested with 
0.25% trypsin (Invitrogen) in HBSS supplemented with 7 mM HEPES for 15 
minutes at 37ºC. After digestion tissue was washed three times with HBSS 
supplemented with 7 mM Hepes and subsequently triturated with a fire-polished 
glass pipette. Dissociated neurons were plated at a density of 25.000 cell/well on 
rat glial cells on 18 mm glass coverslips (Menzel Glaser, Braunschweig, 
Germany) in 12 well plates. Cells were cultured in neurobasal medium 
(Invitrogen) supplemented with B27 supplement (Invitrogen), 18 mM HEPES, 
0.5 mM Glutamax (Invitrogen) and penicillin/streptomycin (Invitrogen). Once a 
week half of the medium was replaced. The hippocampal cultures were 
transfected using Lipofectamine 2000 (Invitrogen). Before transfection, half of 
the neurobasal medium was collected from each well and replaced with new 
neurobasal medium. For one well, 1 #l of Lipofectamine was added to 25 #l of 
serum free glutamax (Invitrogen) medium and incubated for 5 minutes. 
Subsequently, from each construct 1 #g of DNA was added to 25 #l of serum free 
glutamax and immediately mixed with the 25 #l of serum free glutamax 
containing Lipofectamine. This mixture was incubated for 30 minutes before 
adding to the cells. After 4-6 hours of incubation on the cells, half of the 
neurobasal medium was replaced again with the earlier collected neurobasal 
medium. Cells were routinely transfected at DIV2-7 and imaged at DIV10-14. 
 
Immunocytochemistry 
For immunocytochemistry, neuronal cells were fixed in 4% paraformaldehyde in 
phosphate buffered saline (PBS) (pH 7.4) for 20 minutes at room temperature. 
Cells were washed in PBS and blocked in PBS containing 4% fetal calf serum and 
0.2% Triton X-100 for 20 minutes at room temperature. Cells were incubated 
overnight with primary antibodies at 4ºC in PBS containing 0.2% Triton X-100. 
As primary antibodies monoclonal MAP2 (Chemicon), and polyclonal Piccolo 
(Synaptic Systems) and Synapsin (E028) were used. After incubation in primary 
antibodies, cells were washed three times using PBS. Subsequently, cells were 
incubated in Alexa Fluor-conjugated secondary antibodies (Invitrogen) in PBS 
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for one hour at room temperature. All antibodies were used in a 1:1000 dilution. 
Finally, cells were washed three times in PBS and mounted using Dabco-Mowiol.  
For immunohistochemistry on mouse brain slices, mice were anaesthetized 
and transcardially perfused with 4% paraformaldehyde (PFA) in PBS (pH 7.4). 
Brains were post fixed in PFA for one day, and subsequently cryoprotected in 
increasing concentrations of sucrose. Thirty µm coronal adult brain slices were 
made using a Cryostat (Leica). Midbrain slices containing the dorsal and medial 
raphe nucleus were blocked for two hours in PBS containing 10% normal goat 
serum and 0.5% Triton X-100. Subsequently, the slices were incubated overnight 
in primary antibodies in PBS containing 0.5% Triton X-100 at 4ºC. Brain slices 
were washed three times two hours in PBS and incubated in secondary 
antibodies in PBS overnight at 4ºC. After washing three times two hours, slices 
were mounted using Dabco-Mowiol. As primary antibodies monoclonal Tph 
(Sigma, recognizing both Tph2 and Tph2) and polyclonal Piccolo (Synaptic 
systems) were used in a 1:1000 dilution. Alexa Fluor-conjugated secondary 
antibodies (Invitrogen) were used in a 1:1000 dilution. Cells and slices were 
examined on a Zeiss LSM 510 confocal laser scanning microscope (Zeiss, BV The 
Netherlands). 
 
Live cell imaging 
Cells were imaged in a chamber perfused with Tyrode’s solution (119 mM NaCl, 
2.5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 30 mM glucose, 25 mM HEPES, pH 7.4) 
on an Axiovert II Microscope (Zeiss, Oberkochen, Germany) equipped with a 
Coolsnap HQ camera (Photometrics, Tucson, Arizona, USA) and a Polychrome 
IV illumination unit (TILL photonics, Grafelfing, Germany). Images were 
acquired in MetaMorph 6.2 software (Universal Imaging, Downingtown, 
Philadelphia, USA) using a 100x oil objective. 
 
Image analysis 
To analyze the trafficking of mCherry-hSERT, image stacks were converted to 
.avi movie files using ImageJ software. Movies were analyzed using the Fluotrack 
software program (Broeke et al., 2008) to quantify the average number of 
moving puncta, the average velocity of moving puncta, the average pausing time 
of moving puncta and the direction of moving puncta.  
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Abstract 
 
The serotonin (5-HT) system densely innervates many brain areas and is 
important for proper brain development. To specifically ablate the 5-HT system 
we generated mutant mice carrying a floxed Munc18-1 gene and Cre recombinase 
driven by the 5-HT-specific serotonin reuptake transporter (SERT) promoter. 
Mutant mice were smaller than their control littermates and the majority died 
within a few days after birth. Immunohistochemical analysis of brains of these 
mice showed that initially 5-HT neurons are formed and the cortex is innervated 
with 5-HT projections. From embryonic day (E) 16 onwards, however, 5-HT 
neurons started to degenerate and at postnatal day (P) 2 hardly any 5-HT 
projections were present in the cortex. The 5-HT system of mice heterozygous for 
the floxed Munc18-1 allele was indistinguishable from control mice. Behavioural 
analysis of these heterozygous mice showed that there is no difference in basal 
behaviour, conditioning and anxiety-related behaviour compared to control 
mice. These data show that deletion of Munc18-1 in 5-HT neurons results in 
rapid degeneration of the 5-HT system and suggests that the 5-HT system is 
important for postnatal survival.  
 
Introduction 
 
The 5-HT system consists of clusters of cell bodies in the midbrain raphe nuclei, 
with the largest clusters in the median raphe nucleus (MRN) and the dorsal 
raphe nucleus (DRN). Several brain areas receive dense 5-HT innervation and 5-
HT is released both synaptically and as volume transmission (Ridet et al., 1993; 
Bunin and Wightman, 1998). Due to this and to the several 5-HT receptor 
subtypes which are present in the brain, 5-HT has many roles and influences 
many processes in the brain (Jacobs and Azmitia, 1992). 
Neurogenesis of 5-HT neurons in the mouse brain occurs in the ventral 
rhombencephalon around E10 (Wallace and Lauder, 1983). One day later, 5-HT 
neurons begin to synthesize and secrete 5-HT and start growing out axons. 
Around birth, target areas such as the forebrain and the hippocampus are 
densely innervated with 5-HT projections. Only after birth, the maturation of the 
5-HT network is completed.  
Several studies have addressed the role of 5-HT on the development of the 5-
HT system and brain development. In a conditional Lmx1b knockout (KO) 
mouse, almost all 5-HT neurons fail to survive, resulting in a significant decrease 
in brain tissue 5-HT levels (Zhao et al., 2006). However, these mice do not show 
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an overt phenotype and survive to adulthood (Zhao et al., 2006). In contrast, it 
was shown that maternal 5-HT is required for embryonic development (Cote et 
al., 2007). Furthermore, in tryptophan hydroxylase 2 (Tph2) KO mice 5-HT 
neurons are completely devoid of 5-HT, but the morphology and neurite 
distribution of the 5-HT system is not affected, and these mice do not show any 
behavioural phenotype (Gutknecht et al., 2008). Neonatal depletion of 5-HT by 
the neurotoxin 5,7-Dihydroxytryptamine results in rather subtle changes in 
behavioural response and brain development (Hohmann et al., 2007; Bennett-
Clarke et al., 1995).  
In this study we silenced the 5-HT system by conditional deletion of 
Munc18-1 in 5-HT neurons. Neurons that lack the presynaptic protein Munc18-1 
have a complete absence of neurotransmitter secretion and these mice are born 
paralyzed and die immediately after birth (Verhage et al., 2000). In these mice, 
initially synapses are formed and the assembly of the brain is normal. However, 
in later stages of brain development there is massive neuronal cell death and 
brain degeneration (Verhage et al., 2000).  
In SERT-Crecre/wt Munc18-1lox/lox mice 5-HT neurons were initially generated 
and 5-HT projections innervated the midbrain and cortex, later followed by 
degeneration and loss of 5-HT projections in the cortex. The majority of these 
mice died within a few days after birth. These data suggest that the 5-HT system 
contributes importantly to postnatal brain development. 
 
Results 
 
Deletion of Munc18-1 in SERT expressing neurons results in postnatal lethality 
We have shown previously that Munc18-1 mutant mice lack regulated secretion 
and have a lethal phenotype (Verhage et al., 2000). Therefore, we have generated 
Munc18-1lox/lox mutant mice in order to conditionally delete Munc18-1. Crossing 
these mice with a L7-Cre line, with Cre expressed in Purkinje neurons in the 
cerebellum, resulted in mice which developed severe ataxia, suggesting a 
cerebellar phenotype (Heeroma et al., 2004). Here we crossed Munc18-1lox/lox 
mice with SERT-Cre mice, which express Cre in SERT expressing neurons. These 
are the 5-HT neurons in the raphe nuclei, but also some hippocampal neurons 
and thalamocortical neurons which express SERT transiently during 
development (Zhuang et al., 2005; Narboux-Neme et al., 2008). Crossing SERT-
Cre mice with Munc18-1lox/lox mice results in mice in which Munc18-1 is 
specifically removed in SERT expressing neurons (Fig. 1A). We crossed SERT-
Crecre/wt Munc18-1lox/wt mice with SERT-Crewt/wt Munc18-1lox/wt mice which should 
result in 12.5% of offspring which have SERT-Crecre/wt and Munc18-1lox/lox 
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genotypes. Genotyping mice sacrificed at E16 or E18 revealed that there were 
more SERT-Crecre/wt Munc18-1lox/lox and SERT-Crewt/wt Munc18-1lox/lox mice and 
less SERT-Crecre/wt Munc18-1lox/wt mice then expected (p= 0.007) (Fig. 1B). 
Genotyping 101 mice three weeks after birth revealed that genotype frequencies 
were not distributed at Mendelian ratio (p= 0.027). Only three SERT-Crecre/wt 
Munc18-1lox/lox mice were found, whereas based on Mendelian ratio the expected 
number of SERT-Crecre/wt Munc18-1lox/lox mice should be 13, giving a 77% 
mortality rate in SERT-Crecre/wt Munc18-1lox/lox mice (Fig. 1C). Also, SERT-Crecre/wt 
Munc18-1lox/lox mice were smaller compared to littermates (data not shown). 
These three remaining SERT-Crecre/wt Munc18-1lox/lox mice all died in the fourth 
postnatal week. This shows that Munc18-1 deletion in SERT expressing neurons 
results in postnatal lethality. 
 
 
Figure 1. Postnatal 
lethality in SERT-
Crecre/wt Munc18-
1lox/lox mice 
(A) Overview of 
breeding approach. 
Crossing SERT-Cre with 
Munc18-1lox/lox mice 
results in deletion of 
Munc18-1 only and 
specifically in SERT 
expressing neurons, 
whereas all other 
neurons still express 
Munc18-1.  
(B) Genotypes of mice 
sacrificed at E16 or E18 
differed from the 
expected Mendelian 
ratio. (C) Genotyping 
mice after weaning at 3 
weeks of age revealed 
that only few  SERT-
Crecre/wt Munc18-1lox/lox 
mice survived up to 
three weeks.  
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5-HT neurons are initially generated but then quickly degenerate  
To assess the effect of Munc18-1 deletion in 5-HT neurons on the development of 
the 5-HT system, we made coronal sections of paraformaldehyde (PFA) fixed 
brains at different developmental stadia and performed immunohistochemistry 
for 5-HT. As developmental time points we chose E16, E18 and P2. Expression of 
SERT, and thus of Cre recombinase, starts at E11 and the earliest recombination 
observed in the DRN in SERT-Cre mice was at E12.5 (Narboux-Neme et al., 
2008). Since it will take some days before all remaining Munc18-1 mRNA and 
protein is degraded, we chose E16 as the first time point. We first focused on the 
5-HT cell bodies in the DRN. Immunohistochemistry for 5-HT on brain slices 
from E16 SERT-Crecre/wt Munc18-1lox/lox and control mice showed that in the DRN 
5-HT neurons are present and these showed the characteristic DRN topology 
(Fig. 2A,B). The number of 5-HT neurons did not differ from control (control 312 
± 17.67, SERT-Crecre/wt Munc18-1lox/lox 305 ± 25.43, Fig. 2G,H,O). However, 
morphological analysis of the neurons showed that these were already 
degenerating, as assessed by the round morphology and reduced number of 
primary neurites. At E18, there was a ~80% decrease in the number of 5-HT 
neurons in SERT-Crecre/wt M18lox/lox mice compared to control (control 358 ± 
10.82, SERT-Crecre/wt Munc18-1lox/lox 59 ± 4.84, Fig. 2C,D,O). At P2 there were 
only few 5-HT neurons left in the DRN (control 364 ± 19.68, SERT-Crecre/wt 
Munc18-1lox/lox 25 ± 2.89, Fig. 2E,F,O). At E18 and P2 the remaining 5-HT 
neurons in SERT-Crecre/wt Munc18-1lox/lox brain sections displayed an altered 
morphology compared to control 5-HT neurons (Fig. 2I,J,K,L). 5-HT neurons in 
control brains had a characteristic fusiform or ovoid shape and grew out several 
primary neurites (Fig. 2M). In contrast, the mutant 5-HT neurons had a rounded 
morphology and the majority did not contain primary neurites, indicative of 
degenerating neurons (Fig. 2N).  This showed that between E16 and P2 there is a 
massive degeneration of 5-HT neurons in the DRN. 
  
5-HT projections innervate the DRN and cortex but are degenerated at P2 
Next, we focused on the innervation of the midbrain and cortex with 5-HT 
projections. Midbrain and cortex are the first regions which are densely 
innervated with 5-HT projections during development. We quantified 5-HT 
neurite density first in DRN midbrain sections at E16, E18 and P2. At E16 the 
sections from both control and SERT-Crecre/wt Munc18-1lox/lox mice contained 
several 5-HT neurites and there was no significant difference in 5-HT 
innervation density (1.31 ± 0.51% and 0.63 ± 0.24% respectively, Fig. 3A,B). At 
E18, in control sections the 5-HT innervation density was slightly increased 
compared to E16 (Fig. 3C). However, in SERT-Crecre/wt Munc18-1lox/lox sections the 
5-HT innervation density was decreased compared to control (control 2.32 ± 
0.86%, SERT-Crecre/wt Munc18-1lox/lox 0.31 ± 0.27%, Fig. 3D).  
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Figure 2. Rapid degeneration of 5-HT neurons in SERT-Crecre/wt Munc18-1lox/lox 
mice 
We compared the number of 5-HT cell bodies in the DRN in control and SERT-Crecre/wt 
Munc18-1lox/lox mice at E16, E18 and P2. (A-F) At E16, in both control mice (A) and SERT-
Crecre/wt Munc18-1lox/lox (lox/lox) mice (B) the 5-HT cell bodies are distributed in the DRN 
topology. At E18 and P2, however, in midbrain sections from SERT-Crecre/wt Munc18-1lox/lox 
brains (D, F respectively) only few 5-HT neurons are present compared to control sections 
(C, E respectively). (G-L) Zooming in on 5-HT cell bodies shows that in control sections at 
E16 (G), E18 (I) and P2 (K) the cell bodies grow out several neurites and have a fusiform or 
ovoid morphology. However, remaining 5-HT cell bodies in SERT-Crecre/wt Munc18-1lox/lox 
sections at E16 (H), E18 (J) and P2 (L) have a round morphology with hardly any neurites. 
(M,N) Blow up of some 5-HT cell bodies in control and SERT-Crecre/wt Munc18-1lox/lox mice 
sections shows the differences in 5-HT cell body morphology. (O) Analysis of the number 
of 5-HT cell bodies in the sections showed that there is no difference at E16, but at E18 and 
P2 there is a decrease of 70% to 80% in SERT-Crecre/wt Munc18-1lox/lox sections. Scale bars: 
200 µm in F, 50 µm in L and 20 µm in N. Data shown are mean ± standard error of the 
mean (SEM). * p < 0.05. 
 
At P2 only few 5-HT neurites are left in SERT-Crecre/wt Munc18-1lox/lox sections 
(control 1.6 ± 0.41%, SERT-Crecre/wt Munc18-1lox/lox 0.33 ± 0.14%, Fig. 3E,F). 
Next, we focused on the 5-HT innervation density in the cortex. This revealed 
that already at E16 there is a reduction in 5-HT innervation density in SERT-
Crecre/wt Munc18-1lox/lox sections (control 3.27 ± 1.14%, SERT-Crecre/wt Munc18-
1lox/lox 0.65 ± 0.19%, Fig. 3G,H). At E18 and P2 the reduction in 5-HT innervation 
density is augmented, with only very few 5-HT neurites left at P2 in the cortex 
(E18 control 1.73 ± 0.45%, SERT-Crecre/wt Munc18-1lox/lox 0.36 ± 0.18%, P2 control 
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1.78 ± 0.52%, SERT-Crecre/wt Munc18-1lox/lox 0.19 ± 0.04%, Fig. 3I,J,K,L). 
Quantification showed that in the midbrain sections the 5-HT innervation 
density was reduced to ~20% and ~10% at E18 and P2 respectively (Fig. 3M). In 
the cortex, the 5-HT innervation density was reduced to ~20%, ~10% and ~5% at 
E16, E18 and P2 respectively (Fig. 3N). 
In summary, deletion of Munc18-1 in 5-HT neurons resulted in rapid 
degeneration of 5-HT cell bodies and the absence of 5-HT projections in the 
postnatal brain. 
 
Figure 3. Degeneration of 5-
HT neurites in DRN and 
cortex 
(A-F) At E16 in the midbrain 
containing the DRN, there was no 
difference in 5-HT neurite density 
between control (A) and SERT-
Crecre/wt Munc18-1lox/lox (B) mice. 
In control sections at E18 (C) and 
P2 (E) several 5-HT neurites were 
present. However, in SERT-
Crecre/wt Munc18-1lox/lox sections at 
E18 (D) and P2 (F) only very few 
5-HT neurites are left. (G-L) In 
the cortex already at E16 there is a 
reduction in 5-HT neurite density 
in sections from SERT-Crecre/wt 
Munc18-1lox/lox (H) mice 
compared to control (G). At E18 
(J) and P2 (L), in cortical sections 
from SERT-Crecre/wt Munc18-
1lox/lox mice only very few 
remaining 5-HT neurites are 
present, in contrast to E18 (I) and 
P2 (K) control cortical sections. 
(M) Quantification of the 5-HT 
neurite density in the DRN 
revealed that at E16 there is no 
difference, but at E18 and P2 5-
HT neurite density is reduced to 
~20% and ~10% respectively. (N) 
In cortical sections, at E16 the 5-
HT neurite density is reduced to 
~20% and at E18 and P2 the 5-HT 
neurite density is reduced to 
~10% and ~5% respectively. Scale 
bar 50 µm in L. Data shown are 
mean ± SEM * p < 0.05.  
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Basal  behaviour is not affected in SERT-Crecre/wt Munc18-1lox/wt mice 
Finally, we were interested whether deletion of one allele of Munc18-1 in SERT 
expressing cells affected mouse behaviour. Previously, we have shown that 
Munc18-1 expression levels regulate the readily releasable pool (RRP) size. In 
Munc18-1 heterozygous mice there is a faster synaptic rundown during episodes 
of high activity, a decreased RRP size and a decrease in docked vesicles at the 
synapse (Toonen et al., 2006). Therefore it is likely that deletion of one 
functional Munc18-1 allele in SERT expressing neurons affects the efficacy of 5-
HT neurotransmission.  
Figure 4. Deletion of one functional allele of Munc18-1 in SERT expressing 
neurons does not affect number of 5-HT cell bodies and 5-HT innervation 
density 
(A-D) Midbrain sections containing the DRN from control (A) and hz (B) mice shows that 
5-HT neurons are distributed in the characteristic DRN topology. Zooming in on 5-HT cell 
bodies show that both in control (C) and hz sections (D) these neurons have a fusiform or 
ovoid morphology and grow out several neurites. (E-H) 5-HT neurite density is not 
different between control and hz mice in the midbrain containing the DRN (E and F 
respectively) or in cortical sections from control and hz mice (G and H respectively). (I) 
Number of 5-HT cell bodies per section does not differ between control and hz. (J) 5-HT 
neurite density in midbrain containing DRN and cortical sections is not different between 
control and hz. Scale bars: 200 µm in B, 50 µm in D and H.  
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First, we investigated whether deletion of one allele of Munc18-1 in SERT 
expressing neurons affected the number of 5-HT cell bodies in the DRN, or the 5-
HT fiber density in the DRN and cortex. Analysis of midbrain sections from 
control and SERT-Crecre/wt Munc18-1lox/wt (hz) mice showed that 5-HT neurons 
are distributed in the characteristic DRN topology, and control and hz are 
indistinguishable (Fig. 4A,B). 5-HT cell bodies in both control and hz had a 
fusiform or ovoid shape (Fig. 4C,D). Quantification of the number of 5-HT cell 
bodies in the DRN revealed no difference between control and hz (control 364 ± 
14.78, hz 361 ± 15.01, Fig. 4I). Likewise, the 5-HT neurite density in the midbrain 
and cortex were similar (midbrain control 4.38 ± 0.93%, hz 4.67 ± 0.55%; cortex 
control 2.18 ± 0.35%, hz 2.87 ± 0.99%, Fig. 4E-H,J). Thus, deletion of one allele 
of Munc18-1 does not affect 5-HT neuronal survival, 5-HT neurite outgrowth or 
5-HT projection density.  
We tested several behavioural characteristics of hz mice by monitoring them 
for six days in home cages equipped with a video camera on top to visualize and 
analyze mouse behaviour. We analyzed the behaviour of eleven hz mice and 
compared several behavioural parameters with eleven control mice. First, we 
analyzed whether there was a difference in total distance moved in the open 
space and time spent under the shelter. Control and hz mice moved a similar 
total distance in the open space (control dark phase 2231.78 ± 139.39 cm/hour, 
light phase 483.91 ± 32.30 cm/hour; hz dark phase 2150.61 ± 112.70 cm/hour, 
light phase 433.69 ± 26.15 cm/hour; Fig. 5A,B), spent a similar proportion of 
time in a sheltered compartment (control dark phase 58.99 ± 2.03%, light phase 
86.37 ± 2.36%; hz dark phase 60.04 ± 1.11%, light phase 90.38 ± 0.45%; Fig. 5C) 
and spent a similar time drinking (control dark phase 33.92 ± 1.99 s/hour, light 
phase 7.50 ± 0.52 s/hour; hz dark phase 41.06 ± 4.72 s/hour, light phase 8.06 ± 
0.79 s/hour; Fig. 5D). Also, time spent in the feeder was indistinguishable 
between control and hz (control dark phase 476.77 ± 15.17 s/hour, light phase 
160.55 ± 6.58 s/hour; hz dark phase 497.73 ± 18.41 s/ hour, light phase 165.33 ± 
6.99 s/hour; Fig. 5E). Thus, basal behavioural parameters were indistinguishable 
between control and hz. 
 
Conditioning and anxiety related behaviour is not affected in SERT-Crecre/wt 
Munc18-1lox/wt mice 
To investigate whether hz mice display altered conditioning behaviour, a free 
operant conditioning task was performed, where a jump on the shelter resulted 
in the drop of a sucrose pellet. The number of directed short movement bouts 
(SMBs) increased during day four and five compared to day 1-3, but this 
conditioning behaviour did not differ between control and hz.  
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 Figure 5. Hz mice do not display altered basal behaviour 
(A) Six day plot of average distance moved (cm / 12 hours) during dark and light phase. 
Note the increase in distance moved during the dark phase at day 4 due to the free operant 
conditioning test. (B) No difference in average distance moved (cm/hour) between control 
and hz mice during the dark and light phase. (C) Proportion of time spent under the 
shelter does not differ between control and hz mice. (D) There is no difference in time 
spent drinking (s/hour) between control and hz mice. (E) Also, there is no difference in 
time spent in the feeder (s/hour). Data shown are mean ± SEM. 
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(day 1-3 control 17.07 ± 2.12, hz 16.33 ± 2.17; day 4-5 control 45.3 ± 5.27, hz 
46.32 ± 5.78; Fig. 6A). Number of pellets dropped during pre-training phase 
(session 1-10, day four) did not differ between control and hz mice (control 4.88 
± 0.43, hz 5.99 ± 0.45; Fig. 6B). Also during the sessions at day five (session 11-
12), there was no difference in the number of pellets dropped (control 20.36 ± 
2.81, hz 19.95 ± 2.34; Fig. 6B). 
To assess whether hz mice displayed altered anxiety related behaviour, a one 
trial anxiety task was performed at day six. To this end a lightspot was created at 
the feeder place, and the duration of time the animal spent in the lightspot and 
the feeder was recorded and compared with the time the animal spent at the 
feeder without a lightspot on. At day five (baseline) and day six (test) there was 
no difference between control and hz, but both groups spent less time in the 
lightspot at day six (day five control 1798.72 ± 208.1 s, hz 2108.01 ± 284.63 s; 
day six control 668.76 ± 61.28 s, hz 682.19 ± 83.98 s; Fig. 6C). Next, we 
investigated whether the frequency of entering the feeder zone at day five 
(baseline) and day six (test) was different. Frequency of entering the feeder zone 
did not differ between control and hz mice, but both groups displayed a 
decreased frequency during the lightspot test during day six (day five control 
16.64 ± 2.51, hz 23.09 ± 3.51; day six control 7.15 ± 1.40, hz 8.12 ± 1.56; Fig. 6D). 
Also, time spent in the feeder zone during day five and day six did not differ 
between control and hz (day five control 528.15 ± 50.21 s, hz 621.91 ± 65.99 s; 
day six control 191.01 ± 30.36 s, hz 198.46 ± 33.53 s; Fig. 6E). Finally, analysis of 
latency to enter the lightspot zone after lightspot off revealed that this did not 
differ between control and hz (control 1567.71 ± 377.86 s; hz 1293.87 ± 329.17 s; 
Fig. 6F). Thus, mice in which one allele of Munc18-1 is deleted in SERT 
expressing neurons do not display altered basal, conditioning or anxiety-related 
behaviour. 
 
Discussion 
 
In this study, we showed that SERT-Crecre/wt Munc18-1lox/lox mice display a 
postnatal lethality phenotype, accompanied by a rapid degeneration of the 5-HT 
system. Inactivation of one allele of Munc18-1 in SERT expressing neurons does 
not affect 5-HT cell number or 5-HT innervation density, and does not affect 
anxiety related behaviour or conditioning related behaviour. 
Crossing Munc18-1lox/lox mice with SERT-Cre mice results in deletion of 
Munc18-1 from SERT expressing cells. It was shown previously that crossing 
SERT-Cre mice with loxSTOPlox-EYFP mice results in >99% of 5-HT neurons in 
the DRN which are EYFP positively labeled (Zhuang et al., 2005). 
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 Figure 6. Hz behaviour on free operant conditioning test and one trial anxiety 
test does not differ from control 
(A) The number of directional SMB’s is increased at day 4 and 5 compared to day 1-3, but 
does not differ between control and hz. (B) Number of sucrose pellets acquired is 
increased at session 11 and 12 (day 5), compared to session 1-10 (day 4, pre-training day), 
but does not differ between control and hz. (C) Time spent in the lightspot (s) is decreased 
at day 6 (lightspot on) compared to day 5 (baseline, without lightspot on), but does not 
differ between control and hz. (D) Frequency of entering the feeder zone is decreased at 
day 6 compared to day 5, but there is no difference between control and hz mice. (E) 
During lightspot on on day 6 mice spent less time in the feeder (s) which does not differ 
between control and hz. (F) No difference in latency (s) to enter the lightspot zone after 
lightspot off. Data shown are mean ± SEM.  
 
However, SERT is also transiently expressed in some other brain regions during 
development, such as the thalamocortical neurons (Lebrand et al., 1996). In 
SERT-Cre ROSA-loxstoplox-LacZ double positive mice, strong LacZ expression 
was not only observed in the DRN, but also in the thalamus, cingulate cortex and 
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in the CA3 region of the hippocampus (Zhuang et al., 2005; Narboux-Neme et 
al., 2008). Therefore, in SERT-Cre Munc18-1lox/lox mice also in some non-5-HT 
neurons Munc18-1 will be deleted. Genotyping sacrificed mice at E16 or E18 
revealed that there were more SERT-Crecre/wt Munc18-1lox/lox mice then expected, 
showing that these mice do not die during embryonic development. However, 
genotyping mice three weeks after birth showed that the majority of  SERT-
Crecre/wt Munc18-1lox/lox mice had died, and the remaining SERT-Crecre/wt Munc18-
1lox/lox mice died within the fourth postnatal week. SERT-Crecre/wt Munc18-1lox/lox 
mice were smaller compared to control mice which is in analogy with the VMAT2 
KO mice which are hypoactive, smaller compared to control littermates, do not 
feed and die within a few days after birth (Fon et al., 1997; Wang et al., 1997). 
Previously we showed that in Munc18-1 KO mice, the neuromuscular 
junction initially develops, but at later stages most of the motor neuronal cell 
bodies in the spinal cord degenerate (Heeroma et al., 2003). In analogy with this, 
in the absence of regulated secretion the hypothalamo-neurohypophysial system 
is initially normally formed, but in later stages of development degenerates 
(Korteweg et al., 2004). This is consistent with our observation that Munc18-1 is 
dispensable for initial generation and outgrowth of 5-HT neurons, but required 
for their survival. 
Since also in some other neurons Munc18-1 is deleted, it is unclear whether 
the observed phenotypes can be attributed to the degeneration of the 5-HT 
system. In Tph2 KO mice, 5-HT neurons are completely devoid of 5-HT, yet 
there are no alterations in 5-HT neuron morphology and 5-HT neurite 
distribution (Gutknecht et al., 2008). Although these mice can survive into 
adulthood, approximately 50% does not survive the first 4 weeks and surviving 
mice have growth retardation (Alenina et al., 2009). Additionally, in a 
conditional Lmx1b KO mouse, 5-HT neurons are initially formed but almost all 
central 5-HT neurons fail to survive and brain 5-HT levels are reduced to ~10% 
(Zhao et al., 2006). Remarkably, these mice display normal locomotor behaviour 
and show no abnormalities in gross brain morphology. Recently, it was shown 
that these mice have severe apnea and have a ~20% mortality rate during the 
neonatal period, although the majority of these mice survive beyond P28 
(Hodges et al., 2008; Hodges et al., 2009). 
Apparently, even the absence of central 5-HT synthesis or an almost 
complete removal of 5-HT neurons does not result in a severe (postnatal) 
lethality phenotype. Thus, although several of these mice display high (postnatal) 
mortality, the phenotypes observed are not as severe as in the SERT-Crecre/wt 
Munc18-1lox/lox mice.  
On the other hand, mice which lack GAP43, display disrupted barrel cortex 
formation and thalamocortical connections fail to form. These mice display a 
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postnatal lethality phenotype, with 50% of homozygotes which die between P0 
and P2, and >95% of homozygotes which die before P21 (Maier et al., 1999). 
Although these mutant mice display a reduced 5-HT innervation in the cortex 
and hippocampus, they have no significant difference in the number of 5-HT 
neurons, and other areas such as the piriform cortex and amygdale receive 
normal 5-HT innervation (Donovan et al., 2002). Thus, based on these data it is 
unclear whether the postnatal lethality phenotype observed in this study is 
attributable to a degeneration of thalamocortical or 5-HT neurons. It would be 
very interesting to delete the Munc18-1 gene specifically in 5-HT neurons using 
the Pet-Cre transgenic line, in which expression of Cre is restricted to 5-HT 
neurons (Scott et al., 2005). This approach could be used to investigate whether 
the phenotype we observed could indeed be attributed to degeneration of the 5-
HT system rather than degeneration of thalamocortical neurons.  
We have shown that mice in which one allele of Munc18-1 is deleted in SERT 
expressing neurons did not display altered basal, conditioning or anxiety-related 
behaviour. In these mice number of 5-HT neurons and 5-HT neurite density was 
indistinguishable from control mice. However, we have shown previously in 
neurons cultured from Munc18-1 heterozygous mice that there is a subtle 
secretion phenotype (Toonen et al., 2006). Thus, one could argue that possibly 
deletion of one functional allele of Munc18-1 affects 5-HT release and thus 
efficacy of 5-HT neurotransmission.  
There could be a few explanations why reduced 5-HT neurotransmission in 
the heterozygous mice used in this study does not affect behaviour. First of all, 
the reduction in 5-HT neurotransmission might just be too subtle to affect mouse 
behaviour. In Munc18-1+/- neuronal cultures, there is a ~25% reduction in 
synaptic vesicle release (Toonen et al., 2006). In contrast, expression of tetanus 
toxin light chain in 5-HT neurons in vivo results in a robust (>90%) inhibition in 
5-HT neurotransmission and these mice display decreased anxiety-related 
behaviour and enhanced associative learning (Kim et al., 2009). This suggests 
that a substantial reduction in 5-HT release is required to affect behaviour and 
that deletion of only one allele of Munc18-1 is not sufficient to achieve this 
reduction in 5-HT release. 
Secondly, in Munc18-1 null mice synaptic vesicle release is completely 
abolished. However, at least in chromaffin cells lacking Munc18-1, there is still 
some large dense core vesicle (LDCV) release, although this is reduced to ~10% 
(Voets et al., 2001). In Munc18-1 heterozygous mice LDCV release is presumably 
largely unaffected. In the 5-HT system, the bulk amount of 5-HT is released from 
LDCVs, which contain up to ~17 times as much 5-HT molecules as a single 
synaptic vesicle (Bruns and Jahn, 1995). Thus, if 5-HT released from synaptic 
vesicles is more severely affected than 5-HT released from LDCVs, there is only a 
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minor reduction in release of 5-HT and thus in efficacy of 5-HT 
neurotransmission.  Finally, (minor) reductions in extracellular 5-HT levels 
might be compensated for, such as by reduced SERT levels at the synaptic 
membrane and/or increased expression of postsynaptic 5-HT receptors, to 
guarantee proper levels of 5-HT neurotransmission. 
In conclusion, deletion of one allele of Munc18-1 in 5-HT neurons does not 
affect mouse behaviour presumably due to the fact that there is a too subtle 
reduction in 5-HT neurotransmission in these mice. However, deletion of both 
alleles of Munc18-1 in SERT expressing neurons results in a rapid degeneration 
of the 5-HT system and postnatal lethality. 
 
EXPERIMENTAL PROCEDURES 
 
Laboratory animals 
Generation and characterization of SERT-Cre mice has been described (Zhuang 
et al., 2005). Briefly, immediately upstream of the SERT translational start 
codon a cassette containing Cre and a FRT-flanked neomycin cassette was 
inserted. To generate conditional Munc18-1 mice (Heeroma et al., 2004), floxed 
Munc18-1 mice were generated by insertion of LoxP sites flanking the second 
exon using homologous recombination. To obtain SERT-Crecre/wt Munc18-1lox/lox 
mice, SERT-Crecre/wt Munc18-1lox/wt mice were crossed with SERT-Crewt/wt 
Munc18-1lox/wt mice. Pregnant females were sacrificed by cervical dislocation. 
Mouse embryos were obtained by caesarean section of pregnant females from 
timed matings. To investigate the effect of deletion of Munc18-1 in the 5-HT 
system on the development of the 5-HT system, SERT-Crecre/wt Munc18-1lox/lox 
mice were used. SERT-Crewt/wt Munc18-1lox/lox, SERT-Crewt/wt Munc18-1lox/wt, or 
SERT-Crecre/wt Munc18-1wt/wt littermates were not different from SERT-Crewt/wt 
Munc18-1wt/wt mice and were used as controls. SERT-Cre mice were genotyped as 
has been previously described (Zhuang et al., 2005). For genotyping of 
Munc18lox/lox mice the following primers were used: 5’-ttggtggtcgaatgggcaggtag-
3’, 5’-cctgtatgggtactgttcgttcactaaaata-3’ and 5’-ttctgaacttgaggccagtctgagacacag-3’. 
Animals were housed and bred according to institutional and Dutch guidelines. 
 
Immunohistochemistry 
For immunohistochemical analysis of 5-HT, embryonic mouse brains were 
dissected and immediately fixed by immersion in 4% PFA in phosphate buffered 
saline (PBS, pH 7.4). For analysis of 5-HT neurons and projections in adult 
brains, mice were anaesthetized and transcardially perfused with 4% PFA in 
PBS. For post-fixation, brains were incubated in 4% PFA in PBS overnight. For 
cryoprotection, brains were incubated in increasing concentrations of sucrose. 
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Subsequently, coronal slices of 40 #m were made. For immunohistochemistry, 
brain slices were first incubated in blocking buffer containing PBS supplemented 
with 0.5% Triton X-100 and 10% normal goat serum for two hours. 
Subsequently, slices were incubated overnight with primary antibodies in PBS 
containing 0.5% Triton X-100 at 4°C in under gentle agitation. The next day, the 
slices were washed three times two hours in PBS and incubated with secondary 
antibodies in PBS for one hour under gentle agitation. Finally, slices were 
washed again three times two hours in PBS and mounted in Dabco-Mowiol for 
analysis. All procedures were performed at room temperature unless otherwise 
stated. Polyclonal anti-5-HT (1:1000) (Immunostar/Diasorin) was used as the 
primary antibody, and as a secondary antibody GAR-546 (1:1000) was used 
(Invitrogen). To analyze number of 5-HT cell bodies in DRN sections, at least 
three sections per experimental group were imaged using a CLSM 510 
microscope. Number of 5-HT cell bodies was manually counted in the slices. For 
analysis of 5-HT fiber density in DRN and cortex a Z-stack of at least three 
positions per group was made. To analyze the 5-HT fiber density, the Z-stacks 
were projected in a single image and binarized. The 5-HT fiber density was 
quantified as the area in the image occupied by 5-HT neurites compared to the 
total area.  
 
Mouse behaviour 
Behavioural analysis of mice was tested in the Phenotyper ® (Noldus Information 
Technology, Wageningen, The Netherlands). For the home cage test, one animal 
per cage was tested for six days. Eleven SERT-Crecre/wt Munc18-1lox/wt mice were 
used in the experimental group and eleven SERT-Crewt/wt Munc18-1lox/wt mice 
were used as a control group. Each cage contains a top unit equipped with built-
in hardware for videotracking, containing a digital infrared sensitive video 
camera and infrared lights. Using this method the animal behaviour can be 
continuously assessed, both in the light and in the dark phase. Ethovision 3.0 
software was used as videotracking software. The phenotyper cages (30x30x35 
cm) were made of transparent Perspex walls with an aluminium floor, and a 
feeding station and a water bottle attached to the outside. To the waterspout a 
lickometer was attached to determine the total duration the animal is touching 
the waterspout.  A shelter unit (diameter: 9 cm, height: 10 cm, non-transparant 
material) was placed in the cage, which was defined as a hidden zone in 
Ethovision, and the software program could distinguish between in the shelter 
and on the shelter. Videotracking was performed at a rate of 12.5 samples per 
second and the following parameters were determined: average velocity of 
movement, total distance moved in the open space, proportion of time spent in 
the feeder, proportion of time spent in the shelter, and time spent drinking. 
120
These parameters were calculated in two hour bins for both the dark and light 
phase. For the analysis of movement and velocity, only movement was scored 
when the mouse moved at a velocity of 3.5 cm/s and higher, averaged over twelve 
samples. Furthermore, total proportion of time spent in a zone of the home cage 
(on shelter, in shelter, feeder, pellet or waterspout), frequency of zone visits and 
frequency on the shelter during the dark period was quantified. 
On day four and five a free operant conditioning task was performed as 
follows. The number of  SMBs was quantified, which is a directed movement of 
the animal from one point in the cage to another. A distinction is made between 
raw and directional SMBs; When the animal moves with a higher velocity than 
the threshold value, which is determined by dividing the total distance moved by 
the total duration of movement, the SMB is considered to be a directional SMB. 
When the animal is moving at a lower velocity, it is considered as a raw SMB. 
Thus, in a directional SMB the animal is either moving with a greater velocity, or 
is taking a shorter route. At day four and five, when the mice gets on its shelter, 
this will result in the drop of a sucrose pellet. Thus, the mouse ‘learns’ that it has 
to jump onto its shelter in order to receive a new sucrose pellet. 
One day six a one trial anxiety test was performed as follows. Fifteen 
minutes after the change from light to dark phase, a lightspot is on the feeder, 
thus creating a lightspot zone. The lightspot lasts for three hours, and the total 
amount of time the animal is in the lightspot zone in this period is recorded and 
compared with a baseline reference. The baseline reference is acquired by 
recording the amount of time the animal is in the feeder zone at day five at the 
corresponding hours, without a lightspot on. 
 
Statistical analysis 
Data were analyzed using SPSS 17.0. For analysis of number of 5-HT cell bodies 
in DRN and 5-HT neurite density in DRN and cortex, data was analyzed using 
the independent samples t-test. To analyze whether observed genotype 
frequencies differed significantly from a Mendelian ratio, a one-way chi-square 
test was performed. Mouse behaviour parameters were analyzed using the non-
parametric Wilcoxon test after checking for normal distribution. Data shown are 
mean ± SEM. Significance level was set at p <0.05. 
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Abstract 
 
Altered connectivity of the serotonin (5-HT) system might underlie 
psychopathological processes such as anxiety and depression. Therefore, it would 
be very interesting to be able to visualize all 5-HT fibers, axons or presynaptic 
terminals/varicosities in living mouse brain. To specifically label 5-HT neurons 
and fibers, our aim is to express Cre recombinase in the 5-HT system. We 
describe here the generation of a tryptophan hydroxylase 2 (Tph2)-iCre targeting 
construct, the targeting of mouse embryonic stem (ES) cells and the blastocyst 
injections of positively targeted clones. Moreover, to study 5-HT connectivity in 
vivo, we generated several transgenic lines using the loxSTOPlox (LSL) 
methodology.  
Eventually, we hope to use these techniques to create mice in which specifically 
in the 5-HT system reporter genes are expressed, so that these can be used to 
study the 5-HT outgrowth and connectivity in vivo. 
 
Introduction 
 
The 5-HT system has its cell bodies in the midbrain raphe nuclei. Although only 
few 5-HT neurons are present, virtually every brain area receives dense 5-HT 
innervation which triggers signaling pathways through several different 5-HT 
receptors. For these reasons the 5-HT system influences a wide variety of 
processes. Moreover, the 5-HT system is implicated in major depressive disorder 
and anxiety. One of the current hypotheses for psychopathological processes 
such as anxiety and depression is that 5-HT connectivity might be affected. 
Therefore, it would be very interesting to study the connectivity of the 5-HT 
system in vivo.   
To study 5-HT outgrowth and connectivity in vivo, our aim is to generate a 
mouse line with expression of improved Cre recombinase (iCre) specifically in 5-
HT neurons. As locus for the iCre knockin, we selected the Tph2 gene, which is 
selectively expressed in the 5-HT neurons in the raphe nuclei (Patel et al., 2004; 
Zhang et al., 2005; Clark et al., 2006). To be able to specifically express 
transgenes in the 5-HT system, we relied on the Cre-loxP technique (Tsien et al., 
1996; Nagy, 2000). We selected to use iCre instead of Cre, since iCre gives 
improved Cre expression due to the application of mammalian codon usage 
(Shimshek et al., 2002).  
In addition we generated several transgenic lines that carry a ubiquitous 
promoter, a LSL sequence and synaptically or axonally targeted fluorescent 
fusion proteins. Our ultimate goal is to combine the Tph2-iCre knockin allele 
with these transgenes, which would constitute an ideal model to study 5-HT 
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connectivity and dynamics in the living mouse brain. Here we describe the 
generation of the Tph2-iCre targeting construct, and the generation of Tph2-iCre 
chimaeric mice. Additionally, we describe the generation of several LSL 
transgenic lines. 
 
Results 
 
Construction and design of the Tph2-iCre targeting construct 
In order to specifically express iCre in 5-HT neurons, we selected the locus for 
Tph2 which is localized at chromosome 10 D2. Tph2 is the rate limiting enzyme 
in 5-HT synthesis and is specifically expressed in 5-HT neurons in the brain. To 
generate mice with expression of iCre specifically in 5-HT neurons, our approach 
was to generate a targeting construct in which iCre cDNA is inserted at the 
endogenous Tph2 start codon We designed the targeting construct in a way that 
the 1.2 kb short arm at the 5’ side of the construct stops just upstream of the 
endogenous Tph2 start codon. The 5.5 kb long arm was designed to start 53 bp 
downstream of the short arm, so that only 53 bp of endogenous DNA, including 
the endogenous Tph2 start codon, was deleted in case of homologous 
recombination (Fig. 1A). In between the short and long arm the iCreVenus cDNA 
was inserted and a neomycin phosphotransferase cassette (neo) for positive 
selection, flanked by FRT sites. These can be used to later on remove the neo 
cassette using the flippase/FRT system (O'Gorman et al., 1991).  
In case of homologous recombination of the targeting construct in ES cells and 
subsequent generation of Tph2-iCre mice our approach was to use heterozygous 
Tph2-iCre mice. These contain one functional allele with Tph2 expression, 
whereas in the other allele, part of the first exon of Tph2 including the start 
codon is replaced for iCreVenus. In this case these mice will still have a 
functional Tph2 allele and expression of iCreVenus from the Tph2 promoter (Fig. 
1B). 
 
Generation of Tph2-iCre chimaeric mice 
After designing and constructing the Tph2-iCre targeting construct, the construct 
was sequence verified. This showed that the construct had been correctly made 
and that the iCreVenus cDNA contained no mutations. The linearized targeting 
construct was used for ES cell transfection. The antibiotic G418 was used for 
positive selection of the neomycin resistance marker (Gossler et al., 1986). 
Eventually five clones were found in which homologous recombination had 
occurred. Blastocyst injection of clone 1C11 resulted in several chimaeric mice. 
Although we performed several rounds of chimaeric breeding, we have 
unfortunately not achieved germline transmission of the Tph2-iCre allele until 
now.   
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 Figure 1. Tph2-Cre knockin approach 
(A) The targeting construct was created to replace the start codon of the first exon of Tph2 
with a iCre cassette and a neomycin resistance cassette flanked with FRT sites. The 
targeting construct consisted of a short arm of 1.2 kb, a long arm of 5.5 kb and a iCreVenus 
and neo cassette. In case of homologous recombination only 53 bp of endogenous DNA is 
deleted and replaced for the iCreVenus cassette and the neomycin resistance cassette. To 
identify ES cell clones in which homologous recombination occurred, a PCR screening 
approach was used. A forward primer (arrow) outside the short arm of the targeting 
construct and a reverse primer (arrow) in the iCre cassette were used to amplify a 1.5 kb 
fragment of DNA in case of homologous recombination (dotted line). (B) Approach for 
Southern blot screening of ES cell clones. An inside and an outside probe were used (grey 
boxes). For the inside probe, genomic DNA is digested with BsrGI. This will result in a 5.3 
kb fragment in WT DNA, but in a 3.3 kb fragment in clones in which homologous 
recombination occurred due to the presence of an additional BsrGI site in the targeting 
construct. For the outside probe, genomic DNA is digested with SwaI, which will result in a 
14.2 kb fragment in WT DNA, but in a 9.8 kb fragment in clones in which homologous 
recombination occurred, due to the presence of an additional SwaI site in the targeting 
construct. 
 
Generation of LSL transgene lines 
For construction of LSL transgene lines we used several marker genes tagged 
with either EGFP or mCherry, which is an improved variant of mRFP that 
matures more completely and is more photostable (Shaner et al., 2004). As 
marker genes we used SynaptophysinpHluorin (SypHy), TMSyxEGFP and 
TMSyxmCherry, which all specifically label axons and presynaptic terminals, and 
VenusKras4b which is a general membrane marker.  
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 Figure 2. Validation of transgene constructs 
To investigate whether the LSL approach worked, we expressed LSL transgene construct 
with our without iCre cDNA in HEK293 cells. (A,B) No Expression of SypHy or 
TMSyxEGFP in HEK293 cells after transfection of LSL-SypHy or LSL-TMSyxEGFP 
without iCre. (C,D) After transfection of LSL-SypHy or LSL-TMSyxEGFP with iCre, SypHy 
and TMSyxEGFP were expressed in HEK293 cells respectively. (E,F) In neurons, 
VenusKras4b or TMSyxEGFP are not expressed when transfected without iCre. (G) Upon 
transfection of LSL-VenusKras4b with iCre, VenusKras4b is expressed in neurons, and the 
membrane is labeled, also in growth cones (inset). (H) Upon transfection of LSL-
TMSyxEGFP with iCre, TMSyxEGFP is expressed in axons, as shown by the absence of 
MAP2 staining. Immunocytochemistry for the synaptic marker Synapsin shows that there 
is colocalization between TMSyxEGFP and Synapsin, showing that TMSyxEGFP is 
targeted to synapses. Scale bars: A-G 10 µm, inset in G 2 µm, H 5 µm. 
 
SypHy is the improved variant of SynaptopHluorin and detects secretion events 
due to the increase in pH in synaptic vesicles after exposure to the extracellular 
medium (Miesenbock et al., 1998; Granseth et al., 2006). TMSyxEGFP contains 
part of the transmembrane domain of Syntaxin1A coupled to EGFP; 
TMSyxmCherry is the same but with a red fluorophore.  VenusKras4b is the 
EYFP derived Venus fused with the 20 amino acid C-terminal plasma membrane 
targeting domain of Kras4b (Welman et al., 2000). As ubiquitous promoter 
either the chicken !-actin promoter or the Thy1 promoter was used (Aigner et al., 
1995; Ludin et al., 1996). In between the promoter and the transgene, we 
inserted a floxed stop sequence in order to acquire iCre mediated transgene 
expression (Lakso et al., 1992). Some of the constructs were expressed in 
heterologous cells or neurons to test whether the floxed stop sequence prevented 
expression and whether co-transfection of iCre resulted in expression of the 
transgene. Transfection of !-actin-LSL-SypHy or Thy1-LSL-TMSyxEGFP alone 
in heterologous cells did not result in expression of the transgene (Fig. 2A,B). In 
contrast, after co-transfection with iCre, there was strong expression of  
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both transgenes (Fig. 2C,D). Also in neurons, expression of !-actin-LSL-
VenusKras4b or Thy1-LSL-TMSyxEGFP alone did not result in detectable 
transgene expression (Fig. 2E,F). However, after co-expression with iCre, 
VenusKras4b expression was detected (Fig. 2G). After co-expression of iCre and 
Thy1-LSL-TMSyxEGFP neurons were found which expressed TMSyxEGFP and 
this localized exclusively to axons and synapses as shown by the absence of 
staining for the dendritic marker MAP2 and co-localization with the synaptic 
marker Synapsin (Fig. 2H). 
These transgenic constructs were linearized and injected in oocytes to generate 
seven founder lines of !-actin-LSL-SypHy, five founder lines of !-actin-LSL-
VenusKras4b, five founder lines of Thy1-LSL-TMSyxEGFP and eleven founder 
lines of Thy1-LSL-TMSyxmCherry. 
 
Screening of expression of transgenes in founder lines 
In order to screen the expression of the transgenes per founder line, and to find 
out whether there are lines with expression of the transgene in the raphe nuclei, 
we first removed the LSL cassette by crossing the founder lines with the CMV-
Cre mouse line, a line in which Cre is ubiquitously expressed (Schwenk et al., 
1995).  
This breeding strategy resulted in mice in which the LSL cassette was removed in 
all cells (Fig. 3A). This in contrast to crossing with Tph2-iCre mice, which is 
expected to result in removal of the LSL cassette only and specifically in 5-HT 
neurons. Thus, in 5-HT neurons the transgene will be expressed, whereas in all 
other cells the LSL is still present and the transgene is not expressed (Fig. 3B).  
After screening all transgenic founder lines, we found several lines in which the 
transgene was very low and mosaically expressed. For !-actin-LSL-SypHy we 
found one founder line with low expression in the Purkinje cell layer of the 
cerebellum, and two founder lines with expression in the hippocampal CA1-CA3 
region and dentate gyrus (data not shown). For !-actin-LSL-VenusKras4b we 
only found very low and mosaic expression of the transgene (data not shown). 
For Thy1-LSL-TMSyxEGFP and TMSyxmCherry, we found one line with 
TMSyxEGFP ubiquitously expressed in neocortex, and one line with 
TMSyxmCherry mosaically expressed in cortex and hippocampus (data not 
shown). Unfortunately, not one founder line did show expression of the 
transgene in midbrain or raphe nuclei areas. 
 
Discussion 
 
Here we have described the generation of Tph2-iCre chimaeric mice and several 
LSL transgenic mouse lines. We would like to eventually create mice with 
expression of a marker gene specifically in 5-HT neurons. This would allow us to  
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Figure 3. Approach for screening expression pattern of transgenic mice 
(A) To screen the expression pattern of LSL transgenic mice, these mice were crossed with 
a CMV-Cre mouse, which ubiquitously expressed Cre recombinase. This results in mice in 
which the LSL is removed in all cells, thus allowing an analysis of transgene expression 
pattern. (B) Once LSL mice are identified with expression in the 5-HT system, they can be 
used to cross with Tph2-Cre mice to drive transgene expression specifically in the 5-HT 
system. 
 
label fibers or presynaptic terminals of 5-HT neurons, and to image 5-HT fiber 
outgrowth and connectivity changes in living mouse brain using 2-photon in vivo 
microscopy (Kerr and Denk, 2008). Since one of the hypotheses for major 
depressive disorder is that the connectivity of the 5-HT system might be affected, 
such a mouse model would be valuable to study this aspect.  
We choose to target iCreVenus to the first exon of Tph2, so that the endogenous 
start codon and small part of the first exon of Tph2 is replaced for iCreVenus. In 
this way we anticipated that Tph2 expression relies on endogenous Tph2 
promoter activity and is specifically expressed in 5-HT neurons in which Tph2 is 
expressed. In contrast to this approach we could also have chosen to target 
iCreVenus to the 3’ side of the Tph2 open reading frame using an internal 
ribosomal entry site (IRES). We did, however, not use this approach because the 
expression of a reporter gene behind an IRES is often rather low. Although using 
our approach we sacrifice one functional Tph2 allele, we expect that this will not 
significantly affect brain development and behaviour in Tph2 heterozygotes. 
Deletion of both Tyrosine hydroxylase alleles results in mid-gestational lethality. 
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However, TH heterozygotes showed no obvious anatomical or behavioural 
defects (Zhou et al., 1995). Therefore, we reason that our approach will not 
significantly affect brain development or behaviour.  
Using a transgenic approach with a LSL cassette to allow transgene expression 
only in cells in which iCre is also present, we aimed to express these marker 
genes specifically in 5-HT neurons. However, none of the founder lines we 
screened showed expression of the transgene construct in the midbrain or raphe 
nuclei. It has been shown for both the chicken !-actin and mouse Thy1 promoter 
that these are able to induce expression of transgenes in the cortex and 
hippocampus (Feng et al., 2000; Roelandse et al., 2003). However, it appears 
more difficult to also induce expression in midbrain and raphe nuclei for these 
promoters, since none of our transgenic lines expressed the transgene in these 
regions. Recently, it was shown that a 1.8 kb region immediately upstream the 
Pet-1 gene is sufficient to acquire 5-HT neuron specific expression of a transgene 
(Scott et al., 2005a; Scott et al., 2005b). Therefore, in new experiments we could 
try to rely on the Pet-1 promoter to express transgenes in the 5-HT neurons. 
Possibly, future experiments with novel blastocyst injections of Tph2-iCre 
targeted ES clones and transgene injections using the Pet-1 promoter will result 
in a Tph2-iCre mouse line and transgenic mouse lines with expression of 
reporter genes in 5-HT neurons. These mouse lines can then be used to create 
mouse lines with expression of reporter genes specifically in 5-HT neurons to 
possibly resolve the longstanding question whether psychopathological processes 
are a result of altered 5-HT network connectivity. 
 
EXPERIMENTAL PROCEDURES 
 
Generation of Tph2-iCre targeting construct 
The Tph2-iCre targeting construct was designed in such a way that in the 
wildtype Tph2 locus, 53 bp in exon 1 are deleted, including the start codon, and 
replaced for a iCreVenus cassette. The Tph2-iCre targeting construct was 
generated as follows. The 1.2 kb short arm upstream the endogenous start codon 
of Tph2 was generated with PCR primers forward 
5’CATGCATAGAAAGTGTCCAG3’ reverse 5’TTCTTTCTCAGCAGCAGGGG3’. The 
5.5 kb long arm starting 34 bp behind the Tph2 start codon was generated with 
PCR primers forward 5’GGGCCAGGAGAGGGTTGTCCTTGGATTCTG3’ and 
reverse 5’CCGTACATGAGGACTCGGTGAGAGCATCTG3’. Both arms were 
subcloned in the pGEM-T easy vector (Promega). In the piCreVenus vector the 
NotI site behind Venus was removed and a linker containing SwaI, BsiWI, MluI 
and NotI sites was placed in the AflII site behind the polyA tail. The short arm 
was cloned sticky using EcoRI in front of iCreVenus in the modified iCreVenus 
vector. A neomycin resistance cassette flanked by FRT sites was removed from 
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the ploxPFRTNEOFRTloxP vector (a kind gift from Jeroen Pasterkamp, Utrecht) 
using partial digestion with BamHI and cloned blunt in the unique SpeI site 
behind the long arm in the pGEM-T easy vector. Finally, the FRTNEOFRT long 
arm Tph2 was cloned sticky behind the short arm iCreVenus using NotI. The 
construct was verified by sequence analysis. The construct was linearized with 
KspI for targeting.  
 
Targeting ES cells 
In order to target ES cells with the Tph2-iCre targeting construct, approximately 
1 x 109 ES cells (line E14.1) were electroporated with 100 #g of linearized Tph2-
Cre targeting construct and plated on murine embryonic feeders. The subsequent 
day, neomycin selection was started by adding 400 #g/ml G418. After 10 days, 
non targeted clones had died and 700 surviving clones were picked and 
individually grown. DNA of all these clones was screened to distinguish between 
clones in which the targeting construct was randomly inserted and clones in 
which homologous recombination had occurred.  
To select for clones in which homologous recombination occurred, the clones 
were screened with a nested pcr approach using the following primers: 1st pcr 
forward 5’CACTTTTCTTCACACCCTTCTC3’ and reverse 5’ 
CCTGACTTCATCAGAGGTGGCATCC3’ nested pcr forward 5’ 
TTATTTGTGTGAGCACGTGA3’ and reverse 5’ TTTTGGTGCACAGTCAGCAG3’ 
which results in a 1.6 kb pcr fragment in positively targeted clones. From the 700 
targeted clones, eventually 5 clones were selected in which homologous 
recombination occurred designated 2F11, 1A1, 1C11, 4E1 and 2E11. Homologous 
recombination was verified using a 5’ primer outside the forbidden construct and 
sequence analysis of this region. ES cell clones  1C11 and 4E1 were injected in 
blastocysts to generate chimaeric mice. 
 
Generation of transgenic mice 
In order to generate transgenic mice for conditional expression of reporter genes, 
the LSL cassette derived from the Pbs302 vector was used (Sauer, 1993). As 
promoter, the chicken !-actin and regulatory elements of the mouse Thy1 gene 
were used. As reporter genes, SypHy (a kind gift from Andreas Jeromin), 
VenusKras4b, TMSyx (transmembrane Syntaxin1A) EGFP and TMSyxmCherry 
were used. The constructs were cloned as follows. For !-actin-LSL-SypHy, the 
LSL cassette was excised from the Pbs302 vector using EcoRI and SpeI and 
cloned blunt in the unique XbaI site in the p!-actin-SypHy vector. For !-actin-
LSL-VenusKras4b, the LSL cassette was excised from the Pbs302 vector using 
EcoRI and SpeI and cloned blunt in the BglII site in the pVenusKras4b vector. 
Subsequently, LSL-VenusKras4b was excised using NheI and XbaI and cloned 
blunt in BlnI and XbaI in p!-actin-EGFP to replace EGFP. Both !-actin-LSL-
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SypHy and !-actin-LSL-VenusKras4b were linearized with AatII for transgene 
injection. For Thy1-LSL-TMSyxEGFP, TMSyxEGFP was excised with NheI and 
SspI and cloned blunt in the unique NotI site in pThy1-LSL (a kind gift from 
Christiaan Levelt, Amsterdam). To clone TMSyxmCherry, TMSyx was excised 
from pTMSyxEGFP using NheI and EcoRI and cloned blunt in pmCherry-N3 in 
the EclXI site. Then TMSyxmCherry was excised using NheI and SspI and cloned 
blunt in the NotI site the in pThy1-LSL vector. Both Thy1-LSL-TMSyxEGFP and 
Thy1-LSL-TMSyxmCherry were linearized with AatII for transgene injection. To 
create transgenic mice, linearized DNA constructs were injected in the 
pronucleus of fertilized C57BL/6 oocytes. 
 
Transfection of transgene plasmids in heterologous cells and neurons 
Transgene plasmids were transfected in HEK293 cells or neurons using 
Lipofectamine 2000 reagent according to the manufacturer’s protocol. HEK293 
cells and neurons were cultured as has been published before (Groffen et al., 
2004; de Wit et al., 2006). In HEK293 cells, one day post-transfection 
expression of transgene constructs was visualized using an inverted microscope 
fitted with fluorescence filters. In neurons and HEK293 cells, expression of 
transgene constructs was analyzed using a LSM510 confocal laser scanning 
microscope (Zeiss, B.V. The Netherlands). Immunocytochemical analysis of 
neurons was performed as has been described before using monoclonal MAP2 
(Chemicon) and polyclonal Synapsin I (E028) as primary antibodies and goat-
anti-mouse Alexa 543/644 and goat-anti-rabbit Alexa 543 (Molecular Probes) 
(de Wit et al., 2006). 
 
Screening of expression pattern 
In order to investigate the expression pattern of the transgene construct per 
transgenic line, the founder lines were crossed with the 129-Cre mouse line, 
which has ubiquitous expression of Cre (Schwenk et al., 1995). Pups positive for 
Cre and the transgene were used for in vivo paraformaldehyde (PFA) perfusion 
between two and four months age. For in vivo PFA fixation, mice were 
anaesthetized and transcardially perfused with 4% PFA dissolved in phosphate 
buffered saline (PBS) (pH 7.4). After fixation, brains were removed and postfixed 
in 4% PFA for 24 hours at 4ºC. Subsequently, brains were cryoprotected in 
increasing concentrations of sucrose dissolved in PBS at 4ºC. For screening of 
expression pattern of the transgenes, the fixed and cryoprotected brains were 
sagitally cut in 30 #m slices using a microtome. In case the EGFP fluorescence 
was too low, Immunohistochemistry was performed using the free floating 
method. To this end, slices were first blocked using blocking solution which 
contained 0.1% Triton X-100 and 10% normal goat serum for two hours under 
gentle agitation. Slices were incubated overnight at 4ºC using primary antibody, 
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washed three times two hours the next day with PBS 0.1% Triton X-100 and 
incubated with the secondary antibody for two hours. After washing for three 
times two hours in PBS, slices were positioned on a glass slide, allowed to dry 
and overlaid with a glass coverslip using Dabco Mowiol. All reactions were 
carried out at room temperature unless otherwise stated. 
 
Analysis of transgene expression 
To analyze the expression pattern of the transgene constructs, brain slices were 
analyzed using an inverted microscope equipped with fluorescence filters and a 
Sony camera. A LSM510 confocal laser scanning microscope was used to 
investigate the expression of the transgene constructs in individual neurons. 
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Chapter 
 
 
 
 
 
General 
discussion 
 
General discussion 
 
The aim of the studies described in this thesis was to investigate different cellular 
aspects of the outgrowth and connectivity of the brain 5-HT system. The 5-HT 
system has the remarkable feature that although there are only few 5-HT 
neurons, localized in the midbrain raphe nuclei, virtually every brain area 
receives dense 5-HT innervations. These innervations contain several 5-HT 
varicosities, where 5-HT is released both synaptically and as volume 
transmission. Due to several 5-HT receptors which are present in the brain, 5-HT 
has many functions and influences a wide variety of processes. Moreover, the 5-
HT system is implicated in several psychopathological processes such as anxiety 
and depression. Despite the high social and economical importance of these 
conditions, there is a lot of uncertainty about the involved mechanisms. 
Therefore, a further cellular characterization of the outgrowth and connectivity 
of the 5-HT system is of high interest. We used several experimental approaches 
to study different cellular aspects of the outgrowth and connectivity of the 5-HT 
system.  
 
In chapter 2 we used organotypic slice cultures to study 5-HT outgrowth and 
connectivity and the effect of pharmacological manipulations in vitro. This 
revealed that the 5-HT neurite density was not affected by blocking the SERT or 
application of a 5-HT1A agonist, but the density was reduced by application of a 
5-HT2 agonist. This was presumably due to inhibited outgrowth of the 5-HT 
system.  
In chapter 3, we investigated the trafficking of SERT. We expressed SERT 
tagged with the fluorescent protein mCherry in hippocampal neurons. We 
showed that mCherry-SERT is transported in vesicles which displayed a dynamic 
trafficking.  
In chapter 4 we used the same approach as in chapter 3, but now we studied 
the localization and trafficking of Tph2, the rate limiting enzyme in 5-HT 
synthesis. We tagged Tph2 with EGFP and studied the localization of Tph2-
EGFP in hippocampal neurons. In axons Tph2-EGFP displayed a punctate 
distribution and co-localized with Synaptophysin-mCherry, a marker for 
synaptic terminals, suggesting that Tph2-EGFP localized to synaptic terminals.  
In chapter 5 we studied the effect of a SNP in the presynaptic gene Piccolo on 
the trafficking and localization of SERT. Knockdown of Piccolo in neurons did 
not affect mCherry-SERT trafficking. The SNP in Piccolo possibly affects the 
localization of SERT, although future research is needed to further resolve this 
issue. 
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In chapter 6 we crossed SERT-Cre mice with floxed Munc18-1 mice to 
specifically abolish Munc18-1 in SERT expressing neurons. This resulted in early 
postnatal lethality and a rapid degeneration of the 5-HT system. We used 
heterozygous mice to study the effect of removal of one Munc18-1 allele in SERT 
expressing neurons on behaviour using a phenotyping experiment. Basal 
behaviour, conditioning and anxiety related behaviour were not affected. 
In chapter 7 we describe our approach to create mice which have Cre 
expression specifically in 5-HT neurons. Moreover, we show that we have 
generated transgenic lines with a floxed stop cassette which can be used for 
spatial regulation of transgene expression upon Cre mediated recombination. In 
the future, these mice can be used to specifically label 5-HT neurons, or to 
specifically remove a gene in 5-HT neurons. 
 
Roles of 5-HT in outgrowth, connectivity and behaviour 
 
One of the current hypotheses for psychopathological processes such as 
depression is that altered 5-HT network connectivity might be involved in these 
processes. Furthermore, it is hypothesized that antidepressants such as 
fluoxetine might restore aberrant 5-HT network connectivity (Castren, 2005). 
We used organotypic slices to study these processes in an in vitro model system. 
Our data showed that fluoxetine did not affect 5-HT innervation density.  
In adult rats, chronic fluoxetine application did result in an increased density of 
5-HT projections in the forebrain (Zhou et al., 2006). Interestingly, an in vivo 
study using chronic fluoxetine treatment either during development or during 
adulthood, showed that when applied during adulthood, fluoxetine did not affect 
behaviour. In contrast, fluoxetine treatment during development resulted in 
increased anxiety-related behaviour during adulthood (Ansorge et al., 2004; 
Ansorge et al., 2008). Our data suggests, although it is in vitro, that this effect of 
fluoxetine on behaviour does not result from an altered innervation of 5-HT 
projections. However, in our model system we were unable to investigate 
whether the number of 5-HT varicosities was affected by fluoxetine application. 
Thus, although 5-HT projection density is unaffected, connectivity of the 5-HT 
system might be affected due to an altered number of 5-HT varicosities or an 
altered rate of 5-HT release. 
At least in the snail Helisoma, 5-HT acts as an autotrophic factor on its own 
outgrowth; 5-HT applied at µM concentrations to the growth cones of 5-HT 
neurons resulted in an abrupt cessation of growth cone motility and outgrowth 
(Haydon et al., 1984; Haydon et al., 1987). 
The 5-HT1A and 5-HT2C receptor might mediate this effect of 5-HT, as these 
receptors are expressed in the DRN (Wright et al., 1995; Clemett et al., 2000). 
Our data showed that 5-HT1A receptor activation slightly increased 5-HT neurite 
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density whereas chronic activation of the 5-HT2 receptor decreased 5-HT neurite 
density. It is tempting to speculate that these receptors act in concert during 
outgrowth to regulate a proper development of 5-HT projections towards target 
areas mediated by 5-HT. Interestingly, 5-HT1A and 5-HT2 receptors have 
different affinities for 5-HT; 5-HT1A receptors are high affinity 5-HT receptors 
which have an EC50 value in the nM range, whereas 5-HT2 receptors are low 
affinity 5-HT receptors, which have an EC50 value in the µM range (Fargin et al., 
1989; Marek and Aghajanian, 1994; Azmitia, 2001). The 5-HT2C receptor is 
present on GABA-ergic cells in the DRN, and it is unknown whether this receptor 
is present on 5-HT neurons (Serrats et al., 2005). This suggests that the 
inhibitory effect of 5-HT2C receptor activation is not a direct effect on 5-HT 
neurons, but might be an indirect effect via GABA-ergic neurons. Indeed, in vivo 
data supports that 5-HT2C receptor activation inhibits neuronal firing of 5-HT 
neurons via GABA-ergic neurons (Boothman et al., 2006). Thus, in the DRN µM 
levels of 5-HT might inhibit outgrowth, whereas nM levels might stimulate 
outgrowth of 5-HT innervations.  
Mice in which the 5-HT1A receptor is deleted have increased anxiety-related 
behaviour, as they spend less time in the center in the open field test and avoid 
the open arms in the elevated plus maze (Parks et al., 1998; Ramboz et al., 1998). 
Overexpression of the 5-HT1A receptor, on the other hand, results in reduced 
anxiety-related behaviour (Deng et al., 2007). A very elegant study was 
performed by Gross and colleagues, who showed that restoring 5-HT1A receptor 
expression in the forebrain during development, but not during adulthood 
rescued the behavioural phenotype of 5-HT1A KO mice. (Gross et al., 2002). 
Clearly, the 5-HT1A receptor is important during development to establish 
normal anxiety-like behaviour. Unfortunately, no studies were performed to 
resolve whether 5-HT connectivity is affected in these mice. 
Deletion of the 5-HT2C receptor, on the other hand, results in compulsive-
like behaviour, and these mice are obese and suffer from seizures (Tecott et al., 
1995; Chou-Green et al., 2003). Unfortunately, also for these mice it is not 
known whether 5-HT connectivity is affected.  
 
Trafficking of SERT and Tph2 in neurons 
 
As the 5-HT system has long projections to several brain areas, proteins involved 
in 5-HT synthesis and reuptake are transported over large distances towards 
axonal growth cones and varicosities. In chapter 3 and 4 we focused on SERT 
and Tph2 transport in hippocampal neurons and observed that SERT and Tph2 
displayed a distinct distribution. SERT was predominantly localized extra-
synaptically and some SERT puncta localized in the vicinity of presynaptic 
terminals. In contrast, Tph2 accumulated in puncta which colocalized with 
142
synaptic markers. Obviously, Tph2 is required at presynaptic terminals and 
varicosities for local synthesis of 5-HT. Indeed in 5-HT neurons Tph is enriched 
in presynaptic terminals (Pickel et al., 1976; Pickel et al., 1977). On the other 
hand, SERT is localized extra-synaptically to transport extracellular 5-HT which 
has diffused away from its release sites back into the neuron. An electron 
microscopy study showed that the majority of SERT in 5-HT neurons was located 
outside synapses (Zhou et al., 1998). Thus, the distribution of Tph2 and SERT 
which we found in hippocampal neurons seems to mimic the distribution of 
endogenous SERT and Tph2 in 5-HT neurons. 
We also showed that SERT and Tph2 are transported in distinct ways 
through the neuron. In contrast to Tph2, SERT displayed a vesicular trafficking. 
Apparently, SERT contains a signal peptides which mediates the transport in 
vesicles. Alternatively, SERT contains transmembrane domains, which requires 
that SERT is transported in vesicles as these lipophilic domains are insoluble.  
As SERT is transported in secretory vesicles, there should be one or more 
motor proteins responsible for this transport. There are several families of motor 
proteins which are involved in the transport of several different proteins through 
neurites (for a review see (Schlager and Hoogenraad, 2009). The average velocity 
of SERT transport vesicles and the fact that these do not display a preference for 
direction of movement is in accordance with the average velocity of transport 
vesicles containing glycine (Maas et al., 2006). Also in this study, it was shown 
that dynein motors are responsible for the retrograde transport of glycine (Maas 
et al., 2006). Dynein motors are involved in transporting other cargo molecules 
through neurons, such as the Trkb receptor and Bassoon (Yano et al., 2001; 
Fejtova et al., 2009). The trafficking dynamics of Trkb and Bassoon are 
comparable with the trafficking dynamics of SERT, strongly suggesting that the 
dynein motor protein is responsible for SERT transport (Ha et al., 2008; Fejtova 
et al., 2009). 
 
A SNP in Piccolo associates with depression 
 
Recently, a SNP in Piccolo was found which was associated with depression 
(Sullivan et al., 2008; Bochdanovits et al., 2009). Piccolo is a structural 
component of the presynaptic cytoskeletal cytomatrix (PCM) and structurally 
related to Bassoon, another component of the PCM (Cases-Langhoff et al., 1996; 
tom Dieck et al., 1998; Fenster et al., 2000). Piccolo is a multidomain zinc finger 
protein which contains several coiled coil domains and a PDZ domain (Fenster 
and Garner, 2002). Piccolo also contains two C2 domains, C2A and C2B, of 
which C2A functions as a low-affinity calcium sensor in presynaptic terminals 
(Gerber et al., 2001). The SNP in Piccolo was found to be closely localized to the 
C2A domain (Sullivan et al., 2008).  
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In the presynaptic terminal, Piccolo is involved in different processes. First of all, 
Piccolo, together with Bassoon, is involved in presynaptic terminal formation. 
Piccolo and Bassoon are transported in Piccolo-Bassoon transport vesicles 
together with other constituents of presynaptic terminals, and two or three of 
these vesicles are sufficient to form an active synapse (Zhai et al., 2001; Shapira 
et al., 2003; Tao-Cheng, 2007). In chapter 5 we have shown that 5-HT neurons 
contain Piccolo. Thus, in 5-HT varicosities Piccolo might be involved in 
formation of varicosities, regulating 5-HT secretion and regulation of SERT 
internalization. We have shown that knockdown of Piccolo did not affect SERT 
trafficking dynamics, suggesting that Piccolo is not involved in SERT transport.  
Secondly, since Piccolo is present in the presynaptic terminal, Piccolo might be 
involved in the modulation of synaptic vesicle exocytosis. Indeed, Piccolo 
influences synaptic function by negatively regulating synaptic vesicle exocytosis, 
possibly via a calmodulin kinase II-dependent mechanism, mediated through the 
modulation of Synapsin1A dynamics (Leal-Ortiz et al., 2008). Thus, Piccolo 
might be involved in modulating 5-HT release from synaptic vesicles. However, 
the majority of 5-HT is secreted as bulk release from large dense core vesicles 
(LDCVs) (Bruns and Jahn, 1995). Therefore, although it might be that a SNP in 
Piccolo could modulate 5-HT release from synaptic vesicles, this would probably 
only have minor effects on extracellular 5-HT levels. 
Thirdly, it was shown in heterologous cells that Piccolo is involved in the 
regulation of DAT internalization. Specifically, the C2A domain was involved in 
this process (Cen et al., 2008). As DAT and SERT belong to the same gene family 
and are structurally related it is conceivable that Piccolo could be involved in 
SERT internalization. In chapter 5, we have investigated in heterologous cells 
whether the SNP in the C2A domain of Piccolo alters the localization of mCherry-
SERT. This showed that expression of the C2A domain of Piccolo containing the 
SNP seemed to alter the membrane distribution of SERT compared to the 
control C2A variant. It would be very interesting to further investigate whether 
the SNP in the C2A domain affects varicosity density of 5-HT projections or 
regulation of SERT membrane localization. If so, this would be the first cellular 
evidence that altered 5-HT network connectivity might be involved in the 
etiology of depression.  
 
Deletion of Munc18-1 in SERT expressing neurons results in early 
postnatal lethality 
 
Our data in chapter 6 showed that deletion of Munc18-1 in SERT expressing 
neurons resulted in early postnatal lethality. Although neurons are initially 
formed and there is normal brain development, deletion of Munc18-1 eventually 
results in degeneration (Verhage et al., 2000; Heeroma et al., 2003; Korteweg et 
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al., 2004). Our data showed that also 5-HT neurons in which Munc18-1 is 
deleted initially develop and grow out projections which innervated the cortex. 
However, after the initial generation, the 5-HT neurons undergo rapid 
degeneration, and at P2 only very few 5-HT neurons were left. This is the first 
mouse model which has a complete removal of the 5-HT system. This in contrast 
to the Tph2 KO mouse, which has no 5-HT synthesis in the central nervous 
system, but still 5-HT neurons and projections are unaffected.  
Deletion of Tph2 resulted in ~50% lethality in the first four weeks (Alenina 
et al., 2009). Surprisingly, however, another research group did not find any 
increased lethality in Tph2-/- mice ((Savelieva et al., 2008) and personal 
communication). Deletion of Pet1 and Lmx1b results in mice in which ~70% and 
>99% of 5-HT neurons fail to survive respectively. Concerning the marked 
reduction in 5-HT neurons and projections in these mice, it is surprising that 
these mice only display subtle phenotypes (Ding et al., 2003; Hendricks et al., 
2003; Zhao et al., 2006) 
Unfortunately, as also thalamocortical neurons and some hippocampal 
neurons briefly express SERT, and thus Cre recombinase, during development, it 
is difficult to assess whether the observed phenotype is attributable to a 
degenerating 5-HT system. Therefore, crossing floxed Munc18-1 mice with Pet-
Cre or Tph2-Cre mice which express Cre exclusively in 5-HT neurons should 
finally resolve whether complete removal of the 5-HT system affects brain 
development and survival. 
 
Altered connectivity of the 5-HT system in human psychopathological 
processes? 
 
Descriptive studies on the effect of psychopathological processes on human 5-HT 
connectivity rely on postmortem brain tissue. The last decade, however, more 
and more human imaging studies are performed using functional magnetic 
resonance imaging (fMRI) and positron emission tomographic (PET) imaging to 
resolve whether brain circuitry is affected in psychopathological processes 
associated with the 5-HT system.   
Research on postmortem brain material from depressive people who 
committed suicide predominantly focused on mRNA expression levels or binding 
of radiolabeled 5-HT to 5-HT receptors. Several studies showed that there is an 
elevated 5-HT2A and 5-HT2C receptor abundance in the frontal cortex of 
depressed suicide victims (Arango et al., 1990; Xu and Pandey, 2000; Prasad et 
al., 2005). Other studies reported either reduced or increased binding or 
availability of 5-HT1A receptors, depending on the brain region studied (Drevets 
et al., 2007). From these data, however, it cannot be deduced whether the altered 
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levels of mRNA expression or altered levels of receptor binding are the result of 
an alteration in expression levels or of an altered 5-HT projection density.  
PET imaging is used to measure cerebral blood flow and rate of glucose 
metabolism as a measure for brain activity. Functional MRI is used to measure 
blood oxygen level dependent (BOLD) fluctuations which are a measure for 
activity and connectivity of brain regions. PET and fMRI studies have reported a 
decreased activation of cortical areas such as the dorsolateral prefrontal cortex 
and the anterior cingulate cortex in depressed subjects (Drevets et al., 1997; 
Mayberg et al., 1999). On the other hand, other studies reported an increased 
activation of limbic areas such as the amygdala in depression (Sheline et al., 
2001; Siegle et al., 2002). Several studies have explored whether antidepressants 
restore aberrant activation patterns observed in depression. Antidepressant 
treatment increases glucose metabolism in prefrontal cortex and reduces activity 
in limbic areas (Sheline et al., 2001; Harvey et al., 2004b).  
Although it is difficult to conclude from these imaging studies if altered 
brain network connectivity is a cause or consequence of the depression, one 
could at least speculate that connectivity changes occur at some stage. Clearly, 
more research is needed to further elucidate whether network connectivity 
alterations underlie psychopathological processes associated with the 5-HT 
system. 
 
Future perspectives 
 
There are a number of approaches which could be taken to further elucidate the 
connectivity of the 5-HT system, the relation between the 5-HT system and 
behaviour, and the involvement of the 5-HT system in psychopathology. First of 
all, it would be of great interest to label all 5-HT neurons and neurites with 
fluorescent markers. This could be achieved by creating knockin mice using the 
Tph2 promoter to drive expression of Cre and to cross these mice with floxed 
stop fluorescent reporter mice. Additionally, it has already been shown that Pet-
Cre mice express Cre specifically in 5-HT neurons, and crossing with reporter 
mice showed that >99% of 5-HT neurons were labeled (Scott et al., 2005). These 
mice could then be used to reconstruct the connectivity of the 5-HT system.  
Secondly, there are several subpopulations of 5-HT neurons that can be 
distinguished based upon their precursor genes (Jensen et al., 2008). If Cre 
mouse lines could be made for these specific subpopulations, these could be 
crossed with reporter mice or with the so-called brainbow mice (Livet et al., 
2007). It would be very interesting to find out whether different subpopulations 
of 5-HT neurons innervate different brain regions, and are involved in different 
aspects of behaviour. 
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Additionally, these mouse lines could be used to specifically inhibit 
neurotransmission from these populations of 5-HT neurons, or to inhibit 
neurotransmission from all 5-HT neurons using Tph2-Cre mice. Expressing 
tetanus toxin in neurons blocks synaptic activity since tetanus toxin cleaves 
VAMP2 which is a protein necessary for vesicle fusion. It has been shown that 
this approach works in vivo, e.g. in the retina, but also for 5-HT neurons 
(Kerschensteiner et al., 2009; Kim et al., 2009). The work of Kim et al showed 
that silencing a subset of 5-HT neurons resulted in mice with behavioural 
alterations (Kim et al., 2009). These mice could be used to further explore the 
role of the 5-HT system and subsets of the 5-HT system on behaviour and to 
what extend these contribute to pathophysiological processes such as anxiety and 
depression. The other way around, these mice could be used to study whether 
silencing of 5-HT neurons affects 5-HT connectivity, i.e. 5-HT projection and 
varicosity density.  
A third interesting future direction is to use mice which express Cre 
specifically in 5-HT neurons to inactivate 5-HT autoreceptors only in 5-HT 
neurons. A lot of research has been conducted in elucidating the role of 5-HT 
autoreceptors in determining 5-HT transmission and behaviour. The 5-HT1A and 
5-HT1B knockout mice display altered anxiety-related and aggression-related 
behaviours. However, in these mice it is difficult to assess whether these 
phenotypes observed are due to deletion of 5-HT autoreceptors, or deletion of 
these receptors from non-5-HT neurons. A far more elegant approach, however, 
would be to generate floxed 5-HT1A and 5-HT1B mice and cross these with Pet-Cre 
or Tph2-Cre mice to selectively inactivate these receptors only in 5-HT neurons. 
This will allow to distinguish between the role of 5-HT autoreceptors and 
heteroreceptors, and to investigate to what extend the deletion of 5-HT 
autoreceptors affects mouse behaviour.  
Recently, also a tamoxifen inducible Tph2-Cre mouse line has been 
generated, which allows to temporally regulate Cre expression in 5-HT neurons 
(Weber et al., 2009). This mouse line allows to investigate whether deleting a 
gene in the 5-HT system either during development or during adulthood affects 
5-HT outgrowth, connectivity or mouse behaviour. 
Finally, it would be interesting to further investigate whether connectivity is 
affected in anxiety and depression in human subjects. Novel brain imaging 
techniques, such as pharmaco MRI are being developed to further explore this 
relationship (Windischberger et al.) 
(Pickel et al., 1976, , 1977; Haydon et al., 1984, , 1987) 
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De menselijke hersenen bestaan uit ongeveer 100 miljard zenuwcellen 
(neuronen). Neuronen zijn de basis elementen die bijvoorbeeld gedrag en 
geheugen mogelijk maken. Neuronen hebben een aantal uitlopers waarmee ze 
met elkaar kunnen communiceren. Een neuron heeft een axon, waarmee het 
signalen naar een ander neuron kan versturen, en meerdere dendrieten, 
waarmee een neuron signalen van andere neuronen kan ontvangen. Neuronen 
communiceren met elkaar door het uitscheiden van signaalstoffen, 
neurotransmitters genaamd. Deze neurotransmitters kunnen binden aan 
bepaalde receptoren in een ontvangende cel, waardoor een signaal doorgegeven 
kan worden. De punten waar twee cellen met elkaar communiceren worden 
synapsen genoemd. Hier wordt door de zendende cel een presynaptische 
terminal gevormd op de ontvangende cel. Vanuit deze presynaptische terminal 
worden de neurotransmitters uitgescheiden, en deze worden opgevangen door 
receptoren in de postsynaptische terminal in de ontvangende cel. 
Er zijn veel verschillende soorten neuronen, deze worden onder andere in 
groepen ingedeeld door de neurotransmitter die ze uitscheiden. Een van de 
groepen neuronen zijn de zogenoemde serotonerge neuronen, neuronen die de 
neurotransmitter serotonine uitscheiden. Deze neuronen zijn in een aantal 
clusters gelokaliseerd in de hersenstam. In tegenstelling tot vele andere groepen 
neuronen, hebben de serotonerge neuronen een aantal opvallende kenmerken. 
Ten eerste is het een erg kleine groep neuronen, in de menselijke hersenen gaat 
het ongeveer om een half miljoen cellen. Ten tweede zijn ondanks dit kleine 
aantal in bijna alle andere hersengedeelten uitlopers van deze serotonerge 
neuronen aanwezig. Ten derde wordt deze neurotransmitter in deze 
hersengebieden in grote hoeveelheden uitgescheiden, waardoor grote groepen 
andere neuronen door deze serotonerge neuronen beïnvloed kunnen worden. 
Ten vierde zijn deze serotonerge neuronen, het zogenaamde serotonerge 
systeem, betrokken bij het beïnvloeden van verschillende soorten gedrag. Als 
laatste is het serotonerge systeem betrokken bij aandoeningen zoals 
depressiviteit, angststoornissen, autisme en obsessief compulsief gedrag. Een 
welbekend antidepressivum zoals Prozac grijpt bijvoorbeeld aan op de 
serotonerge neuronen, door de heropname van uitgescheiden serotonine terug 
het neuron in te blokkeren. 
Het idee achter aandoeningen zoals depressie is dat er een verandering 
ontstaat in de uitlopers van deze serotonerge neuronen naar andere 
hersengebieden en dat antidepressiva de uitlopers weer in de oude, gezonde staat 
terugbrengen. In dit proefschrift hebben we op een aantal verschillende 
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manieren geprobeerd te kijken naar de dynamiek van de uitgroei van deze 
serotonerge neuronen. 
In hoofdstuk 2 hebben we uit muizenhersenen, die we als modelsysteem 
hebben gebruikt, de serotonerge neuronen gesneden in een hersenplakje, een 
zogenaamde organotypische slice. Dit plakje hebben we naast een plakje van een 
ander hersengebied, de hippocampus, gelegd om te kijken of in dit kweeksysteem 
de serotonerge neuronen uitlopers vormden het hippocampale plakje in. 
Inderdaad bleken de uitlopers van de serotonerge neuronen binnen vier dagen 
het andere plakje in te groeien. Vervolgens hebben we onderzocht of door 
toediening van stoffen zoals het hierboven genoemde Prozac de uitgroei van de 
serotonerge neuronen geremd of juist gestimuleerd werd. Voor de stof Prozac 
bleek dat het toedienen geen effect had op de uitgroei van de serotonerge 
neuronen. Echter, toediening van een andere stof die aan een bepaalde 
serotonerge receptor bindt, bleek een effect te hebben op de serotonerge 
uitlopers. Na zeven dagen waren er namelijk minder serotonerge uitlopers in het 
hippocampale plakje dan zonder de toediening van deze stof. Hieruit blijkt dat 
chronische activatie van deze serotonerge receptor leidt tot een remming in de 
uitgroei van de serotonerge neuronen. 
In hoofdstuk 3 hebben we een belangrijk eiwit in serotonerge neuronen, 
het eiwit dat zorgt voor heropname van serotonine in het neuron na afgifte (de 
serotonine heropname transporter, SERT) voorzien van een rood fluorescerend 
eiwit (mCherry). Dit zogenaamde fusie-eiwit, mCherry-SERT genaamd, hebben 
we tot expressie gebracht in neuronen om te onderzoeken hoe de verdeling van 
dit eiwit er in neuronen uitziet. Het bleek dat dit eiwit in het neuron aanwezig 
was in vesicles. Dit zijn pakketjes waarmee eiwitten in een neuron 
getransporteerd worden. Vervolgens hebben we door middel van microscopie 
‘live’ naar de beweging van pakketjes mCherry-SERT gekeken. Uit de analyse van 
de snelheid en de richting van de beweging bleek dat de pakketjes zich 
voortbewogen met een gemiddelde snelheid van 1.2 µm/s (=4.32 mm/uur) en 
dat de pakketjes geen voorkeur hadden voor de richting waarin ze zich 
voortbewogen in de uitlopers.  
In hoofdstuk 4 hebben we een soortgelijke aanpak gekozen als in 
hoofdstuk 3. Echter, nu hebben we gekeken naar het eiwit dat belangrijk is voor 
de aanmaak van serotonine, tryptophan hydroxylase 2 (Tph2). Dit eiwit hebben 
we voorzien van een groen fluorescerend eiwit, (Enhanced Green Fluorescent 
Protein, EGFP). Dit fusie-eiwit hebben we tot expressie gebracht in neuronen om 
de verdeling van dit eiwit, ook in vergelijking met mCherry-SERT, te 
onderzoeken. Hieruit bleek dat, in tegenstelling tot mCherry-SERT, Tph2-EGFP 
zich door de hele cel bevond, en niet in vesicles zat. In jonge neuronen had Tph2-
EGFP geen voorkeur voor een bepaald deel van de cel. In oudere neuronen 
echter, bleek dat Tph2-EGFP voornamelijk aanwezig was in presynaptische 
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terminals, maar tegelijkertijd ook in de dendrieten. Ook in deze cellen hebben we 
door middel van microscopie live naar de beweging van Tph2-EGFP gekeken. 
Hieruit bleek dat Tph2-EGFP, in tegenstelling tot mCherry-SERT, zich niet in 
vesicles bevond en daardoor ook geen beweging liet zien. 
In hoofdstuk 5 hebben we onderzocht of een variatie in een gen dat codeert 
voor het eiwit Piccolo, effect heeft op de verdeling en dynamiek van het eiwit 
SERT. Deze variatie in het gen wordt geassocieerd met depressie, waardoor het 
erg interessant is om te onderzoeken of de variatie in dit gen verantwoordelijk is 
voor een verandering in de dynamiek van het serotonine systeem. 
Hiertoe hebben we eerst onderzocht of het eiwit Piccolo voorkwam in de 
serotonerge neuronen en uitlopers, en dit bleek inderdaad het geval. Vervolgens 
hebben we een zogenaamde knockdown construct gemaakt waarmee de 
hoeveelheid Piccolo in een cel grotendeels gereduceerd kan worden. Na het tot 
expressie brengen van dit construct in neuronen bleek inderdaad dat de 
hoeveelheid Piccolo in een cel met meer dan 80% gereduceerd was. Vervolgens 
hebben we onderzocht of een vermindering in de hoeveelheid Piccolo van invloed 
is op de beweging en dynamiek van het eiwit SERT. Om dit te onderzoeken 
hebben we mCherry-SERT tot expressie gebracht in neuronen waarin de 
hoeveelheid Piccolo gereduceerd was en hebben we door middel van live 
microscopie naar de dynamiek van het eiwit mCherry-SERT gekeken. Dit hebben 
we vergeleken met neuronen waarin de hoeveelheid Piccolo niet gereduceerd 
was. We concludeerden uit deze vergelijking dat een vermindering in de 
hoeveelheid Piccolo geen effect heeft op de beweging en snelheid van bewegen 
van mCherry-SERT. Als laatste hebben we gekeken, in een ander cel type, of de 
mutante variant van het eiwit Piccolo, in vergelijking met de normale variant de 
verdeling van het eiwit SERT beïnvloedt. Om dit te onderzoeken hebben we de 
mutante variant van Piccolo en mCherry-SERT in cellen tot expressie gebracht 
en gekeken of de verdeling van mCherry-SERT veranderd was. In cellen waarin 
mCherry-SERT tot expressie gebracht was met de normale variant van Piccolo 
was mCherry-SERT, zoals verwacht, gelokaliseerd aan het membraan. Na 
expressie van mCherry-SERT met de mutante variant van Piccolo bleek echter 
dat de hoeveelheid mCherry-SERT aan het membraan vermindert was. Hieruit 
concludeerden wij dat mogelijk in serotonerge neuronen de mutante variant van 
het eiwit Piccolo ervoor zorgt dat er een verandering is in de hoeveelheid SERT 
aan het membraan. Hierdoor zou de signaaldoorgifte van serotonerge neuronen 
naar andere neuronen verstoord kunnen zijn. 
In hoofdstuk 6 hebben we onderzocht wat het effect is van het uitschakelen 
van het serotonine systeem in de muis. Om dit te onderzoeken hebben we door 
muizen te kruisen een muis verkregen waarbij een gen in het serotonine systeem 
uitgeschakeld is. Uit onderzoek naar de embryonale ontwikkeling van het 
serotonerge systeem in deze muizen bleek dat het serotonerge systeem in eerste 
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instantie tot ontwikkeling kwam. De serotonerge neuronen waren aanwezig, en 
serotonerge vezels groeiden uit naar andere hersengebieden. We hebben het  
serotonerge systeem ook bestudeerd iets later in de hersenontwikkeling van deze 
muizen. Dit toonde aan dat de serotonerge neuronen een veranderde morfologie 
vertoonden, waaruit afgeleid kan worden dat deze neuronen degenereren. 
Uiteindelijk zijn bijna al de serotonerge neuronen verdwenen. Ook de projecties 
van deze neuronen verdwenen later tijdens de hersenontwikkeling. Hieruit 
concludeerden wij dat het uitschakelen van dit gen uiteindelijk leidt tot een 
verdwijning van de serotonerge neuronen. Vervolgens hebben we gekeken wat 
het effect hiervan is op de ontwikkeling en het overleven van deze muizen. Dit 
toonde aan dat de meeste muizen vlak na de geboorte doodgingen. Enkele 
muizen die wel overleefden waren kleiner dan controle muizen die dit gen nog 
wel hadden, en gingen uiteindelijk ook binnen drie weken dood. We waren ook 
geïnteresseerd of het gedrag van de muizen veranderd was. Echter, aangezien de 
meeste muizen al snel na de geboorte dood gingen, was dit niet mogelijk. 
Daarom hebben we het gedrag geanalyseerd van muizen die nog een kopie van 
dit gen hadden, en dit vergeleken met controle muizen. Om het gedrag van deze 
muizen te analyseren hebben we deze muizen zeven dagen in een speciale kooi 
gehouden. Deze kooien bevatten een videocamera zodat later een groot aantal 
parameters geanalyseerd kan worden, zoals de hoeveelheid beweging, hoe vaak 
deze muizen drinken of hoeveel deze muizen eten. Verder konden we ook nog het 
angst gerelateerde gedrag en het leergedrag van deze muizen analyseren. Uit 
analyses van muizen met een kopie van het gen bleek dat deze geen veranderd 
gedrag vertoonden ten opzichte van controle muizen. 
Het doel in hoofdstuk 7 was om een muis te maken waarbij alle 
serotonerge neuronen en uitlopers naar andere hersengebieden gelabeld waren. 
Om dit doel te bereiken hebben we een gen gebruikt dat specifiek tot expressie 
komt in serotonerge neuronen, Tph2. Een stuk DNA voor een gen, een promoter 
genoemd, is verantwoordelijk voor waar en wanneer het gen afgeschreven wordt. 
Achter de promoter van Tph2 hebben een eiwit genaamd Cre recombinase gezet, 
zodat de expressie van Cre recombinase wordt gereguleerd door de Tph2 
promoter en zodoende alleen tot expressie komt in serotonerge neuronen. In dit 
hoofdstuk hebben we beschreven hoe we embryonale stamcellen gemanipuleerd 
hebben en hoe we deze hebben geïnjecteerd in muizen blastocysten. Helaas is het 
nog niet gelukt om deze muis te genereren. Om specifiek serotonerge neuronen 
te labelen hebben we nog een aantal andere muizen gemaakt, waarbij het eiwit 
alleen aangemaakt wordt als in de cell Cre recombinase tot expressie komt. Door 
deze muizen met elkaar te kruisen zou Cre recombinase alleen in serotonerge 
neuronen ‘aan’ staan, en zou alleen in deze neuronen een zogenaamd reporter 
eiwit aangezet worden. Op deze manier hopen we uiteindelijk muizen te hebben 
waarbij specifiek in serotonerge neuronen reporter genen tot expressie komen, 
157
waardoor we deze uiteindelijk kunnen gebruiken om in levende muizen naar de 
dynamische uitgroei en connectiviteit van het serotonerge systeem te kijken. 
Verder kunnen we dan onderzoeken of manipulatie aan dit systeem leidt tot een 
verandering in uitgroei van serotonerge neuronen en tot muizen die bepaalde 
aspecten van humane depressiviteit nabootsen. Aan de andere kant kunnen we 
symptomen van humane depressiviteit in muizen induceren, en onderzoeken of 
dit leidt tot veranderingen in het serotonerge systeem. Uiteindelijk zouden we op 
deze manier ook kunnen onderzoeken of medicatie tegen depressiviteit leidt tot 
een verandering in de connectiviteit van het serotonerge systeem en deze weer 
terugbrengt in de oude staat. 
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List of abbreviations 
 
5-HIAA   5-hydroxyindolacetic acid  
5-HT    serotonin  
5-HT   5-hydroxytryptamine 
8-OH-DPAT  8-hydroxy-2-(di-n-propylamino)tetraline 
BOLD    blood oxygen level dependent  
cAMP    cyclic adenosine monophosphate 
CSF    cerebrospinal fluid  
DAT    dopamine transporter  
dGBSS   dissection Gey’s balanced salt solution 
DIV    days in vitro  
DOI hydrochloride (+-)-2,5-dimethoxy-4-iodoamphetamine hydrochloride 
DRN    dorsal raphe nucleus  
E    embryonic day 
EGFP    enhanced green fluorescent protein 
ES    embryonic stem  
fMRI    functional magnetic resonance imaging  
GIRK    G protein-activated inwardly rectifying K+ 
HBSS   Hanks Balanced Salt Solution 
iCre    improved Cre recombinase  
IP3    inositol 3-phosphate  
IRES    internal ribosomal entry site 
KO    knockout  
l    long  
LAT1    large neutral amino acid transporter 
LDCV   large dense core vesicle 
Lmx1   LIM homeobox transcription factor 1  
LSD    lysergic acid diethylamide  
LSL    loxSTOPlox  
MAO-A   monoamine Oxidase-A 
MAP2    microtubule associated protein 2  
MDMA    3,4-methylenedioxy-N-methylamphetamine  
MHO    midbrain-hindbrain organizing centre  
MRN    median raphe nucleus  
neo    neomycin phosphotransferase cassette  
OCD    obsessive-compulsive disorder  
P    postnatal day  
PBS   phosphate buffered saline  
PCM    presynaptic cytoskeletal cytomatrix  
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PCPA   p-chlorophenylalanine 
PET    positron emission tomography  
Pet1   PC12 Ets factor  
PFA    paraformaldehyde  
PKA    protein kinase A  
PKC    Protein kinase C  
PKG    protein kinase G  
!-PMA   !-phorbol 12-myristate 13-acetate 
RRP    readily releasable pool 
s    short 
SEM    standard error of mean 
SERT    5-HT reuptake transporter 
SMB    short movement bouts  
SNP   short nucleotide polymorphism 
SSRI    selective serotonin reuptake inhibitor 
SSV    small synaptic vesicle 
Tetrahydrobiopterin BH4 (6R)-L-erythro-5,6,7,8-Tetrahydrobiopterin 
TH    tyrosine hydroxylase  
tPA-GFP   tissue plasminogen activator-GFP 
Tph    tryptophan hydroxylase  
Tph1    tryptophan hydroxylase 1  
Tph2    tryptophan hydroxylase 2  
VAMP2   synaptobrevin-2  
VMAT2   Vesicular Monoamine Transporter 2  
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Nu ik aan het einde van mijn promotietraject ben gekomen en het boekje af is, 
besef ik dat ik een ontzettend leuke en leerzame tijd heb gehad, en daar wil ik 
graag een aantal mensen voor bedanken. 
In de eerste plaats mijn promotor Matthijs. Beste Matthijs, ik wil je bedanken 
voor het feit dat ik dit project op je lab heb mogen uitvoeren, de begeleiding en 
de dingen die ik van je geleerd heb. Verder ben ik je dankbaar dat ik ook de 
ruimte kreeg om mijn eigen invulling aan dit project te geven.  
In de tweede plaats mijn copromotor Sander: Beste Sander, door een stage die ik 
bij jou gelopen heb ben ik op dit lab terecht gekomen, ik ben je daar nog steeds 
dankbaar voor. Tijdens mijn promotieproject dank ik je voor de begeleiding en 
het nakijken van mijn manuscripten. 
De leescommissie dank ik voor de aandacht die ze aan mijn proefschrift hebben 
willen besteden. 
Verder heb ik veel gehad aan de suggesties en input van Ruud en Joris tijdens 
onze meetings, mijn dank daarvoor. Oliver, ik zou je graag willen bedanken voor 
de suggesties met betrekking tot gedragsproeven in muizen en de hulp met de 
perfusies. Ik dank Pieter Voorn en Menno Witter voor het meedenken met het 
slice hoofdstuk en Pieter en Allert tevens voor alle hulp op de MCID microscoop. 
 
Mijn dank gaat uit naar mijn beide paranimfen. Beste Joost, bedankt voor al die 
keren dat je me op het lab een hoetje(s) liet schrikken ! Ik heb altijd met heel 
veel plezier met jou samengewerkt op het lab, maar we hebben ook heel veel lol 
gehad buiten het werk om. 
Beste Arthur, ondanks dat je pas in mijn laatste jaar mijn kamergenoot werd, 
bleek al snel dat we het qua humor goed met elkaar konden vinden. Behalve onze 
liefde voor flauwekul bleek ook onze liefde voor (speciale) bier(en) overeen te 
komen (zou daar een relatie tussen zitten?). Ik wens je alle succes met jouw 
verdere afronding van je promotietraject en met de voortzetting van het door ons 
opgezette ‘bureau voor flauwekul’. 
 
Beste Ineke, ik wil je danken voor alle gezelligheid, maar ook voor alle goede 
gesprekken over de wetenschap en aanverwante zaken. Ik wens je heel veel 
succes met de verdere afronding van je opleiding tot klinisch chemicus.  
 
Buiten het feit dat ik veel geleerd heb, heb ik ook de sfeer op de afdeling en het 
lab altijd als zeer positief ervaren. Op het DNA lab, het kloppend hart van de 
afdeling, heb ik altijd met heel veel plezier gewerkt. Niet in de laatste plaats door 
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alle gezelligheid die daar altijd te vinden was. Voor al deze gezelligheid, maar 
zeker ook voor alle hulp ben ik de analisten grote dank verschuldigd. 
Beste Robbie, Mr. Salmon, ik ben je dankbaar voor de stage die ik bij jou gelopen 
heb waarin je me hebt ingewijd in de geheimen van het kloneren. Hoewel ik nog 
niet eens jouw pipetten mag vasthouden denk ik dat ik inmiddels aardig kan 
kloneren. 
Beste Ingrid, bedankt voor je humor op het lab en voor de hulp met de 
kloneringen. N.B. Ik heb in de wandelgangen vernomen dat zelfs jij nu getrouwd 
bent ;-) 
Ik ben ook veel dank verschuldigd aan Desiree en later Boukje voor alle hulp met 
de neuronen kweek. Bastijn, jou dank ik voor het uitwerken van de Phenotyper 
data. 
Beste Joke, bedankt voor alle hulp met de muizen, maar zeker ook voor je altijd 
vriendelijke houding.  
Dit proefschrift was ook zeker niet mogelijk geweest zonder alle hulp vanuit de 
muizenstallen. Dus Chris, Bert en Lieselotte, ook jullie hartelijk dank voor alle 
hulp met de muizen. 
 
Mijn mede aio’s Jurjen, Juliane, Sabine, Marieke, Asiya, Rhea, Jiun, Tony en 
Gregoire dank ik voor alle discussies en ik wens jullie allen veel succes met de 
verdere voortzetting van jullie project en de afronding van jullie proefschrift. 
 
Tina en Els jullie dank ik voor alle administratieve ondersteuning. Els, als ik een 
vraag had wist je die altijd binnen no time te beantwoorden. 
 
Alle andere nog niet genoemde collega’s van het lab dank ik voor alle discussies 
tijdens labmeetings, gezelligheid tijdens de dagelijkse lablunch en het jaarlijkse 
labuitje. 
 
Roel, ik dank je voor alle gezelligheid tijdens de treinreizen vanuit Hoofddorp, en 
ik vind het erg leuk dat we elkaar nog weleens tegenkomen. 
 
Mijn nieuwe lab Neuromedische Genetica op het NIN dank ik voor de 
gastvrijheid waarmee ik in hun lab ben opgenomen en de plezierige werksfeer. 
 
Gijs, Ray en Robert, we hebben altijd ontzettend veel lol gehad tijdens onze 
studieperiode. Ik ben blij dat we nog weleens afspreken. Wanneer gaan we weer 
poolen (of was het nou snooker...?).  
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Als laatste zou ik graag een aantal mensen willen bedanken uit mijn persoonlijke 
omgeving. 
De mannen uit Renesse: Alex, Bart, Kenneth, Michael; bedankt voor alle 
nachtelijk stapuurtjes en (wintersport) vakanties.  
 
Beste familie Visser, ik dank jullie voor alle gezelligheid en alle borreltjes die we 
al met elkaar gedronken hebben. Wat is het bij jullie toch altijd lekker rustig… ;-)  
 
Ik dank mijn schoonouders, Jan en Christien, mijn schoonzussen en zwagers 
voor de interesse in mijn proefschrift en alle feesten, familiedagen en andere 
gezellige activiteiten. Is die Eiffeltoren nou al gevonden? 
 
Mijn broer(tje) en zus(je), ik dank jullie voor de interesse in mijn proefschrift, de 
gezelligheid tijdens het meerijden naar Renesse en ik wens jullie alle succes met 
de afronding van jullie studie. 
 
Mijn ouders, ‘promoveren zit dat erin dan?’, Frans en Lia, ik ben heel trots op 
jullie en ik ben blij jullie zoon te zijn. Ik realiseer me maar al te vaak wat een 
rijkdom het was om zo te mogen opgroeien. Ik dank jullie voor alle steun en 
vertrouwen, maar ook voor alle gezelligheid. Als we elkaar zien is het altijd erg 
gezellig en vaak ineens midden in de nacht als we zitten te kletsen onder het 
genot van een wijntje. 
 
Als laatste dank ik natuurlijk mijn lieve vrouw Judith. Sinds die kapotte printer 
zijn we alweer bijna 7 jaar bij elkaar, wonen we al ruim 3 jaar in Hoofddorp en 
zijn we al ruim 1 jaar getrouwd. Time flies when having fun, wil ik daar alleen 
maar even mee zeggen. Ik wens jou ook alle succes met de verdere afronding van 
jouw promotieproject en boekje, en heb zin om samen de toekomst tegemoet te 
gaan! 
 
Jeroen 
 
 
Hoofddorp, Juli 2010 
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calcium afhankelijke translocatie van het presynaptische eiwit Doc2B, begeleidt 
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Zalm, cloneerde hij een targeting construct en gebruikte deze om muis 
embryonale stamcellen mee te targetten. Zijn masterscriptie schreef hij onder 
leiding van Dr. J. Pronk en ging over de in silico clonering en karakterisatie van 
het eiwit Tph2. In augustus 2004 studeerde hij af aan de Vrije Universiteit te 
Amsterdam. Van oktober 2004 tot april 2009 deed hij zijn promotieonderzoek 
naar de uitgroei en connectiviteit van het serotonerge systeem. Dit onderzoek 
deed hij onder begeleiding van professor Verhage aan de vakgroep Functionele 
Genoomanalyse aan de Vrije Universiteit te Amsterdam. De resultaten van dit 
promotieonderzoek zijn in dit proefschrift beschreven. Vanaf april 2009 werkt 
hij als postdoctoraal onderzoeker op het Nederlands Instituut voor 
Neurowetenschappen (NIN) bij de vakgroep Neuromedische Genetica onder 
leiding van Dr. J. Wijnholds. Hier doet hij onderzoek naar de functionele rol van 
het eiwit MPP3 in het Crumbs complex en in neuronale cellen. 
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English version 
 
Jacobus Johannis Dudok was born on the 13th of June 1981 in Zierikzee, the 
Netherlands. In 1993 he started his secondary education at the Buys Ballot 
College in Goes, where he graduated in 1999. In august 1999 he started the 
Bachelor Medical Biology at the Vrije Universiteit Amsterdam. During this 
Bachelor he carried out a research project from February 2002 to June 2002 at 
the research department of pathology at the VU medical center. Here he studied 
the different aggregation states of A!1-42, the peptide involved in Alzheimer’s 
disease, supervised by Dr. R. Veerhuis and Ing. E. van Elk. In September 2002 
he started the Master of Neuroscience at the Vrije Universiteit Amsterdam. 
During this master he carried out two research projects at the department of 
Functional Genomics. During his first research project he studied the calcium 
dependent translocation of the presynaptic protein Doc2B, supervised by Dr. S. 
Groffen. During his second research project he constructed a targeting construct 
and used this to target mouse embryonic stem cells, supervised by Ing. R. Zalm. 
He wrote his Master Thesis under supervision of Dr. J. Pronk about the in silico 
cloning and characterization of the protein Tph2. In august 2004 he graduated at 
the Vrije Universiteit Amsterdam. From October 2004 until April 2009 he did 
his PhD project on the outgrowth and connectivity of the serotonin system. This 
PhD project was supervised by professor Verhage and carried out at the 
department of Functional Genomics at the Vrije Universiteit Amsterdam. The 
results of that study are described in this thesis. He is currently working as a 
postdoctoral fellow at the Netherlands Institute for Neuroscience (NIN) in the 
department of Neuromedical Genetics headed by Dr. J. Wijnholds. Here he 
studies the functional role of the protein MPP3 in the Crumbs complex and in 
neuronal cells. 
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